


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:52:57Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406673" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406673</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>aac</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="iso-abbrev">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="pmc-domain-id">82</journal-id><journal-id journal-id-type="pmc-domain">aac</journal-id><journal-id journal-id-type="publisher-id">aac</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology (ASM)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406673</article-id><article-id pub-id-type="pmcid-ver">PMC12406673.1</article-id><article-id pub-id-type="pmcaid">12406673</article-id><article-id pub-id-type="pmcaiid">12406673</article-id><article-id pub-id-type="pmid">40741956</article-id><article-id pub-id-type="doi">10.1128/aac.01904-24</article-id><article-id pub-id-type="publisher-id">aac01904-24</article-id><article-id pub-id-type="publisher-id">aac.01904-24</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Clinical Therapeutics</subject></subj-group><subj-group subj-group-type="biological-terms"><compound-subject><compound-subject-part content-type="code">antimicrobial-chemotherapy</compound-subject-part><compound-subject-part content-type="label">Antimicrobial Chemotherapy</compound-subject-part></compound-subject></subj-group></article-categories><title-group><article-title>Clinical pharmacokinetics of metronidazole: a systematic review and meta-analysis</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Shahzad</surname><given-names initials="I">Iqra</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Alasmari</surname><given-names initials="MS">Mohammed S.</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zamir</surname><given-names initials="A">Ammara</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review and editing</role></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8607-8583</contrib-id><name name-style="western"><surname>Rasool</surname><given-names initials="MF">Muhammad Fawad</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor1" ref-type="corresp"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><email>fawadrasool@bzu.edu.pk</email></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3924-593X</contrib-id><name name-style="western"><surname>Alqahtani</surname><given-names initials="F">Faleh</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="cor2" ref-type="corresp"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><email>afaleh@ksu.edu.sa</email></contrib><aff id="aff1"><label>1</label><institution-wrap><institution>Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University</institution><institution-id institution-id-type="ringgold">511766</institution-id><institution-id institution-id-type="ror">https://ror.org/05x817c41</institution-id></institution-wrap>, <city>Multan</city>, <country>Pakistan</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution>General Directorate of Medical Services, Security Forces Hospital Program, Ministry of Interior</institution><institution-id institution-id-type="ringgold">48061</institution-id><institution-id institution-id-type="ror">https://ror.org/035n3nf68</institution-id></institution-wrap>, <city>Riyadh</city>, <country>Saudi Arabia</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution>Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University</institution><institution-id institution-id-type="ringgold">108788</institution-id><institution-id institution-id-type="ror">https://ror.org/02f81g417</institution-id></institution-wrap>, <city>Riyadh</city>, <country>Saudi Arabia</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution>King Salman Center for Disability Research</institution><institution-id institution-id-type="ringgold">600567</institution-id><institution-id institution-id-type="ror">https://ror.org/01ht2b307</institution-id></institution-wrap>, <city>Riyadh</city>, <country>Saudi Arabia</country></aff></contrib-group><contrib-group><contrib contrib-type="editor"><role>Editor</role><name name-style="western"><surname>Leggett</surname><given-names initials="JE">James E.</given-names></name><aff><institution-wrap><institution>Providence Portland Medical Center</institution></institution-wrap>, <city>Portland</city>, <state>Oregon</state>, <country>USA</country></aff></contrib></contrib-group><author-notes><corresp id="cor1">Address correspondence to Muhammad Fawad Rasool, <email xlink:href="mailto:fawadrasool@bzu.edu.pk">fawadrasool@bzu.edu.pk</email></corresp><corresp id="cor2">Address correspondence to Faleh Alqahtani, <email xlink:href="mailto:afaleh@ksu.edu.sa">afaleh@ksu.edu.sa</email></corresp><fn fn-type="equal"><p>Iqra Shahzad and Mohammed S. Alasmari contributed equally to this article. Author order was determined both alphabetically and in order of increasing seniority.</p></fn><fn fn-type="COI-statement"><p>The authors declare no conflict of interest.</p></fn></author-notes><pub-date publication-format="electronic" date-type="collection"><month>9</month><year>2025</year></pub-date><pub-date date-type="pub" publication-format="electronic"><day>31</day><month>7</month><year>2025</year></pub-date><volume>69</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496152</issue-id><elocation-id>e01904-24</elocation-id><history><date date-type="received"><day>19</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>11</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>31</day><month>07</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Shahzad et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Shahzad et al.</copyright-holder><ali:free_to_read start_date="2025-07-31"/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="aac.01904-24.pdf"/><self-uri content-type="pdf" xlink:href="aac.01904-24.pdf"/><abstract abstract-type="primary"><title>ABSTRACT</title><p>Metronidazole (MTZ) is used in various clinical settings; however, its pharmacokinetics may vary across patient populations due to physiological and pathological differences. Understanding these variations is important for personalized dosing and optimization of therapeutic outcomes. This study aimed to systematically review clinical pharmacokinetic studies of MTZ and perform a meta-analysis of the area under the concentration-time curve (AUC). AUC was selected for meta-analysis as it provides a direct and comprehensive measure of total drug exposure over time, facilitating standardized comparisons across populations. Four databases, including PubMed, ScienceDirect, Cochrane Library, and Google Scholar, were screened for pharmacokinetic studies on MTZ using systematic search strategies until July 2024. Out of 1,882 articles identified in the literature search, only 67 studies that fulfilled eligibility criteria were included in this systematic review. A meta-analysis of AUC was performed using random-effects models, with heterogeneity assessed by <italic toggle="yes">I</italic>&#178; statistic. Effect sizes (pooled AUC) were compared across populations and visually presented with their corresponding 95% confidence intervals. Meta-analysis revealed significant differences in AUC across populations, with substantial heterogeneity among studies. This study provides a comprehensive evaluation of the MTZ pharmacokinetic profile across diverse patient populations. The findings emphasize the importance of tailored dosing strategies and support evidence-based clinical decision-making for optimizing the safety and efficacy of MTZ.</p></abstract><kwd-group><title>KEYWORDS</title><kwd>metronidazole</kwd><kwd>pharmacokinetics</kwd><kwd><italic toggle="yes">C</italic><sub>max</sub></kwd><kwd>AUC</kwd><kwd>clearance</kwd></kwd-group><funding-group specific-use="FundRef"><award-group award-type="grant" id="award-1"><funding-source><institution-wrap><institution>King Salman Center for Disability Research</institution><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100019345</institution-id></institution-wrap></funding-source><award-id>KSRG-2024-433</award-id><principal-award-recipient><name name-style="western"><surname>Alqahtani</surname><given-names>Faleh</given-names></name></principal-award-recipient></award-group></funding-group><counts><count count="1" count-type="supplementary-material"/><count count-type="authors" count="5"/><fig-count count="14"/><table-count count="5"/><equation-count count="0"/><ref-count count="107"/><page-count count="31"/><word-count count="14850"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>INTRODUCTION</title><p>Metronidazole (MTZ) is a synthetic antimicrobial drug of the Nitroimidazole family that was derived from azomycin and produced by the two genera, that is, Proteobacteria and Actinobacteria. It was introduced in 1959 (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>), and its uses against anaerobic infections were first published by Shinn in 1962 (<xref rid="B3" ref-type="bibr">3</xref>), followed by its approval from the U.S. Food and Drug Administration (FDA) in 1963 for various anaerobic bacteria and protozoa infections (<xref rid="B4" ref-type="bibr">4</xref><xref rid="B5" ref-type="bibr">&#8211;</xref><xref rid="B7" ref-type="bibr">7</xref>). It is used to treat trichomoniasis and vaginosis during pregnancy, infections after cesarean section, postpartum hemorrhage, and bowel surgery, Crohn&#8217;s disease, giardiasis, amoebiasis, dysentery, liver abscess, meningitis, endocarditis, dental, skin, bone, and joint infections (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B8" ref-type="bibr">8</xref><xref rid="B9" ref-type="bibr">&#8211;</xref><xref rid="B11" ref-type="bibr">11</xref>). The off-label uses of MTZ include the treatment of pouchitis, balantidiases, animal bite infections, <italic toggle="yes">Helicobacter pylori</italic> ulcer, periodontitis, and tetanus (<xref rid="B12" ref-type="bibr">12</xref>). The exact mechanism of action of MTZ is still unknown, but it penetrates the bacterial cell membrane by passive diffusion, where ferredoxin reduces the compound&#8217;s nitro group to nitro radicals, causing DNA strand breakage resulting in cell death (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>). It is available in oral (PO), intravenous (IV), and topical (TOP) dosage forms (<xref rid="B15" ref-type="bibr">15</xref>).</p><p>MTZ belongs to the Biopharmaceutical Classification System class 1, being a highly soluble and permeable drug. It has excellent gastrointestinal (GIT) absorption with more than 90% oral bioavailability, and its elimination half-life (<italic toggle="yes">t</italic><sub>1/2</sub>) ranges from 6 to 14 h (<xref rid="B16" ref-type="bibr">16</xref>). The plasma protein binding and volume of distribution of MTZ are 10&#8211;15% and 0.51&#8211;1.1 L/kg, respectively (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B18" ref-type="bibr">18</xref>). The liver metabolizes MTZ into two metabolites, that is, l-(2-hydroxy-ethyl)&#8722;2-hydroxymethyl-5-nitroimidazole (hydroxy metabolite) and 2-methyl-5-nitroimidazole-<sc>l</sc>-acetic acid (acid metabolite) (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>). Its major route of excretion is the kidney, which accounts for 60&#8211;80% of the total dose (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B21" ref-type="bibr">21</xref>).</p><p>MTZ has the chemical formula C<sub>6</sub>H<sub>9</sub>N<sub>3</sub>O<sub>3</sub> and a molecular weight of 171.16 g/mol (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>). Its water solubility is 10 mg/mL at 25&#176;C with the pK<sub>a</sub> and log <italic toggle="yes">P</italic> values of 2.62 and &#8722;0.02, respectively (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>). Various analytical techniques have been documented in the literature which includes high-performance liquid chromatography (HPLC), liquid chromatography-mass spectrometry (LCMS), high-performance liquid chromatography-ultraviolet spectroscopy (HPLC-UV), thin layer chromatography (TLC), ultra-performance liquid chromatography (UPLC), liquid chromatography (LC), polarography, densitometry, and bioassay (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B26" ref-type="bibr">26</xref><xref rid="B27" ref-type="bibr">&#8211;</xref><xref rid="B32" ref-type="bibr">32</xref>).</p><p>MTZ belongs to pregnancy risk category B and may permeate into the breast milk but would not harm the child. Furthermore, it can also cross the blood-brain barrier but rarely cause neurotoxicity (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>). The common adverse effects of MTZ include GIT problems, unpleasant taste, tongue furrowing, dizziness, lethargy, minor skin rashes, neutropenia, and disulfiram-like reaction with alcohol (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B35" ref-type="bibr">35</xref>). It is contraindicated in patients with Cockayne syndrome and interacts with alcohol, disulfiram, and warfarin (<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B36" ref-type="bibr">36</xref>). According to a study, MTZ must always be administered with another broad-spectrum antibiotic to avoid resistance (<xref rid="B37" ref-type="bibr">37</xref>).</p><p>Although a few reviews on MTZ PK have been published (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B39" ref-type="bibr">39</xref>), detailed and focused analyses specific to MTZ remain limited. This work provides new insights into MTZ&#8217;s pharmacokinetics (PK) profile by comprehensively evaluating data from various studies involving healthy individuals, patients with diverse conditions, and special populations. The study systematically reviewed clinical PK data of MTZ across different patient populations and performed a meta-analysis of the AUC to characterize MTZ exposure. By analyzing data from IV, oral, rectal, and vaginal administration routes, this study identified gaps in the existing literature to guide the development of PK models. These findings aim to support personalized treatment strategies and optimize dosing regimens for improved therapeutic outcomes.</p></sec><sec sec-type="materials|methods" id="s2"><title>MATERIALS AND METHODS</title><sec id="s2-1"><title>Study design and search strategy for literature screening</title><p>Following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) (<xref rid="B40" ref-type="bibr">40</xref>) and Cochrane Handbook guidelines (<xref rid="B41" ref-type="bibr">41</xref>), the current systematic review was conducted. The published studies on the PK of MTZ were retrieved using Google Scholar, PubMed, Science Direct, Cochrane Library, and citation tracking after a thorough literature review until July 2024. In addition, a Boolean strategy, mesh terms, keywords, and free-text terms were employed to narrow the literature search. The search was conducted using the following terms: PK, clinical PK, pharmacokinetic parameters, area under concentration-time curve (AUC), half-life (<italic toggle="yes">t</italic><sub>1/2</sub>), maximum plasma concentration (<italic toggle="yes">C</italic><sub>max</sub>), time required to reach maximum plasma concentration (<italic toggle="yes">T</italic><sub>max</sub>), volume of distribution (<italic toggle="yes">V</italic><sub>d</sub>), clearance (Cl), MTZ, and human. <xref rid="F1" ref-type="fig">Figure 1</xref> details all the applied search methodologies.</p><fig position="float" fig-type="figure" id="F1" orientation="portrait"><label>Fig 1</label><caption><p>Literature search strategy.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.01904-24.f001.jpg"><alt-text>Search strategy flow chart summarizing article selection on metronidazole pharmacokinetics from PubMed, Cochrane Library, ScienceDirect, Google Scholar, and manual search with filters for article type, language, and species.</alt-text></graphic></fig></sec><sec id="s2-2"><title>Eligibility criteria (inclusion/exclusion)</title><p>All relevant studies extracted through a detailed literature review were then exported to EndNote version 20, and the duplicates were removed using the option &#8220;find duplicates.&#8221; The retrieved articles underwent screening based on the titles, abstracts, animals, non-accessibility, books, language, thesis, and irrelevance. Moreover, conference abstracts, short reviews, letters to the editor, and commentaries were also excluded. After meeting the eligibility criteria, full-text reading was used to screen the articles further. The details of all excluded articles are given in <xref rid="SuF1" ref-type="supplementary-material">Table S1</xref>. The original research articles presenting PK parameters of MTZ in healthy, diseased, and special populations were included. These inclusions were made regardless of dosage forms, dosing regimen, route of administration, and year of publication. Furthermore, all publications that reported drug-drug interactions and drug-food interactions were included to observe the effect of these variables on the PK of MTZ.</p></sec><sec id="s2-3"><title>Extraction of data</title><p>The required data extracted from eligible studies were as follows: authors, populations, number of participants, age of subjects, dosage form, route of administration, drug used, regimen (dose and frequency), and assay method (see <xref rid="T1" ref-type="table">Table 1</xref>). Additionally, the PK data included volume of distribution (<italic toggle="yes">V</italic><sub>d</sub>), elimination half-life (<italic toggle="yes">t</italic><sub>1/2</sub>), the area under concentration-time curve from 0 to &#8734; (AUC<sub>0&#8211;&#8734;</sub>), renal clearance (Cl<sub>R</sub>), total body clearance (Cl<sub>T</sub>), maximum plasma concentration (<italic toggle="yes">C</italic><sub>max</sub>), and time required to reach maximum plasma concentration (<italic toggle="yes">T</italic><sub>max</sub>). For uniformity, the units of PK parameters were changed to standard units so that readers could more effectively compare the results. Moreover, the data screening and extraction were carried out by two independent reviewers, that is, Muhammad Fawad Rasool and Ammara Zamir.</p><table-wrap position="float" id="T1" orientation="portrait"><label>TABLE 1</label><caption><p>Characteristics of included studies<xref rid="T1_FN5" ref-type="table-fn"><sup><italic toggle="yes">e</italic></sup></xref></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" valign="top" colspan="1" rowspan="1">Sr. No.</th><th align="left" valign="top" colspan="1" rowspan="1">Authors</th><th align="left" valign="top" colspan="1" rowspan="1">Population</th><th align="left" valign="top" colspan="1" rowspan="1">
<italic toggle="yes">N</italic>
<xref rid="T1_FN1" ref-type="table-fn">
<sup>
<italic toggle="yes">a</italic>
</sup>
</xref>
</th><th align="left" valign="top" colspan="1" rowspan="1">Age (years)</th><th align="left" valign="top" colspan="1" rowspan="1">Route</th><th align="left" valign="top" colspan="1" rowspan="1">Dosage form</th><th align="left" valign="top" colspan="1" rowspan="1">Drugs used</th><th align="left" valign="top" colspan="1" rowspan="1">Dose (mg)</th><th align="left" valign="top" colspan="1" rowspan="1">Frequency</th><th align="left" valign="top" colspan="1" rowspan="1">Method of assay</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="1" rowspan="1">1</td><td align="left" valign="top" colspan="1" rowspan="1">Fonnes et al. (<xref rid="B1" ref-type="bibr">1</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Patients with appendectomy</td><td align="left" valign="top" colspan="1" rowspan="1">8</td><td align="left" valign="top" colspan="1" rowspan="1">18&#8211;48</td><td align="left" valign="top" colspan="1" rowspan="1">IP</td><td align="left" valign="top" colspan="1" rowspan="1">Irrigation</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">1,000</td><td align="left" valign="top" colspan="1" rowspan="1">QD</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">2</td><td align="left" valign="top" rowspan="3" colspan="1">Sakurai et al. (<xref rid="B26" ref-type="bibr">26</xref>)</td><td align="left" valign="top" rowspan="3" colspan="1">Healthy</td><td align="left" valign="top" rowspan="3" colspan="1">12</td><td align="left" valign="top" rowspan="3" colspan="1">20&#8211;35</td><td align="left" valign="top" rowspan="3" colspan="1">PO</td><td align="left" valign="top" rowspan="3" colspan="1">Tablet</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">250</td><td align="left" valign="top" rowspan="3" colspan="1">BID</td><td align="left" valign="top" rowspan="3" colspan="1">LCMS</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">AMOX</td><td align="left" valign="top" colspan="1" rowspan="1">750</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">VPZ</td><td align="left" valign="top" colspan="1" rowspan="1">20</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">3</td><td align="left" valign="top" colspan="1" rowspan="1">Visser et al. (<xref rid="B42" ref-type="bibr">42</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Pregnant women</td><td align="left" valign="top" colspan="1" rowspan="1">16</td><td align="left" valign="top" colspan="1" rowspan="1">&#8805;18</td><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">Infusion</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">500</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">4</td><td align="left" valign="top" colspan="1" rowspan="1">de C Bergamaschi et al. (<xref rid="B6" ref-type="bibr">6</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1">13</td><td align="left" valign="top" colspan="1" rowspan="1">18&#8211;30</td><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">Tablet</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">750</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">5</td><td align="left" valign="top" colspan="1" rowspan="1">Somogyi et al. (<xref rid="B19" ref-type="bibr">19</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Renal dysfunction</td><td align="left" valign="top" colspan="1" rowspan="1">6</td><td align="left" valign="top" colspan="1" rowspan="1">23&#8211;75</td><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">Infusion</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">500</td><td align="left" valign="top" colspan="1" rowspan="1">BID</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">6</td><td align="left" valign="top" colspan="1" rowspan="1">Houghton et al. (<xref rid="B7" ref-type="bibr">7</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Renal dysfunctions</td><td align="left" valign="top" colspan="1" rowspan="1">32</td><td align="left" valign="top" colspan="1" rowspan="1">18&#8211;60</td><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">Infusion</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">500</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">7</td><td align="left" valign="top" colspan="1" rowspan="1">Shaffer et al. (<xref rid="B10" ref-type="bibr">10</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Patients with enteric disease</td><td align="left" valign="top" colspan="1" rowspan="1">12</td><td align="left" valign="top" colspan="1" rowspan="1">&#8805;18</td><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">Tablet</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">400</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">8</td><td align="left" valign="top" colspan="1" rowspan="1">Lau et al. (<xref rid="B20" ref-type="bibr">20</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Hepatic dysfunction</td><td align="left" valign="top" colspan="1" rowspan="1">8</td><td align="left" valign="top" colspan="1" rowspan="1">31&#8211;75</td><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">Infusion</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">7.5<xref rid="T1_FN4" ref-type="table-fn"><sup><italic toggle="yes">d</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">9</td><td align="left" valign="top" colspan="1" rowspan="1">Passmore et al. (<xref rid="B9" ref-type="bibr">9</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Nursing mothers and infants</td><td align="left" valign="top" colspan="1" rowspan="1">12</td><td align="left" valign="top" colspan="1" rowspan="1">&#8805;18</td><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">Tablet</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">400</td><td align="left" valign="top" colspan="1" rowspan="1">TID</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">10</td><td align="left" valign="top" colspan="1" rowspan="1">Plaisance et al. (<xref rid="B43" ref-type="bibr">43</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Severely ill patients</td><td align="left" valign="top" colspan="1" rowspan="1">14</td><td align="left" valign="top" colspan="1" rowspan="1">32&#8211;86</td><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">Infusion</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">500</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">11</td><td align="left" valign="top" colspan="1" rowspan="1">Heisterberg and Branebjerg (<xref rid="B44" ref-type="bibr">44</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Nursing mothers and infants</td><td align="left" valign="top" colspan="1" rowspan="1">25</td><td align="left" valign="top" colspan="1" rowspan="1">&#8805;18</td><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">Tablet</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">400</td><td align="left" valign="top" colspan="1" rowspan="1">TID</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">12</td><td align="left" valign="top" colspan="1" rowspan="1">Daneshmend et al. (<xref rid="B45" ref-type="bibr">45</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Hepatic dysfunction</td><td align="left" valign="top" colspan="1" rowspan="1">25</td><td align="left" valign="top" colspan="1" rowspan="1">20&#8211;67</td><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">Tablet</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">500</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">13</td><td align="left" valign="top" colspan="1" rowspan="1">Ti et al. (<xref rid="B46" ref-type="bibr">46</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Patients with anaerobic infection</td><td align="left" valign="top" colspan="1" rowspan="1">54</td><td align="left" valign="top" colspan="1" rowspan="1">21&#8211;90</td><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">Infusion</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">500</td><td align="left" valign="top" colspan="1" rowspan="1">TID</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">14</td><td align="left" valign="top" colspan="1" rowspan="1">Loft et al. (<xref rid="B47" ref-type="bibr">47</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Elderly</td><td align="left" valign="top" colspan="1" rowspan="1">19</td><td align="left" valign="top" colspan="1" rowspan="1">30&#8211;86</td><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">Infusion</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">500</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">15</td><td align="left" valign="top" rowspan="3" colspan="1">Jensen and Gugler (<xref rid="B48" ref-type="bibr">48</xref>)</td><td align="left" valign="top" rowspan="3" colspan="1">Healthy</td><td align="left" valign="top" rowspan="3" colspan="1">7</td><td align="left" valign="top" rowspan="3" colspan="1">19&#8211;31</td><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">Infusion</td><td align="left" valign="top" rowspan="3" colspan="1">MTZ</td><td align="left" valign="top" rowspan="3" colspan="1">400</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" rowspan="3" colspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">Tablet</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">Tablet</td><td align="left" valign="top" colspan="1" rowspan="1">BID</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">16</td><td align="left" valign="top" rowspan="2" colspan="1">Dilger et al. (<xref rid="B49" ref-type="bibr">49</xref>)</td><td align="left" valign="top" rowspan="2" colspan="1">Healthy</td><td align="left" valign="top" rowspan="2" colspan="1">12</td><td align="left" valign="top" rowspan="2" colspan="1">18&#8211;30</td><td align="left" valign="top" rowspan="2" colspan="1">PO</td><td align="left" valign="top" rowspan="2" colspan="1">Tablet</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">750</td><td align="left" valign="top" rowspan="2" colspan="1">BID</td><td align="left" valign="top" rowspan="2" colspan="1">LCMS</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">BDS</td><td align="left" valign="top" colspan="1" rowspan="1">3</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">17</td><td align="left" valign="top" colspan="1" rowspan="1">Muscar&#225; et al. (<xref rid="B50" ref-type="bibr">50</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Liver dysfunction</td><td align="left" valign="top" colspan="1" rowspan="1">52</td><td align="left" valign="top" colspan="1" rowspan="1">&#8805;18</td><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">Infusion</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">500</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">18</td><td align="left" valign="top" colspan="1" rowspan="1">Ashiq et al. (<xref rid="B51" ref-type="bibr">51</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Patients with amoebiasis</td><td align="left" valign="top" colspan="1" rowspan="1">12</td><td align="left" valign="top" colspan="1" rowspan="1">25&#8211;35</td><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">Tablet</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">400</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">19</td><td align="left" valign="top" rowspan="2" colspan="1">Thiercelin et al. (<xref rid="B52" ref-type="bibr">52</xref>)</td><td align="left" valign="top" rowspan="2" colspan="1">Patient undergoing GIT surgery</td><td align="left" valign="top" rowspan="2" colspan="1">17</td><td align="left" valign="top" rowspan="2" colspan="1">42&#8211;73</td><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">Infusion</td><td align="left" valign="top" rowspan="2" colspan="1">MTZ</td><td align="left" valign="top" rowspan="2" colspan="1">500</td><td align="left" valign="top" rowspan="2" colspan="1">TID</td><td align="left" valign="top" rowspan="2" colspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">Tablet</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">20</td><td align="left" valign="top" colspan="1" rowspan="1">Guay et al. (<xref rid="B53" ref-type="bibr">53</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Renal patients on dialysis</td><td align="left" valign="top" colspan="1" rowspan="1">10</td><td align="left" valign="top" colspan="1" rowspan="1">29&#8211;68</td><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">Infusion</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">750</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">21</td><td align="left" valign="top" colspan="1" rowspan="1">Loft et al. (<xref rid="B54" ref-type="bibr">54</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Hepatic encephalopathy</td><td align="left" valign="top" colspan="1" rowspan="1">16</td><td align="left" valign="top" colspan="1" rowspan="1">50&#8211;81</td><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">Infusion</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">500</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">22</td><td align="left" valign="top" colspan="1" rowspan="1">Amon et al. (<xref rid="B27" ref-type="bibr">27</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Female children with vaginitis</td><td align="left" valign="top" colspan="1" rowspan="1">20</td><td align="left" valign="top" colspan="1" rowspan="1">6<xref rid="T1_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref>&#8211;13</td><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">Tablet</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">10&#8211;20<xref rid="T1_FN4" ref-type="table-fn"><sup><italic toggle="yes">d</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">BID</td><td align="left" valign="top" colspan="1" rowspan="1">Polarography</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">23</td><td align="left" valign="top" colspan="1" rowspan="1">Dorn et al. (<xref rid="B28" ref-type="bibr">28</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Obese</td><td align="left" valign="top" colspan="1" rowspan="1">30</td><td align="left" valign="top" colspan="1" rowspan="1">21&#8211;65</td><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">Infusion</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">500</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC-UV</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">24</td><td align="left" valign="top" colspan="1" rowspan="1">Karjagin et al. (<xref rid="B55" ref-type="bibr">55</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Patients with septic shock</td><td align="left" valign="top" colspan="1" rowspan="1">6</td><td align="left" valign="top" colspan="1" rowspan="1">32&#8211;69</td><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">Infusion</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">500</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">25</td><td align="left" valign="top" colspan="1" rowspan="1">Montalli et al. (<xref rid="B56" ref-type="bibr">56</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Smokers</td><td align="left" valign="top" colspan="1" rowspan="1">26</td><td align="left" valign="top" colspan="1" rowspan="1">12&#8211;24</td><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">Tablet</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">750</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC-UV</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">26</td><td align="left" valign="top" colspan="1" rowspan="1">Eradiri et al. (<xref rid="B57" ref-type="bibr">57</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Crohn&#8217;s disease</td><td align="left" valign="top" colspan="1" rowspan="1">6</td><td align="left" valign="top" colspan="1" rowspan="1">25&#8211;62</td><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">Tablet</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">250</td><td align="left" valign="top" colspan="1" rowspan="1">TID</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">27</td><td align="left" valign="top" colspan="1" rowspan="1">Sachwarts et al. (<xref rid="B29" ref-type="bibr">29</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Healthy men</td><td align="left" valign="top" colspan="1" rowspan="1">4</td><td align="left" valign="top" colspan="1" rowspan="1">24&#8211;27</td><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">Tablet</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">75</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">TLC</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">28</td><td align="left" valign="top" rowspan="2" colspan="1">Amon et al. (<xref rid="B58" ref-type="bibr">58</xref>)</td><td align="left" valign="top" rowspan="2" colspan="1">Pregnant women</td><td align="left" valign="top" rowspan="2" colspan="1">19</td><td align="left" valign="top" rowspan="2" colspan="1">29 &#177; 9</td><td align="left" valign="top" rowspan="2" colspan="1">PO</td><td align="left" valign="top" rowspan="2" colspan="1">Tablet</td><td align="left" valign="top" rowspan="2" colspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">1,000</td><td align="left" valign="top" rowspan="2" colspan="1">Single</td><td align="left" valign="top" rowspan="2" colspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">250</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">29</td><td align="left" valign="top" colspan="1" rowspan="1">Bergan et al. (<xref rid="B30" ref-type="bibr">30</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Patients with enteric disease</td><td align="left" valign="top" colspan="1" rowspan="1">34</td><td align="left" valign="top" colspan="1" rowspan="1">30&#8211;62</td><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">Tablet</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">500</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">TLC-densitometry</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">30</td><td align="left" valign="top" rowspan="2" colspan="1">Kim and Park (<xref rid="B59" ref-type="bibr">59</xref>)</td><td align="left" valign="top" rowspan="2" colspan="1">Healthy</td><td align="left" valign="top" rowspan="2" colspan="1">12</td><td align="left" valign="top" rowspan="2" colspan="1">22&#8211;30</td><td align="left" valign="top" rowspan="2" colspan="1">PO</td><td align="left" valign="top" rowspan="2" colspan="1">Tablet</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">500</td><td align="left" valign="top" rowspan="2" colspan="1">TID</td><td align="left" valign="top" rowspan="2" colspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">FEXO</td><td align="left" valign="top" colspan="1" rowspan="1">120</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">31</td><td align="left" valign="top" colspan="1" rowspan="1">Hanifah and Mustofa (<xref rid="B60" ref-type="bibr">60</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Healthy men and women</td><td align="left" valign="top" colspan="1" rowspan="1">12</td><td align="left" valign="top" colspan="1" rowspan="1">20&#8211;40</td><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">Tablet</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">500</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC-UV</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">32</td><td align="left" valign="top" colspan="1" rowspan="1">Lares-Asseff et al. (<xref rid="B61" ref-type="bibr">61</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Malnourished children</td><td align="left" valign="top" colspan="1" rowspan="1">20</td><td align="left" valign="top" colspan="1" rowspan="1">3&#8211;43<xref rid="T1_FN3" ref-type="table-fn"><sup><italic toggle="yes">c</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">Suspension</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">30<xref rid="T1_FN3" ref-type="table-fn"><sup><italic toggle="yes">c</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">33</td><td align="left" valign="top" colspan="1" rowspan="1">Ljungberg et al. (<xref rid="B62" ref-type="bibr">62</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Severely ill patients</td><td align="left" valign="top" colspan="1" rowspan="1">11</td><td align="left" valign="top" colspan="1" rowspan="1">32&#8211;74</td><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">Infusion</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">500</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">34</td><td align="left" valign="top" colspan="1" rowspan="1">Farre et al. (<xref rid="B63" ref-type="bibr">63</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Hepatic dysfunction</td><td align="left" valign="top" colspan="1" rowspan="1">19</td><td align="left" valign="top" colspan="1" rowspan="1">33&#8211;68</td><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">Infusion</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">8<xref rid="T1_FN3" ref-type="table-fn"><sup><italic toggle="yes">c</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">35</td><td align="left" valign="top" rowspan="2" colspan="1">Loft et al. (<xref rid="B64" ref-type="bibr">64</xref>)</td><td align="left" valign="top" rowspan="2" colspan="1">Healthy</td><td align="left" valign="top" rowspan="2" colspan="1">6</td><td align="left" valign="top" rowspan="2" colspan="1">26&#8211;39</td><td align="left" valign="top" rowspan="2" colspan="1">PO</td><td align="left" valign="top" rowspan="2" colspan="1">Tablet</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">250</td><td align="left" valign="top" colspan="1" rowspan="1">BID</td><td align="left" valign="top" rowspan="2" colspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Cimetidine</td><td align="left" valign="top" colspan="1" rowspan="1">200</td><td align="left" valign="top" colspan="1" rowspan="1">TID</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">36</td><td align="left" valign="top" colspan="1" rowspan="1">Somogyi et al. (<xref rid="B65" ref-type="bibr">65</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Renal failure</td><td align="left" valign="top" colspan="1" rowspan="1">6</td><td align="left" valign="top" colspan="1" rowspan="1">18&#8211;60</td><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">Infusion</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">500</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">37</td><td align="left" valign="top" colspan="1" rowspan="1">Kurji et al. (<xref rid="B66" ref-type="bibr">66</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Diabetics</td><td align="left" valign="top" colspan="1" rowspan="1">24</td><td align="left" valign="top" colspan="1" rowspan="1">55 &#177; 10</td><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">Tablet</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">500</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">38</td><td align="left" valign="top" colspan="1" rowspan="1">Jager-Roman et al. (<xref rid="B67" ref-type="bibr">67</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Infants</td><td align="left" valign="top" colspan="1" rowspan="1">11</td><td align="left" valign="top" colspan="1" rowspan="1">28&#8211;40<xref rid="T1_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">Infusion</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">7.5<xref rid="T1_FN3" ref-type="table-fn"><sup><italic toggle="yes">c</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">39</td><td align="left" valign="top" rowspan="3" colspan="1">Das et al. (<xref rid="B31" ref-type="bibr">31</xref>)</td><td align="left" valign="top" rowspan="3" colspan="1">Healthy</td><td align="left" valign="top" rowspan="3" colspan="1">27</td><td align="left" valign="top" rowspan="3" colspan="1">18&#8211;50</td><td align="left" valign="top" rowspan="3" colspan="1">IV</td><td align="left" valign="top" rowspan="3" colspan="1">Infusion</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">500</td><td align="left" valign="top" rowspan="3" colspan="1">QD</td><td align="left" valign="top" rowspan="3" colspan="1">UPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">AVI</td><td align="left" valign="top" colspan="1" rowspan="1">500</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">CAZ</td><td align="left" valign="top" colspan="1" rowspan="1">2,000</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">40</td><td align="left" valign="top" rowspan="2" colspan="1">David et al. (<xref rid="B68" ref-type="bibr">68</xref>)</td><td align="left" valign="top" rowspan="2" colspan="1">Healthy</td><td align="left" valign="top" rowspan="2" colspan="1">14</td><td align="left" valign="top" rowspan="2" colspan="1">19&#8211;35</td><td align="left" valign="top" rowspan="2" colspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">Tablet</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">400</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" rowspan="2" colspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Capsule</td><td align="left" valign="top" colspan="1" rowspan="1">OMEP</td><td align="left" valign="top" colspan="1" rowspan="1">20</td><td align="left" valign="top" colspan="1" rowspan="1">BID</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">41</td><td align="left" valign="top" rowspan="2" colspan="1">Goddard et al. (<xref rid="B69" ref-type="bibr">69</xref>)</td><td align="left" valign="top" rowspan="2" colspan="1">Healthy</td><td align="left" valign="top" rowspan="2" colspan="1">24</td><td align="left" valign="top" rowspan="2" colspan="1">19&#8211;37</td><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">Infusion</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">500</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" rowspan="2" colspan="1">Bioassay</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">Capsule</td><td align="left" valign="top" colspan="1" rowspan="1">OMEP</td><td align="left" valign="top" colspan="1" rowspan="1">40</td><td align="left" valign="top" colspan="1" rowspan="1">BID</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">42</td><td align="left" valign="top" rowspan="2" colspan="1">Calafatti et al. (<xref rid="B70" ref-type="bibr">70</xref>)</td><td align="left" valign="top" rowspan="2" colspan="1"><italic toggle="yes">H. pylori</italic><sup>+</sup> patients</td><td align="left" valign="top" rowspan="2" colspan="1">28</td><td align="left" valign="top" rowspan="2" colspan="1">19 &#177; 35</td><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">Infusion</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">500</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" rowspan="2" colspan="1">HPLC-LC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">Capsules</td><td align="left" valign="top" colspan="1" rowspan="1">OMEP</td><td align="left" valign="top" colspan="1" rowspan="1">20</td><td align="left" valign="top" colspan="1" rowspan="1">BID</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">43</td><td align="left" valign="top" rowspan="2" colspan="1">Houghton et al. (<xref rid="B71" ref-type="bibr">71</xref>)</td><td align="left" valign="top" rowspan="2" colspan="1">Healthy</td><td align="left" valign="top" rowspan="2" colspan="1">19</td><td align="left" valign="top" rowspan="2" colspan="1">19&#8211;50</td><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">Infusion</td><td align="left" valign="top" rowspan="2" colspan="1">MTZ</td><td align="left" valign="top" rowspan="2" colspan="1">500</td><td align="left" valign="top" rowspan="2" colspan="1">Single</td><td align="left" valign="top" rowspan="2" colspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">Tablet</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">44</td><td align="left" valign="top" rowspan="2" colspan="1">Obodozie et al. (<xref rid="B32" ref-type="bibr">32</xref>)</td><td align="left" valign="top" rowspan="2" colspan="1">Healthy</td><td align="left" valign="top" rowspan="2" colspan="1">11</td><td align="left" valign="top" rowspan="2" colspan="1">20&#8211;45</td><td align="left" valign="top" rowspan="2" colspan="1">PO</td><td align="left" valign="top" rowspan="2" colspan="1">Tablet</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">400</td><td align="left" valign="top" rowspan="2" colspan="1">Single</td><td align="left" valign="top" rowspan="2" colspan="1">LC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">NIPRD-AM1</td><td align="left" valign="top" colspan="1" rowspan="1">500</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">45</td><td align="left" valign="top" rowspan="2" colspan="1">Rajnarayana et al. (<xref rid="B72" ref-type="bibr">72</xref>)</td><td align="left" valign="top" rowspan="2" colspan="1">Healthy</td><td align="left" valign="top" rowspan="2" colspan="1">12</td><td align="left" valign="top" rowspan="2" colspan="1">20&#8211;30</td><td align="left" valign="top" rowspan="2" colspan="1">PO</td><td align="left" valign="top" rowspan="2" colspan="1">Tablet</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">800</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" rowspan="2" colspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Diosmin</td><td align="left" valign="top" colspan="1" rowspan="1">500</td><td align="left" valign="top" colspan="1" rowspan="1">QD</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">46</td><td align="left" valign="top" rowspan="2" colspan="1">Rajnarayana et al. (<xref rid="B73" ref-type="bibr">73</xref>)</td><td align="left" valign="top" rowspan="2" colspan="1">Healthy</td><td align="left" valign="top" rowspan="2" colspan="1">12</td><td align="left" valign="top" rowspan="2" colspan="1">23&#8211;30</td><td align="left" valign="top" rowspan="2" colspan="1">PO</td><td align="left" valign="top" rowspan="2" colspan="1">Tablet</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">400</td><td align="left" valign="top" colspan="1" rowspan="1">TID</td><td align="left" valign="top" rowspan="2" colspan="1">HPLC-LC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">SIL</td><td align="left" valign="top" colspan="1" rowspan="1">140</td><td align="left" valign="top" colspan="1" rowspan="1">QD</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">47</td><td align="left" valign="top" colspan="1" rowspan="1">Melande et al. (<xref rid="B74" ref-type="bibr">74</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1">10</td><td align="left" valign="top" colspan="1" rowspan="1">25&#8211;35</td><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">Tablet</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">400</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">Bioassay</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">48</td><td align="left" valign="top" colspan="1" rowspan="1">Wang et al. (<xref rid="B75" ref-type="bibr">75</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Pregnant women</td><td align="left" valign="top" colspan="1" rowspan="1">20</td><td align="left" valign="top" colspan="1" rowspan="1">&#8805;18</td><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">Tablet</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">250</td><td align="left" valign="top" colspan="1" rowspan="1">BID</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">49</td><td align="left" valign="top" rowspan="2" colspan="1">Wang et al. (<xref rid="B76" ref-type="bibr">76</xref>)</td><td align="left" valign="top" rowspan="2" colspan="1">Healthy</td><td align="left" valign="top" rowspan="2" colspan="1">10</td><td align="left" valign="top" rowspan="2" colspan="1">22&#8211;27</td><td align="left" valign="top" rowspan="2" colspan="1">PO</td><td align="left" valign="top" rowspan="2" colspan="1">Tablet</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">400</td><td align="left" valign="top" colspan="1" rowspan="1">BID</td><td align="left" valign="top" rowspan="2" colspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">MDZ</td><td align="left" valign="top" colspan="1" rowspan="1">15</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">50</td><td align="left" valign="top" rowspan="2" colspan="1">Pierce et al. (<xref rid="B77" ref-type="bibr">77</xref>)</td><td align="left" valign="top" rowspan="2" colspan="1">Healthy</td><td align="left" valign="top" rowspan="2" colspan="1">29</td><td align="left" valign="top" rowspan="2" colspan="1">18&#8211;55</td><td align="left" valign="top" rowspan="2" colspan="1">PO</td><td align="left" valign="top" rowspan="2" colspan="1">Tablet</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">750</td><td align="left" valign="top" colspan="1" rowspan="1">BID</td><td align="left" valign="top" rowspan="2" colspan="1">LCMS</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">MMX</td><td align="left" valign="top" colspan="1" rowspan="1">4,800</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">51</td><td align="left" valign="top" rowspan="2" colspan="1">Jessa et al. (<xref rid="B78" ref-type="bibr">78</xref>)</td><td align="left" valign="top" rowspan="2" colspan="1">Healthy</td><td align="left" valign="top" rowspan="2" colspan="1">8</td><td align="left" valign="top" rowspan="2" colspan="1">19&#8211;25</td><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">Infusion</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">500</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" rowspan="2" colspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">Capsule</td><td align="left" valign="top" colspan="1" rowspan="1">OMEP</td><td align="left" valign="top" colspan="1" rowspan="1">40</td><td align="left" valign="top" colspan="1" rowspan="1">BID</td></tr><tr><td align="left" valign="top" rowspan="4" colspan="1">52</td><td align="left" valign="top" rowspan="4" colspan="1">Mattila et al. (<xref rid="B79" ref-type="bibr">79</xref>)</td><td align="left" valign="top" rowspan="4" colspan="1">Healthy</td><td align="left" valign="top" rowspan="4" colspan="1">5</td><td align="left" valign="top" rowspan="4" colspan="1">22&#8211;23</td><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">Infusion</td><td align="left" valign="top" rowspan="4" colspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">500</td><td align="left" valign="top" rowspan="4" colspan="1">Single</td><td align="left" valign="top" rowspan="4" colspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">Tablet</td><td align="left" valign="top" colspan="1" rowspan="1">500</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">PR</td><td align="left" valign="top" colspan="1" rowspan="1">SUP</td><td align="left" valign="top" colspan="1" rowspan="1">1,000</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">VAG</td><td align="left" valign="top" colspan="1" rowspan="1">Pessary</td><td align="left" valign="top" colspan="1" rowspan="1">500</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">53</td><td align="left" valign="top" colspan="1" rowspan="1">Mattie et al. (<xref rid="B80" ref-type="bibr">80</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Patients with mixed infection</td><td align="left" valign="top" colspan="1" rowspan="1">15</td><td align="left" valign="top" colspan="1" rowspan="1">16&#8211;76</td><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">Tablet</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">500</td><td align="left" valign="top" colspan="1" rowspan="1">TID</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">54</td><td align="left" valign="top" colspan="1" rowspan="1">Ventura Cerd&#225; et al. (<xref rid="B81" ref-type="bibr">81</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Patient undergoing Colorectal Surgery</td><td align="left" valign="top" colspan="1" rowspan="1">36</td><td align="left" valign="top" colspan="1" rowspan="1">&gt;18</td><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">Infusion</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">1,500</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">55</td><td align="left" valign="top" colspan="1" rowspan="1">Hamberg et al. (<xref rid="B82" ref-type="bibr">82</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1">9</td><td align="left" valign="top" colspan="1" rowspan="1">21&#8211;29</td><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">Tablet</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">500</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">56</td><td align="left" valign="top" rowspan="3" colspan="1">Sprandel et al. (<xref rid="B83" ref-type="bibr">83</xref>)</td><td align="left" valign="top" rowspan="3" colspan="1">Healthy</td><td align="left" valign="top" rowspan="3" colspan="1">18</td><td align="left" valign="top" rowspan="3" colspan="1">18&#8211;45</td><td align="left" valign="top" rowspan="3" colspan="1">IV</td><td align="left" valign="top" rowspan="3" colspan="1">Infusion</td><td align="left" valign="top" rowspan="3" colspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">500</td><td align="left" valign="top" rowspan="3" colspan="1">Single</td><td align="left" valign="top" rowspan="3" colspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">1,000</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">1,500</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">57</td><td align="left" valign="top" colspan="1" rowspan="1">Wu et al. (<xref rid="B84" ref-type="bibr">84</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1">12</td><td align="left" valign="top" colspan="1" rowspan="1">23&#8211;30</td><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">Tab</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">125</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">LCMS</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">58</td><td align="left" valign="top" colspan="1" rowspan="1">Salas-Herrera et al. (<xref rid="B85" ref-type="bibr">85</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1">12</td><td align="left" valign="top" colspan="1" rowspan="1">22&#8211;31</td><td align="left" valign="top" colspan="1" rowspan="1">VAG</td><td align="left" valign="top" colspan="1" rowspan="1">Pessary</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">500</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">59</td><td align="left" valign="top" rowspan="3" colspan="1">Bergan and Arnold (<xref rid="B15" ref-type="bibr">15</xref>)</td><td align="left" valign="top" rowspan="3" colspan="1">Healthy</td><td align="left" valign="top" rowspan="3" colspan="1">10</td><td align="left" valign="top" rowspan="3" colspan="1">17&#8211;29</td><td align="left" valign="top" rowspan="3" colspan="1">PR</td><td align="left" valign="top" rowspan="3" colspan="1">Suppository<break/>Tab</td><td align="left" valign="top" rowspan="3" colspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">500</td><td align="left" valign="top" rowspan="3" colspan="1">Single</td><td align="left" valign="top" rowspan="3" colspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">1,000</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">2,000</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">60</td><td align="left" valign="top" colspan="1" rowspan="1">Fredricsson et al. (<xref rid="B86" ref-type="bibr">86</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1">5</td><td align="left" valign="top" colspan="1" rowspan="1">21&#8211;24</td><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">Tab</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">400</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">61</td><td align="left" valign="top" colspan="1" rowspan="1">Roux et al. (<xref rid="B87" ref-type="bibr">87</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Renal impairment</td><td align="left" valign="top" colspan="1" rowspan="1">9</td><td align="left" valign="top" colspan="1" rowspan="1">58&#8211;79</td><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">Infusion</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">525</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">62</td><td align="left" valign="top" colspan="1" rowspan="1">Houghton et al. (<xref rid="B88" ref-type="bibr">88</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1">3</td><td align="left" valign="top" colspan="1" rowspan="1">21&#8211;33</td><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">Tab</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">400</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">63</td><td align="left" valign="top" colspan="1" rowspan="1">Loft et al. (<xref rid="B89" ref-type="bibr">89</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1">8</td><td align="left" valign="top" colspan="1" rowspan="1">30 &#177; 6</td><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">Infusion</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">2,000</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">64</td><td align="left" valign="top" colspan="1" rowspan="1">Cunningham et al. (<xref rid="B90" ref-type="bibr">90</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1">12</td><td align="left" valign="top" colspan="1" rowspan="1">24&#8211;35</td><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">Tab</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">500</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">65</td><td align="left" valign="top" colspan="1" rowspan="1">Lau et al. (<xref rid="B91" ref-type="bibr">91</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1">9</td><td align="left" valign="top" colspan="1" rowspan="1">&#8805;18</td><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">Infusion</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">2,000</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">66</td><td align="left" valign="top" rowspan="2" colspan="1">Amon et al. (<xref rid="B92" ref-type="bibr">92</xref>)</td><td align="left" valign="top" rowspan="2" colspan="1">Healthy</td><td align="left" valign="top" rowspan="2" colspan="1">27</td><td align="left" valign="top" rowspan="2" colspan="1">&#8805;18</td><td align="left" valign="top" rowspan="2" colspan="1">PO</td><td align="left" valign="top" rowspan="2" colspan="1">Tab</td><td align="left" valign="top" rowspan="2" colspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">250</td><td align="left" valign="top" rowspan="2" colspan="1">Single</td><td align="left" valign="top" rowspan="2" colspan="1">Polar</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">1,000</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">67</td><td align="left" valign="top" colspan="1" rowspan="1">Alper et al. (<xref rid="B93" ref-type="bibr">93</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1">9</td><td align="left" valign="top" colspan="1" rowspan="1">&#8805;18</td><td align="left" valign="top" colspan="1" rowspan="1">VAG</td><td align="left" valign="top" colspan="1" rowspan="1">Cream</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">500</td><td align="left" valign="top" colspan="1" rowspan="1">Single</td><td align="left" valign="top" colspan="1" rowspan="1">HPLC</td></tr></tbody></table><table-wrap-foot><fn id="T1_FN1"><label>
<sup>
<italic toggle="yes">a</italic>
</sup>
</label><p>number.</p></fn><fn id="T1_FN2"><label>
<sup>
<italic toggle="yes">b</italic>
</sup>
</label><p>weeks.</p></fn><fn id="T1_FN3"><label>
<sup>
<italic toggle="yes">c</italic>
</sup>
</label><p>months.</p></fn><fn id="T1_FN4"><label>
<sup>
<italic toggle="yes">d</italic>
</sup>
</label><p>mg/kg.</p></fn><fn id="T1_FN5"><label>
<sup>
<italic toggle="yes">e</italic>
</sup>
</label><p>ALP: alprazolam, AMOX: amoxicillin, AVI: avibactam, BDS: budesonide, BID: twice a day, CAZ: ceftazidime, FEXO: fexofenadine, HPLC: high-performance liquid chromatography, IP: Intraperitoneal, IV: intravenous, LC: liquid chromatography, LCMS: liquid chromatography-mass spectrometry, LRP: lorazepam, MDZ: midazolam, MMX: mesalamine, MTZ: metronidazole, OMEP: omeprazole, PHT: phenytoin, PO: per oral, PR: per rectal, QD: every day, QID: four times a day, SIL: silymarin, TID: thrice a day, TLC: thin layer chromatography, UPLC: ultra-performance liquid chromatography, UV: ultraviolet spectroscopy, VAG: Intravaginal, VPZ: vonoprazan.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-4"><title>Quality assessment of selected literature</title><p>First, the quality of the retrieved studies was evaluated by the Jadad tool, a 5-item checklist, by checking the presence of randomization, blinding, and dropping out information of participants. Studies were considered high, moderate, and low quality if they scored &gt;4, 3&#8211;4, and &lt;3, respectively (<xref rid="B94" ref-type="bibr">94</xref>, <xref rid="B95" ref-type="bibr">95</xref>). After that, studies were screened by using the Critical Appraisal Skills Programme (CASP), a 10-item checklist, to check the transparency of research practice, wherein a score of &gt;6 shows high quality, 4&#8211;6 suggests moderate quality, and &lt;4 indicates low quality (<xref rid="B96" ref-type="bibr">96</xref>, <xref rid="B97" ref-type="bibr">97</xref>). Then the quality of included studies was assessed by using a 21-item checklist, the Critical Appraisal Clinical Pharmacokinetic Tool (CACPK), according to which studies were categorized as high, fair to moderate, and low-quality studies with scores &gt;13, 12&#8211;13, and &lt;12, respectively (<xref rid="B98" ref-type="bibr">98</xref>). The risk of bias was additionally assessed with the Cochrane Collaboration Tool (CCT), and according to this, studies with scores of &lt;3, 3&#8210;4, and &gt;4 were classified as having a high, moderate, and low risk of bias, respectively (<xref rid="B99" ref-type="bibr">99</xref>, <xref rid="B100" ref-type="bibr">100</xref>).</p></sec><sec id="s2-5"><title>Statistical analysis</title><p>The meta-analysis was conducted by using R programming language and employing the &#8220;metafor&#8221; package (<xref rid="B101" ref-type="bibr">101</xref>). The random-effect model was used in this meta-analysis, and heterogeneity was assessed with the I-squared statistic (<italic toggle="yes">I</italic>&#178;) (<xref rid="B102" ref-type="bibr">102</xref>). For the visual display of individual studies and pooled results, the forest plots were constructed. Not all studies were considered in the meta-analysis. Only those studies that provided the required quantitative information, such as sample size, mean, and standard deviation (SD) of AUC were included. The studies with insufficient data were only evaluated qualitatively in the systematic review.</p></sec></sec><sec sec-type="results" id="s3"><title>RESULTS</title><sec id="s3-1"><title>Results of the literature review</title><p>A total of 1,882 studies were identified after an extensive database search, of which 436 were duplicates. The remaining 1,446 studies were further screened; as a result, 67 were included in this review, and 1,379 that did not meet eligibility criteria were excluded. The details are presented in <xref rid="F2" ref-type="fig">Fig. 2</xref>.</p><fig position="float" fig-type="figure" id="F2" orientation="portrait"><label>Fig 2</label><caption><p>PRISMA flow diagram.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.01904-24.f002.jpg"><alt-text>PRISMA flow diagram summarizing study selection: 1882 articles identified, 436 removed as duplicates, 1446 screened, 739 full texts assessed, and 67 studies included in the final systematic review.</alt-text></graphic></fig></sec><sec id="s3-2"><title>Characteristics of finalized studies</title><p>The characteristics of included studies are reported in <xref rid="T1" ref-type="table">Table 1</xref> covering authors' names, population, number and age of participants, drug used, dosage form, dose and frequency, mode of administration, and assay technique.</p></sec><sec id="s3-3"><title>Quality evaluation of included literature</title><p>The quality of 67 studies was assessed by the Jadad scoring tool, CASP, CACPK, and CCT. According to Jadad scoring, 62 studies were of low quality and 5 studies were of moderate quality (<xref rid="SuF1" ref-type="supplementary-material">Table S2</xref>). Similarly, according to the CASP, 3 studies were of moderate quality and 64 studies were of high quality (<xref rid="SuF1" ref-type="supplementary-material">Table S3</xref>). The CACPK enlisted 3 studies of fair-moderate quality and 64 studies of high quality (<xref rid="SuF1" ref-type="supplementary-material">Table S4</xref>). The risk of bias was high, moderate, and low for 9, 35, and 23 studies, respectively, according to the CCT (<xref rid="SuF1" ref-type="supplementary-material">Table S5</xref>).</p></sec><sec id="s3-4"><title>PK of MTZ in healthy population</title><sec id="s3-4-1"><title>IV administration of MTZ</title><p>Out of total 67 studies reviewed, 9 were conducted in a healthy population after IV administration of MTZ. The reported AUC<sub>0&#8211;24</sub> and <italic toggle="yes">t</italic><sub>1/2</sub> in a study were 81.4 &#177; 27 &#181;g.h/mL and 7.4 &#177; 2.2 h, respectively, following 500 mg IV administration of MTZ (<xref rid="B50" ref-type="bibr">50</xref>). One study has stated a decrease in Cl<sub>R</sub> among the elderly population compared to the young individuals, that is, 87 &#177; 15 mL/min versus 73 &#177; 30 mL/min (<xref rid="B47" ref-type="bibr">47</xref>). In a research study, the reported <italic toggle="yes">C</italic><sub>max</sub> in saliva and plasma were 11.8 &#177; 7.9 &#181;g/mL and 11.3 &#177; 2.06 &#181;g/ml, respectively (<xref rid="B6" ref-type="bibr">6</xref>). The reported Cl<sub>T</sub> was 72 &#177; 16 and 80.1 &#177; 5.2 mL/min in two studies after administering a dose of 500 mg (<xref rid="B50" ref-type="bibr">50</xref>, <xref rid="B79" ref-type="bibr">79</xref>). Another study has depicted higher AUC<sub>0&#8211;&#8734;</sub> via the IV route in comparison to the oral one, that is, 159 &#177; 48 and 151 &#177;42 ug.h/mL, respectively (<xref rid="B71" ref-type="bibr">71</xref>). An increase in <italic toggle="yes">C</italic><sub>max</sub> from 22.2 &#177; 5.0 to 37.7 &#177; 10 &#181;g/mL was recorded in a study when a dose of MTZ was increased from 500 to 1,500 mg (<xref rid="B83" ref-type="bibr">83</xref>). Other PK parameters are given in <xref rid="T2" ref-type="table">Table 2</xref>.</p><table-wrap position="float" id="T2" orientation="portrait"><label>TABLE 2</label><caption><p>Pharmacokinetic parameters of metronidazole in healthy population<xref rid="T2_FN7" ref-type="table-fn"><sup><italic toggle="yes">g</italic></sup></xref></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" valign="top" colspan="1" rowspan="1">Sr. No.</th><th align="left" valign="top" colspan="1" rowspan="1">Authors</th><th align="left" valign="top" colspan="1" rowspan="1">Population</th><th align="left" valign="top" colspan="1" rowspan="1"/><th align="left" valign="top" colspan="1" rowspan="1">ROA</th><th align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">V</italic><sub>d</sub><break/>(L)</th><th align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">t</italic><sub>1/2</sub><break/>(h)</th><th align="left" valign="top" colspan="1" rowspan="1">AUC<sub>0&#8211;&#8734;</sub><break/>(&#181;g&#183;h/mL)</th><th align="left" valign="top" colspan="1" rowspan="1">Cl<sub>T</sub><break/>(mL/min)</th><th align="left" valign="top" colspan="1" rowspan="1">Cl<sub>R</sub><break/>(mL/min)</th><th align="left" valign="top" colspan="1" rowspan="1">C<sub>max</sub><break/>(&#181;g/mL)</th><th align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">T</italic><sub>max</sub><break/>(h)</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="1" rowspan="1">1</td><td align="left" valign="top" colspan="1" rowspan="1">Houghton et al. (<xref rid="B7" ref-type="bibr">7</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">43 &#177; 6.1</td><td align="left" valign="top" colspan="1" rowspan="1">7.0 &#177; 0.80</td><td align="left" valign="top" colspan="1" rowspan="1">123 &#177; 35</td><td align="left" valign="top" colspan="1" rowspan="1">72 &#177; 16</td><td align="left" valign="top" colspan="1" rowspan="1">6.8 &#177; 2.5</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">2</td><td align="left" valign="top" colspan="1" rowspan="1">Muscar&#225; et al.. (<xref rid="B50" ref-type="bibr">50</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">0.80 &#177; 0.32<xref rid="T2_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">7.4 &#177; 2.2</td><td align="left" valign="top" colspan="1" rowspan="1">81.4 &#177; 27<xref rid="T2_FN4" ref-type="table-fn"><sup><italic toggle="yes">d</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">1.53 &#177; 0.37<xref rid="T2_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">3</td><td align="left" valign="top" colspan="1" rowspan="1">Ljungberg et al. (<xref rid="B62" ref-type="bibr">62</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">6.1</td><td align="left" valign="top" colspan="1" rowspan="1">85.0</td><td align="left" valign="top" colspan="1" rowspan="1">117.1<xref rid="T2_FN3" ref-type="table-fn"><sup><italic toggle="yes">c</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">4</td><td align="left" valign="top" rowspan="2" colspan="1">Loft et al. (<xref rid="B47" ref-type="bibr">47</xref>)</td><td align="left" valign="top" rowspan="2" colspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1">Elder</td><td align="left" valign="top" rowspan="2" colspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">47 &#177; 16</td><td align="left" valign="top" colspan="1" rowspan="1">7.8 &#177; 1.9</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">1.20 &#177; 0.53<xref rid="T2_FN3" ref-type="table-fn"><sup><italic toggle="yes">c</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">73 &#177; 30</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Young</td><td align="left" valign="top" colspan="1" rowspan="1">54 &#177; 6</td><td align="left" valign="top" colspan="1" rowspan="1">7.2 &#177; 0.9</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">1.25 &#177; 0.22<xref rid="T2_FN3" ref-type="table-fn"><sup><italic toggle="yes">c</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">87 &#177; 15</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">5</td><td align="left" valign="top" colspan="1" rowspan="1">Jensen and Gugler (<xref rid="B48" ref-type="bibr">48</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">1.052 &#177; 0.14<xref rid="T2_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">8.3 &#177; 0.4</td><td align="left" valign="top" colspan="1" rowspan="1">81.61 &#177; 8.12</td><td align="left" valign="top" colspan="1" rowspan="1">1.306 &#177; 0.1<xref rid="T2_FN3" ref-type="table-fn"><sup><italic toggle="yes">c</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">6</td><td align="left" valign="top" rowspan="2" colspan="1">Houghton et al. (<xref rid="B71" ref-type="bibr">71</xref>)</td><td align="left" valign="top" rowspan="2" colspan="1">Healthy</td><td align="left" valign="top" rowspan="2" colspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">36 &#177; 7.9</td><td align="left" valign="top" colspan="1" rowspan="1">7.3 &#177; 1.0</td><td align="left" valign="top" colspan="1" rowspan="1">151 &#177; 42</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">34 &#177; 8.2</td><td align="left" valign="top" colspan="1" rowspan="1">7.0 &#177; 1.1</td><td align="left" valign="top" colspan="1" rowspan="1">159 &#177; 48</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">7</td><td align="left" valign="top" colspan="1" rowspan="1">Mattila et al. (<xref rid="B79" ref-type="bibr">79</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">53.2 &#177; 1.2</td><td align="left" valign="top" colspan="1" rowspan="1">7.9 &#177; 0.6</td><td align="left" valign="top" colspan="1" rowspan="1">106.9 &#177; 10.7</td><td align="left" valign="top" colspan="1" rowspan="1">80.1 &#177; 5.2</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">9.4 &#177; 0.5</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">8</td><td align="left" valign="top" colspan="1" rowspan="1">Loft et al. (<xref rid="B89" ref-type="bibr">89</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">50 &#177; 8</td><td align="left" valign="top" colspan="1" rowspan="1">7.7 &#177; 1.7</td><td align="left" valign="top" colspan="1" rowspan="1">447 &#177; 67</td><td align="left" valign="top" colspan="1" rowspan="1">74 &#177; 12</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">9</td><td align="left" valign="top" rowspan="3" colspan="1">Sprandel et al. (<xref rid="B83" ref-type="bibr">83</xref>)</td><td align="left" valign="top" rowspan="3" colspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1">500</td><td align="left" valign="top" rowspan="3" colspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">49.2 &#177; 12</td><td align="left" valign="top" colspan="1" rowspan="1">8.0 &#177; 1.3</td><td align="left" valign="top" colspan="1" rowspan="1">356 &#177; 68<xref rid="T2_FN6" ref-type="table-fn"><sup><italic toggle="yes">f</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">62 &#177; 7</td><td align="left" valign="top" colspan="1" rowspan="1">11 &#177; 3</td><td align="left" valign="top" colspan="1" rowspan="1">22.2 &#177; 5.0</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">1,000</td><td align="left" valign="top" colspan="1" rowspan="1">59 &#177; 10</td><td align="left" valign="top" colspan="1" rowspan="1">9.2 &#177; 1.5</td><td align="left" valign="top" colspan="1" rowspan="1">227 &#177; 57<xref rid="T2_FN6" ref-type="table-fn"><sup><italic toggle="yes">f</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">67 &#177; 13</td><td align="left" valign="top" colspan="1" rowspan="1">12 &#177; 2</td><td align="left" valign="top" colspan="1" rowspan="1">24.8 &#177; 6.8</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">1,500</td><td align="left" valign="top" colspan="1" rowspan="1">62.5 &#177; 11</td><td align="left" valign="top" colspan="1" rowspan="1">9.8 &#177; 1.5</td><td align="left" valign="top" colspan="1" rowspan="1">338 &#177; 105<xref rid="T2_FN6" ref-type="table-fn"><sup><italic toggle="yes">f</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">67 &#177; 14</td><td align="left" valign="top" colspan="1" rowspan="1">12 &#177; 5</td><td align="left" valign="top" colspan="1" rowspan="1">37.7 &#177; 10</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">10</td><td align="left" valign="top" rowspan="2" colspan="1">Lau et al. (<xref rid="B91" ref-type="bibr">91</xref>)</td><td align="left" valign="top" rowspan="2" colspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1">2,000</td><td align="left" valign="top" rowspan="2" colspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">250</td><td align="left" valign="top" colspan="1" rowspan="1">0.67<xref rid="T2_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">6.0 &#177; 1.3</td><td align="left" valign="top" colspan="1" rowspan="1">48.4 &#177; 19.3</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">250</td><td align="left" valign="top" colspan="1" rowspan="1">2,000</td><td align="left" valign="top" colspan="1" rowspan="1">0.58<xref rid="T2_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">8.8 &#177; 1.2</td><td align="left" valign="top" colspan="1" rowspan="1">532.2 &#177; 104.3</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">11</td><td align="left" valign="top" colspan="1" rowspan="1">Ashiq et al. (<xref rid="B51" ref-type="bibr">51</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">0.8544 &#177; 0.09<sup>*</sup></td><td align="left" valign="top" colspan="1" rowspan="1">7.782 &#177; 0.78</td><td align="left" valign="top" colspan="1" rowspan="1">103.17 &#177; 6.25</td><td align="left" valign="top" colspan="1" rowspan="1">1.27 &#177; 0.13<xref rid="T2_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">8.041 &#177; 0.4</td><td align="left" valign="top" colspan="1" rowspan="1">1.7 &#177; 0.06</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">12</td><td align="left" valign="top" colspan="1" rowspan="1">Farre et al. (<xref rid="B63" ref-type="bibr">63</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">0.48 &#177; 0.03<xref rid="T2_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">7.9 &#177; 0.7</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">51.9 &#177; 8.7</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">13</td><td align="left" valign="top" rowspan="3" colspan="1">Bergan et al. (<xref rid="B30" ref-type="bibr">30</xref>)</td><td align="left" valign="top" rowspan="3" colspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1">250</td><td align="left" valign="top" rowspan="3" colspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">9.99 &#177; 6.11</td><td align="left" valign="top" colspan="1" rowspan="1">47.40 &#177; 16.57</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">500</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">9.67 &#177; 1.79</td><td align="left" valign="top" colspan="1" rowspan="1">113.54 &#177; 35.45</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">1,000</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">9.31 &#177; 2.15</td><td align="left" valign="top" colspan="1" rowspan="1">214.04 &#177; 35.45</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">14</td><td align="left" valign="top" colspan="1" rowspan="1">Kurji et al. (<xref rid="B66" ref-type="bibr">66</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">10.03 &#177; 2.57</td><td align="left" valign="top" colspan="1" rowspan="1">50.30 &#177; 10.73</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">7.58 &#177; 0.38</td><td align="left" valign="top" colspan="1" rowspan="1">1.45 &#177; 0.1</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">15</td><td align="left" valign="top" rowspan="2" colspan="1">de C Bergamaschi et al. (<xref rid="B6" ref-type="bibr">6</xref>)</td><td align="left" valign="top" rowspan="2" colspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1">Plasma</td><td align="left" valign="top" rowspan="2" colspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">0.625 &#177; 0.19<xref rid="T2_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">210.2 &#177; 45.69</td><td align="left" valign="top" colspan="1" rowspan="1">62.5 &#177; 15.54</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">11.3 &#177; 2.06</td><td align="left" valign="top" colspan="1" rowspan="1">1.77 &#177; 0.7</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Saliva</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">124.2 &#177; 64.10</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">11.8 &#177; 7.9</td><td align="left" valign="top" colspan="1" rowspan="1">1.50 &#177; 0.5</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">16</td><td align="left" valign="top" rowspan="2" colspan="1">Jensen and Gugler (<xref rid="B48" ref-type="bibr">48</xref>)</td><td align="left" valign="top" rowspan="2" colspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1">SOD</td><td align="left" valign="top" rowspan="2" colspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">0.960 &#177; 0.08<sup><xref rid="T2_FN1" ref-type="table-fn"><italic toggle="yes">a</italic></xref></sup></td><td align="left" valign="top" colspan="1" rowspan="1">8.4 &#177; 0.4</td><td align="left" valign="top" colspan="1" rowspan="1">79.97 &#177; 6.73</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">6.9 &#177; 0.9</td><td align="left" valign="top" colspan="1" rowspan="1">2.3 &#177; 0.6</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">MOD</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">8.3 &#177; 0.4</td><td align="left" valign="top" colspan="1" rowspan="1">82.31 &#177; 12.65<xref rid="T2_FN5" ref-type="table-fn"><sup><italic toggle="yes">e</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">11.2 &#177; 1.6</td><td align="left" valign="top" colspan="1" rowspan="1">2.1 &#177; 0.3</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">17</td><td align="left" valign="top" rowspan="2" colspan="1">Montalli et al. (<xref rid="B56" ref-type="bibr">56</xref>)</td><td align="left" valign="top" rowspan="2" colspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1">Smoker</td><td align="left" valign="top" rowspan="2" colspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">1.071 &#177; 0.56<xref rid="T2_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">297.2 &#177; 228.4</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">0.91 &#177; 0.5</td><td align="left" valign="top" colspan="1" rowspan="1">9.7 &#177; 2.9</td><td align="left" valign="top" colspan="1" rowspan="1">2.9 &#177; 1.8</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Non-smoker</td><td align="left" valign="top" colspan="1" rowspan="1">0.809 &#177; 0.26<xref rid="T2_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">29.3 &#177; 114.0</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">0.7 &#177; 0.2</td><td align="left" valign="top" colspan="1" rowspan="1">11.9 &#177; 2.0</td><td align="left" valign="top" colspan="1" rowspan="1">1.8 &#177; 0.9</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">18</td><td align="left" valign="top" colspan="1" rowspan="1">Schwartz et al. (<xref rid="B29" ref-type="bibr">29</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1">Males</td><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">83.03 &#177; 11.98</td><td align="left" valign="top" colspan="1" rowspan="1">8.41 &#177; 1.52</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">12.3</td><td align="left" valign="top" colspan="1" rowspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">19</td><td align="left" valign="top" rowspan="2" colspan="1">Hanifah and Mustofa (<xref rid="B60" ref-type="bibr">60</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1">Males</td><td align="left" valign="top" rowspan="2" colspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">79.49 &#177; 5.678</td><td align="left" valign="top" colspan="1" rowspan="1">11.299 &#177; 0.52</td><td align="left" valign="top" colspan="1" rowspan="1">103.81 &#177; 5.14</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">10.36 &#177; 1.3</td><td align="left" valign="top" colspan="1" rowspan="1">0.67 &#177; 0.1</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1">Females</td><td align="left" valign="top" colspan="1" rowspan="1">64.67 &#177; 9.54</td><td align="left" valign="top" colspan="1" rowspan="1">7.41 &#177; 1.24</td><td align="left" valign="top" colspan="1" rowspan="1">84.36 &#177; 10.48</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">6.89 &#177; 0.39</td><td align="left" valign="top" colspan="1" rowspan="1">0.9 &#177; 0.24</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">20</td><td align="left" valign="top" colspan="1" rowspan="1">Houghton et al. (<xref rid="B71" ref-type="bibr">71</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">34 &#177; 8.2</td><td align="left" valign="top" colspan="1" rowspan="1">7.0 &#177; 1.1</td><td align="left" valign="top" colspan="1" rowspan="1">159 &#177; 48</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">21</td><td align="left" valign="top" colspan="1" rowspan="1">Mattila et al. (<xref rid="B79" ref-type="bibr">79</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">8.9 &#177; 0.6</td><td align="left" valign="top" colspan="1" rowspan="1">122.2 &#177; 10.3</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">9.0 &#177; 0.5</td><td align="left" valign="top" colspan="1" rowspan="1">1.9 &#177; 0.2</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">22</td><td align="left" valign="top" rowspan="2" colspan="1">Daneshmend et al. (<xref rid="B45" ref-type="bibr">45</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1">British</td><td align="left" valign="top" rowspan="2" colspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">0.60 &#177; 0.01<xref rid="T2_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">7.4 &#177; 0.3</td><td align="left" valign="top" colspan="1" rowspan="1">114.6 &#177; 7.8</td><td align="left" valign="top" colspan="1" rowspan="1">1.06 &#177; 0.04<xref rid="T2_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1">Sudanese</td><td align="left" valign="top" colspan="1" rowspan="1">0.76 &#177; 0.07<xref rid="T2_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">7.8 &#177; 0.6</td><td align="left" valign="top" colspan="1" rowspan="1">132.2 &#177; 22.0</td><td align="left" valign="top" colspan="1" rowspan="1">1.21 &#177; 0.16<xref rid="T2_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">23</td><td align="left" valign="top" rowspan="2" colspan="1">Dorn et al. (<xref rid="B28" ref-type="bibr">28</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1">Obese</td><td align="left" valign="top" rowspan="2" colspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">73.9 &#177; 10.3</td><td align="left" valign="top" colspan="1" rowspan="1">11.9 &#177; 3.4</td><td align="left" valign="top" colspan="1" rowspan="1">115.8 &#177; 29.0</td><td align="left" valign="top" colspan="1" rowspan="1">77 &#177; 20.3</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">8.99 &#177; 1.05</td><td align="left" valign="top" colspan="1" rowspan="1">0.5</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1">Non-obese</td><td align="left" valign="top" colspan="1" rowspan="1">51.8 &#177; 9.7</td><td align="left" valign="top" colspan="1" rowspan="1">9.08 &#177; 1.85</td><td align="left" valign="top" colspan="1" rowspan="1">126.9 &#177; 29.6</td><td align="left" valign="top" colspan="1" rowspan="1">68.83 &#177; 14.5</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">14.7 &#177; 4.1</td><td align="left" valign="top" colspan="1" rowspan="1">0.5</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">24</td><td align="left" valign="top" colspan="1" rowspan="1">Fredricsson et al. (<xref rid="B86" ref-type="bibr">86</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">0.65 &#177; 0.05<xref rid="T2_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">7.3 &#177; 0.3</td><td align="left" valign="top" colspan="1" rowspan="1">107 &#177; 10.3</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">25</td><td align="left" valign="top" colspan="1" rowspan="1">Houghton et al. (<xref rid="B88" ref-type="bibr">88</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">8.6 &#177; 1.2</td><td align="left" valign="top" colspan="1" rowspan="1">82 &#177; 17</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">13 &#177; 2.8</td><td align="left" valign="top" colspan="1" rowspan="1">0.61 &#177; 0.7</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">26</td><td align="left" valign="top" colspan="1" rowspan="1">Cunningham et al. (<xref rid="B90" ref-type="bibr">90</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">133 &#177; 43</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">12.7 &#177; 19.5</td><td align="left" valign="top" colspan="1" rowspan="1">1.35 &#177; 0.6</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">27</td><td align="left" valign="top" rowspan="2" colspan="1">Amon et al. (<xref rid="B92" ref-type="bibr">92</xref>)</td><td align="left" valign="top" rowspan="2" colspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1">250</td><td align="left" valign="top" rowspan="2" colspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">0.62 &#177; 0.17<xref rid="T2_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">5.92 &#177; 3.93</td><td align="left" valign="top" colspan="1" rowspan="1">50.18 &#177; 29.69</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">1,000</td><td align="left" valign="top" colspan="1" rowspan="1">0.76<xref rid="T2_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">7.8 &#177; 1.3</td><td align="left" valign="top" colspan="1" rowspan="1">281.9 &#177; 75.4</td><td align="left" valign="top" colspan="1" rowspan="1">72.5</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">19.6 &#177; 3.8</td><td align="left" valign="top" colspan="1" rowspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">28</td><td align="left" valign="top" rowspan="2" colspan="1">Salas-Herrera et al. (<xref rid="B85" ref-type="bibr">85</xref>)</td><td align="left" valign="top" rowspan="2" colspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1">Day 1</td><td align="left" valign="top" rowspan="2" colspan="1">VAG</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">6.6 &#177; 2.7<xref rid="T2_FN5" ref-type="table-fn"><sup><italic toggle="yes">e</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">0.9 &#177; 0.4</td><td align="left" valign="top" colspan="1" rowspan="1">6</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Day 5</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">14.8 &#177; 6.9<xref rid="T2_FN5" ref-type="table-fn"><sup><italic toggle="yes">e</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">1.5 &#177; 0.7</td><td align="left" valign="top" colspan="1" rowspan="1">4</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">29</td><td align="left" valign="top" rowspan="2" colspan="1">Mattila et al. (<xref rid="B79" ref-type="bibr">79</xref>)</td><td align="left" valign="top" rowspan="2" colspan="1">Healthy</td><td align="left" valign="top" rowspan="2" colspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">VAG</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">31 &#177; 5</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">1.9 &#177; 0.2</td><td align="left" valign="top" colspan="1" rowspan="1">7.7 &#177; 1.6</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">PR</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">8.8 &#177; 0.4</td><td align="left" valign="top" colspan="1" rowspan="1">129.8 &#177; 18.6</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">8.8 &#177; 1.1</td><td align="left" valign="top" colspan="1" rowspan="1">2.8 &#177; 0.5</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">30</td><td align="left" valign="top" rowspan="3" colspan="1">Bergan and Arnold (<xref rid="B15" ref-type="bibr">15</xref>)</td><td align="left" valign="top" rowspan="3" colspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1">500</td><td align="left" valign="top" rowspan="3" colspan="1">PR</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">10.45 &#177; 6.06</td><td align="left" valign="top" colspan="1" rowspan="1">89.07 &#177; 24.17</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">5.5</td><td align="left" valign="top" colspan="1" rowspan="1">4</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">1,000</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">8.80 &#177; 2.23</td><td align="left" valign="top" colspan="1" rowspan="1">187.68 &#177; 47</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">9.5</td><td align="left" valign="top" colspan="1" rowspan="1">4</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">2,000</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">9.46 &#177; 3.65</td><td align="left" valign="top" colspan="1" rowspan="1">280.78 &#177; 109</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">14</td><td align="left" valign="top" colspan="1" rowspan="1">4</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">31</td><td align="left" valign="top" rowspan="2" colspan="1">Alper et al. (<xref rid="B93" ref-type="bibr">93</xref>)</td><td align="left" valign="top" rowspan="2" colspan="1">Healthy</td><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">VAG</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">32.4 &#177; 38.4</td><td align="left" valign="top" colspan="1" rowspan="1">1.9 &#177; 0.2</td><td align="left" valign="top" colspan="1" rowspan="1">11.1 &#177; 1.6</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">142 &#177; 17.9</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr></tbody></table><table-wrap-foot><fn id="T2_FN1"><label>
<sup>
<italic toggle="yes">a</italic>
</sup>
</label><p>L/kg.</p></fn><fn id="T2_FN2"><label>
<sup>
<italic toggle="yes">b</italic>
</sup>
</label><p>mL/min/kg.</p></fn><fn id="T2_FN3"><label>
<sup>
<italic toggle="yes">c</italic>
</sup>
</label><p>mL/min &#215; 1.73 m<sup>2</sup>.</p></fn><fn id="T2_FN4"><label>
<sup>
<italic toggle="yes">d</italic>
</sup>
</label><p>AUC<sub>0&#8211;24</sub>.</p></fn><fn id="T2_FN5"><label>
<sup>
<italic toggle="yes">e</italic>
</sup>
</label><p>AUC<sub>0&#8211;12</sub>.</p></fn><fn id="T2_FN6"><label>
<sup>
<italic toggle="yes">f</italic>
</sup>
</label><p>mg.</p></fn><fn id="T2_FN7"><label>
<sup>
<italic toggle="yes">g</italic>
</sup>
</label><p>SOD: single oral dose, MOD: multiple oral doses, VAG: Intravaginal, PR: per rectal, N/M: not mentioned, ROA: route of administration, V<sub>d</sub>: volume of distribution, t<sub>1/2</sub>:elimination half-life, AUC<sub>0-&#8734;</sub>:area under concentration-time curve from 0&#8211;&#8734;,Cl<sub>T:</sub> total body clearance ,C<sub>max</sub>: maximum plasma concentration, T<sub>max</sub>: time to reach maximum plasma concentration, Cl<sub>R</sub>: renal clearance.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-4-2"><title>Oral administration of MTZ</title><p>Among all included studies, 16 were carried out in a healthy population following oral administration of MTZ. In one study, the <italic toggle="yes">C</italic><sub>max</sub> was reported to be 7.58 &#177; 0.38 &#181;g/mL when 500 mg MTZ was delivered to healthy individuals (<xref rid="B66" ref-type="bibr">66</xref>). The Cl<sub>T</sub> of MTZ was demonstrated in two studies, that is, 90.5 &#177; 43.67 and 51.9 &#177; 8.7 mL/min, respectively (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B63" ref-type="bibr">63</xref>). A gender-based difference in the AUC<sub>0&#8211;&#8734;</sub> was observed following oral administration of MTZ, that is, 103.81 &#177; 5.14 &#181;g&#183;h/mL in males and 84.36 &#177; 10.48 &#181;g&#183;h/mL in females (<xref rid="B60" ref-type="bibr">60</xref>). Additionally, compared to a single dose, repeated administration of MTZ resulted in a 1.6-fold increase in <italic toggle="yes">C</italic><sub>max</sub> (<xref rid="B48" ref-type="bibr">48</xref>). Furthermore, higher Cl<sub>T</sub> was depicted among the obese population in comparison to non-obese subjects in a clinical study, that is, 77 &#177; 20.3 mL/min versus 68.83 &#177; 14.5 mL/min (<xref rid="B28" ref-type="bibr">28</xref>). A subsequent investigation has compared the PK parameters between smokers and non-smokers in which higher AUC<sub>0&#8211;&#8734;</sub> was seen in the former, that is, 297.2 &#177; 228.4 &#181;g&#183;h/mL versus 29.3 &#177; 114.0 &#181;g&#183;h/mL (<xref rid="B56" ref-type="bibr">56</xref>). One of the research studies has reported a <italic toggle="yes">C</italic><sub>max</sub> of 12.3 &#181;g/mL after administering 75 mg MTZ to the male population (<xref rid="B29" ref-type="bibr">29</xref>). The details of all other PK parameters are presented in <xref rid="T2" ref-type="table">Table 2</xref>.</p></sec><sec id="s3-4-3"><title>Other routes of administration of MTZ</title><p>A dose-dependent increase in AUC<sub>0&#8211;&#8734;</sub> was seen in a study following rectal administration of MTZ (<xref rid="B15" ref-type="bibr">15</xref>). A study following intravaginal administration of MTZ reported a <italic toggle="yes">C</italic><sub>max</sub> of 1.9 &#177; 0.2 &#181;g/mL (<xref rid="B79" ref-type="bibr">79</xref>). Another study has presented a higher level of AUC<sub>0&#8211;12</sub> on day 5 compared to day 1 after the intravaginal route, that is, 14.8 &#177; 6.9 and 6.6 &#177; 2.7 &#181;g&#183;h/mL, respectively (<xref rid="B85" ref-type="bibr">85</xref>). The additional parameters are presented in <xref rid="T2" ref-type="table">Table 2</xref>.</p></sec></sec><sec id="s3-5"><title>PK of MTZ in diseased population</title><sec id="s3-5-1"><title>IV administration of MTZ</title><sec id="s3-5-1-1"><title>Renal impairment</title><p>Of the 67 included studies, 5 have presented PK data in renal patients after IV administration of MTZ. A study has reported Cl<sub>R</sub> in patients with moderate and severe renal dysfunction, that is, 2.7 &#177; 1.4 and 2.4 &#177; 1.1 mL/min, respectively, while no traces of MTZ were detected in renal failure (<xref rid="B7" ref-type="bibr">7</xref>). Another study has demonstrated AUC<sub>0&#8211;&#8734;</sub> as 205.44 &#177; 41.84 g&#183;h/mL in patients receiving continuous ambulatory peritoneal dialysis (CAPD) (<xref rid="B53" ref-type="bibr">53</xref>). Hemodialysis (HD) causes an increase of 3.1-fold Cl<sub>T</sub> among patients suffering from chronic renal failure (<xref rid="B65" ref-type="bibr">65</xref>).</p></sec><sec id="s3-5-1-2"><title>Hepatic impairment</title><p>A total of five studies were conducted in a population with hepatic impairment; among them, one study depicted Cl<sub>T</sub> in patients with cirrhosis and schistosomiasis, that is, 0.56 &#177; 0.28 and 0.93 &#177; 0.19 mL/min/kg (<xref rid="B50" ref-type="bibr">50</xref>). In two clinical studies, the AUC<sub>0&#8211;&#8734;</sub>was reported as 256.8 &#177; 56.3 and 175.7 &#181;g&#183;h/mL, respectively, in patients with liver dysfunction (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B62" ref-type="bibr">62</xref>). Following IV administration of 500 mg MTZ in patients with hepatic encephalopathy, the Cl<sub>T</sub> was reported as 29 &#177; 10 mL/min (<xref rid="B54" ref-type="bibr">54</xref>). Moreover, in a research study, a 3.1-fold decrease in <italic toggle="yes">C</italic><sub>max</sub> of MTZ hydroxy-metabolite was demonstrated among patients with alcoholic liver disease (<xref rid="B20" ref-type="bibr">20</xref>).</p></sec><sec id="s3-5-1-3"><title>Enteric disease</title><p>A study has reported a <italic toggle="yes">C</italic><sub>max</sub> of 34.7 &#177; 11.1 &#181;g/mL in individuals who underwent colorectal surgery following an IV dose of 500 mg MTZ (<xref rid="B81" ref-type="bibr">81</xref>). In another study, a 1.4-fold increase in area under the concentration time curve at steady state (AUC)<sub>ss</sub> was recorded when IV therapy was switched to the oral route of administration (<xref rid="B52" ref-type="bibr">52</xref>).</p></sec><sec id="s3-5-1-4"><title>Infection</title><p>When MTZ was delivered intravenously to patients with anaerobic infection, the Cl<sub>T</sub> and <italic toggle="yes">t</italic><sub>1/2</sub> were reported as 0.89 &#177; 0.3 mL/min/kg and 10.6 &#177; 4.5 h, respectively (<xref rid="B46" ref-type="bibr">46</xref>). A research study conducted in patients with septic shock has reported lower AUC<sub>0&#8211;10</sub> in muscles compared to plasma, that is, 66 &#177; 8.3 versus 57.9 &#177; 29.9 &#181;g&#183;h/mL (<xref rid="B55" ref-type="bibr">55</xref>), as described in <xref rid="T3" ref-type="table">Table 3</xref>.</p><table-wrap position="float" id="T3" orientation="portrait"><label>TABLE 3</label><caption><p>Pharmacokinetic parameters of metronidazole in the diseased population<xref rid="T3_FN7" ref-type="table-fn"><sup><italic toggle="yes">g</italic></sup></xref></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" valign="top" colspan="1" rowspan="1">Sr. no.</th><th align="left" valign="top" colspan="1" rowspan="1">Authors</th><th align="left" valign="top" colspan="1" rowspan="1">Population</th><th align="left" valign="bottom" colspan="1" rowspan="1"/><th align="left" valign="top" colspan="1" rowspan="1">ROA</th><th align="left" valign="bottom" colspan="1" rowspan="1"><italic toggle="yes">V</italic><sub>d</sub><break/>(L)</th><th align="left" valign="bottom" colspan="1" rowspan="1"><italic toggle="yes">t</italic><sub>1/2</sub><break/>(h)</th><th align="left" valign="bottom" colspan="1" rowspan="1">AUC<sub>0&#8211;&#8734;</sub><break/>(&#181;g&#183;h/mL)</th><th align="left" valign="bottom" colspan="1" rowspan="1">Cl<sub>T</sub><break/>(mL/min)</th><th align="left" valign="bottom" colspan="1" rowspan="1">Cl<sub>R</sub><break/>(mL/min)</th><th align="left" valign="bottom" colspan="1" rowspan="1">C<sub>max</sub><break/>(&#181;g/mL)</th><th align="left" valign="bottom" colspan="1" rowspan="1"><italic toggle="yes">T</italic><sub>max</sub><break/>(h)</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="1" rowspan="1">1</td><td align="left" valign="top" colspan="1" rowspan="1">Somogyi et al. (<xref rid="B19" ref-type="bibr">19</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Renal dysfunction</td><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">45.5 &#177; 8.7</td><td align="left" valign="top" colspan="1" rowspan="1">9.51</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">55.5 &#177; 17.7</td><td align="left" valign="top" colspan="1" rowspan="1">1.43 &#177; 1.36</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" rowspan="6" colspan="1">2</td><td align="left" valign="top" rowspan="6" colspan="1">Houghton et al. (<xref rid="B7" ref-type="bibr">7</xref>)</td><td align="left" valign="top" rowspan="6" colspan="1">Renal dysfunctions</td><td align="left" valign="top" colspan="1" rowspan="1">Moderate</td><td align="left" valign="top" rowspan="6" colspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">36 &#177; 9.4</td><td align="left" valign="top" colspan="1" rowspan="1">7.4 &#177; 2.4</td><td align="left" valign="top" colspan="1" rowspan="1">159 &#177; 52</td><td align="left" valign="top" colspan="1" rowspan="1">60 &#177; 20</td><td align="left" valign="top" colspan="1" rowspan="1">2.7 &#177; 1.4</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">HM</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">16 &#177; 4.5</td><td align="left" valign="top" colspan="1" rowspan="1">131 &#177; 47</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Severe</td><td align="left" valign="top" colspan="1" rowspan="1">48 &#177; 20</td><td align="left" valign="top" colspan="1" rowspan="1">11 &#177; 5.7</td><td align="left" valign="top" colspan="1" rowspan="1">180 &#177; 82</td><td align="left" valign="top" colspan="1" rowspan="1">68 &#177; 59</td><td align="left" valign="top" colspan="1" rowspan="1">2.4 &#177; 1.1</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">HM</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">28 &#177; 36</td><td align="left" valign="top" colspan="1" rowspan="1">136 &#177; 200</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">RF</td><td align="left" valign="top" colspan="1" rowspan="1">55 &#177; 21</td><td align="left" valign="top" colspan="1" rowspan="1">7.2 &#177; 2.3</td><td align="left" valign="top" colspan="1" rowspan="1">99 &#177; 27</td><td align="left" valign="top" colspan="1" rowspan="1">91 &#177; 29</td><td align="left" valign="top" colspan="1" rowspan="1">ND</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">HM</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">34 &#177; 43</td><td align="left" valign="top" colspan="1" rowspan="1">&gt;79</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">3</td><td align="left" valign="top" rowspan="2" colspan="1">Plaisance et al. (<xref rid="B43" ref-type="bibr">43</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Renal dysfunction</td><td align="left" valign="top" rowspan="2" colspan="1"/><td align="left" valign="top" rowspan="2" colspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">0.98-0.68<xref rid="T3_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">11.6-13</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">0.87-0.68<xref rid="T3_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Severe ill patients</td><td align="left" valign="top" colspan="1" rowspan="1">0.78-1.2<xref rid="T3_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">7.98-42.4</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">0.28-1.7<xref rid="T3_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">4</td><td align="left" valign="top" rowspan="2" colspan="1">Guay et al. (<xref rid="B53" ref-type="bibr">53</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Renal patient on HD</td><td align="left" valign="top" rowspan="2" colspan="1"/><td align="left" valign="top" rowspan="2" colspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">719.44 &#177; 14</td><td align="left" valign="top" colspan="1" rowspan="1">8.16 &#177; 1.59</td><td align="left" valign="top" colspan="1" rowspan="1">178.3 &#177; 17.4</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Renal patients on CAPD</td><td align="left" valign="top" colspan="1" rowspan="1">754 &#177; 0.1<xref rid="T3_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">10.93 &#177; 2.01</td><td align="left" valign="top" colspan="1" rowspan="1">205.44 &#177; 41.8</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">5</td><td align="left" valign="top" colspan="1" rowspan="1">Somogyi et al. (<xref rid="B65" ref-type="bibr">65</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Renal patient on HD</td><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">37.9 &#177; 15.6</td><td align="left" valign="top" colspan="1" rowspan="1">2.14</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">196.0 &#177; 60.6</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">6</td><td align="left" valign="top" rowspan="2" colspan="1">Lau et al. (<xref rid="B20" ref-type="bibr">20</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Alcoholic liver disease</td><td align="left" valign="top" rowspan="2" colspan="1"/><td align="left" valign="top" rowspan="2" colspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">0.77 &#177; 0.16<xref rid="T3_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">18.31 &#177; 6.06</td><td align="left" valign="top" colspan="1" rowspan="1">256.8 &#177; 56.3</td><td align="left" valign="top" colspan="1" rowspan="1">0.51 &#177; 0.11<xref rid="T3_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">HM</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">24.99 &#177; 7.65</td><td align="left" valign="top" colspan="1" rowspan="1">63 &#177; 21.5</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">1.66 &#177; 0.41</td><td align="left" valign="top" colspan="1" rowspan="1">10 &#177; 8.7</td></tr><tr><td align="left" valign="top" rowspan="4" colspan="1">7</td><td align="left" valign="top" rowspan="4" colspan="1">Muscar&#225; et al. (<xref rid="B50" ref-type="bibr">50</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Child-Pugh A</td><td align="left" valign="top" rowspan="4" colspan="1"/><td align="left" valign="top" rowspan="4" colspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">0.74 &#177; 0.11<xref rid="T3_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">10.7 &#177; 2.3</td><td align="left" valign="top" colspan="1" rowspan="1">124.9 &#177; 42.3</td><td align="left" valign="top" colspan="1" rowspan="1">0.85 &#177; 0.26<xref rid="T3_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Child-Pugh B</td><td align="left" valign="top" colspan="1" rowspan="1">0.79 &#177; 0.12<xref rid="T3_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">13.5 &#177; 5.1</td><td align="left" valign="top" colspan="1" rowspan="1">124.4 &#177; 25.8</td><td align="left" valign="top" colspan="1" rowspan="1">0.79 &#177; 0.36<xref rid="T3_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Child-Pugh C</td><td align="left" valign="top" colspan="1" rowspan="1">0.81 &#177; 0.14<xref rid="T3_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">21.5 &#177; 12.7</td><td align="left" valign="top" colspan="1" rowspan="1">174.1 &#177; 52<xref rid="T3_FN4" ref-type="table-fn"><sup><italic toggle="yes">d</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">0.56 &#177; 0.28<xref rid="T3_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Patients with schistosomiasis</td><td align="left" valign="top" colspan="1" rowspan="1">0.79 &#177; 0.09<xref rid="T3_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">10.2 &#177; 2.1</td><td align="left" valign="top" colspan="1" rowspan="1">135 &#177; 33.8<xref rid="T3_FN4" ref-type="table-fn"><sup><italic toggle="yes">d</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">0.93 &#177; 0.19<xref rid="T3_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">8</td><td align="left" valign="top" rowspan="2" colspan="1">Loft et al, (<xref rid="B54" ref-type="bibr">54</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Hepatic encephalopathy</td><td align="left" valign="top" rowspan="2" colspan="1"/><td align="left" valign="top" rowspan="2" colspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">44 &#177; 9</td><td align="left" valign="top" colspan="1" rowspan="1">20 &#177; 9</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">29 &#177; 10</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">HM</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">113 &#177; 82</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">13.6 &#177; 13.1</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">30 &#177; 14</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">9</td><td align="left" valign="top" rowspan="2" colspan="1">Ljungberg et al. (<xref rid="B62" ref-type="bibr">62</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Hepatic dysfunction</td><td align="left" valign="top" rowspan="2" colspan="1"/><td align="left" valign="top" rowspan="2" colspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">11.3</td><td align="left" valign="top" colspan="1" rowspan="1">175.7</td><td align="left" valign="top" colspan="1" rowspan="1">50.7<xref rid="T3_FN3" ref-type="table-fn"><sup><italic toggle="yes">c</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Severe renal impairment</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">6.5</td><td align="left" valign="top" colspan="1" rowspan="1">160.25 &#177; 25.8</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">10</td><td align="left" valign="top" colspan="1" rowspan="1">Farre et al. (<xref rid="B63" ref-type="bibr">63</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Hepatic dysfunction</td><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">0.38 &#177; 0.03<xref rid="T3_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">19.9 &#177; 2.5</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">17.5 &#177; 2.4</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">11</td><td align="left" valign="top" colspan="1" rowspan="1">Ti et al. (<xref rid="B46" ref-type="bibr">46</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Patients with anaerobic infection</td><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">0.73 &#177; 0.1<xref rid="T3_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">10.6 &#177; 4.48</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">0.89 &#177; 0.296<xref rid="T3_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">12</td><td align="left" valign="top" rowspan="2" colspan="1">Karjagin et al. (<xref rid="B55" ref-type="bibr">55</xref>)</td><td align="left" valign="top" rowspan="2" colspan="1">Patients with septic shock</td><td align="left" valign="top" colspan="1" rowspan="1">Plasma</td><td align="left" valign="top" rowspan="2" colspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">53.5 &#177; 4</td><td align="left" valign="top" colspan="1" rowspan="1">13.2 &#177; 5.3</td><td align="left" valign="top" colspan="1" rowspan="1">66 &#177; 8.3<xref rid="T3_FN5" ref-type="table-fn"><sup><italic toggle="yes">e</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">56.2 &#177; 26.9</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">11.4 &#177; 2</td><td align="left" valign="top" colspan="1" rowspan="1">0.5</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Muscle</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">27.3 &#177; 23.4</td><td align="left" valign="top" colspan="1" rowspan="1">57.9 &#177; 29.9<xref rid="T3_FN5" ref-type="table-fn"><sup><italic toggle="yes">e</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">8.2 &#177; 4.5</td><td align="left" valign="top" colspan="1" rowspan="1">2.3 &#177; 1.5</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">13</td><td align="left" valign="top" colspan="1" rowspan="1">Ventura Cerd&#225; et al. (<xref rid="B81" ref-type="bibr">81</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Patient undergoing colorectal surgery</td><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">0.68 &#177; 0.20<xref rid="T3_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">52.5 &#177; 20</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">34.7 &#177; 11.1</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">14</td><td align="left" valign="top" colspan="1" rowspan="1">Roux et al. (<xref rid="B87" ref-type="bibr">87</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Renal impairment</td><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">20.2</td><td align="left" valign="top" colspan="1" rowspan="1">6.82</td><td align="left" valign="top" colspan="1" rowspan="1">122.5 &#177; 42</td><td align="left" valign="top" colspan="1" rowspan="1">73.33</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">15</td><td align="left" valign="top" rowspan="2" colspan="1">Thiercelin et al. (<xref rid="B52" ref-type="bibr">52</xref>)</td><td align="left" valign="top" rowspan="2" colspan="1">Patient underwent GIT surgery</td><td align="left" valign="top" rowspan="2" colspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">52.9 &#177; 3.7</td><td align="left" valign="top" colspan="1" rowspan="1">6.03 &#177; 0.44</td><td align="left" valign="top" colspan="1" rowspan="1">83.1 &#177; 4.6<xref rid="T3_FN6" ref-type="table-fn"><sup><italic toggle="yes">f</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">103 &#177; 5.5</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">35.6 &#177; 1.9</td><td align="left" valign="top" colspan="1" rowspan="1">6.08 &#177; 0.34</td><td align="left" valign="top" colspan="1" rowspan="1">124.7 &#177; 6.7<xref rid="T3_FN6" ref-type="table-fn"><sup><italic toggle="yes">f</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">68.5 &#177; 3.66</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">16</td><td align="left" valign="top" rowspan="2" colspan="1">Daneshmend et al. (<xref rid="B45" ref-type="bibr">45</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Patients with cirrhosis</td><td align="left" valign="top" rowspan="2" colspan="1"/><td align="left" valign="top" rowspan="2" colspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">0.74 &#177; 0.04<xref rid="T3_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">10.8 &#177; 2.4</td><td align="left" valign="top" colspan="1" rowspan="1">157.8 &#177; 36.6</td><td align="left" valign="top" colspan="1" rowspan="1">1.15 &#177; 0.26<xref rid="T3_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Patients with schistosomiasis</td><td align="left" valign="top" colspan="1" rowspan="1">0.79 &#177; 0.05<xref rid="T3_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">8.4 &#177; 1.3</td><td align="left" valign="top" colspan="1" rowspan="1">128.7 &#177; 18.0</td><td align="left" valign="top" colspan="1" rowspan="1">1.21 &#177; 0.15<xref rid="T3_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" rowspan="4" colspan="1">17</td><td align="left" valign="top" rowspan="4" colspan="1">Shaffer et al. (<xref rid="B10" ref-type="bibr">10</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Patients with Crohn&#8217;s</td><td align="left" valign="top" rowspan="4" colspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">0.57 &#177; 0.1<xref rid="T3_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">8.5 &#177; 0.7</td><td align="left" valign="top" colspan="1" rowspan="1">124 &#177; 16</td><td align="left" valign="top" colspan="1" rowspan="1">53.3 &#177; 3.3</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Patients with colitis</td><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">0.58 &#177; 0.1<xref rid="T3_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">6.8 &#177; 0.5</td><td align="left" valign="top" colspan="1" rowspan="1">95 &#177; 11</td><td align="left" valign="top" colspan="1" rowspan="1">68.33 &#177; 8.3</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Patients with Crohn&#8217;s</td><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">123 &#177; 7</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Patients with colitis</td><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">103 &#177; 13</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">18</td><td align="left" valign="top" colspan="1" rowspan="1">Ashiq et al. (<xref rid="B51" ref-type="bibr">51</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Patients with amoebiasis</td><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">0.801 &#177; 0.02<xref rid="T3_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">7.451 &#177; 0.32</td><td align="left" valign="top" colspan="1" rowspan="1">87.37 &#177; 2.56</td><td align="left" valign="top" colspan="1" rowspan="1">1.23 &#177; 0.05<xref rid="T3_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">7.03 &#177; 0.2</td><td align="left" valign="top" colspan="1" rowspan="1">1.8 &#177; 0.07</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">19</td><td align="left" valign="top" colspan="1" rowspan="1">Eradiri et al. (<xref rid="B57" ref-type="bibr">57</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Crohn&#8217;s disease</td><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">0.732 &#177; 0.09<xref rid="T3_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">9.5 &#177; 2.1</td><td align="left" valign="top" colspan="1" rowspan="1">70.55 &#177; 22.11</td><td align="left" valign="top" colspan="1" rowspan="1">0.921 &#177; 0.17<xref rid="T3_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">0.1 &#177; 0.02<xref rid="T3_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" rowspan="6" colspan="1">20</td><td align="left" valign="top" rowspan="6" colspan="1">Bergan et al. (<xref rid="B30" ref-type="bibr">30</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Patients with Ileostomy</td><td align="left" valign="top" rowspan="6" colspan="1"/><td align="left" valign="top" rowspan="6" colspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">33.12 &#177; 2.60</td><td align="left" valign="top" colspan="1" rowspan="1">11.9 &#177; 0.6</td><td align="left" valign="top" colspan="1" rowspan="1">199.20 &#177; 28.7</td><td align="left" valign="top" colspan="1" rowspan="1">32.33 &#177; 4.1</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Patients with other enteric diseases</td><td align="left" valign="top" colspan="1" rowspan="1">37.50 &#177; 7.84</td><td align="left" valign="top" colspan="1" rowspan="1">7.2 &#177; 2.2</td><td align="left" valign="top" colspan="1" rowspan="1">130.81 &#177; 42.1</td><td align="left" valign="top" colspan="1" rowspan="1">61.33 &#177; 17.5</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Coeliac</td><td align="left" valign="top" colspan="1" rowspan="1">35.57 &#177; 4.80</td><td align="left" valign="top" colspan="1" rowspan="1">7.4 &#177; 1.8</td><td align="left" valign="top" colspan="1" rowspan="1">151 &#177; 39</td><td align="left" valign="top" colspan="1" rowspan="1">57.8 &#177; 12.33</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Ulcerative colitis</td><td align="left" valign="top" colspan="1" rowspan="1">40.71 &#177; 5.22</td><td align="left" valign="top" colspan="1" rowspan="1">8.2 &#177; 2.6</td><td align="left" valign="top" colspan="1" rowspan="1">147.5 &#177; 56.4</td><td align="left" valign="top" colspan="1" rowspan="1">61.5 &#177; 16.1</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Crohn&#8217;s</td><td align="left" valign="top" colspan="1" rowspan="1">57.73 &#177; 53.52</td><td align="left" valign="top" colspan="1" rowspan="1">5.8 &#177; 2.0</td><td align="left" valign="top" colspan="1" rowspan="1">158 &#177; 58</td><td align="left" valign="top" colspan="1" rowspan="1">59.5 &#177; 25.6</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Jejunoileal shunt</td><td align="left" valign="top" colspan="1" rowspan="1">42.01 &#177; 11.76</td><td align="left" valign="top" colspan="1" rowspan="1">7.5 &#177; 1.8</td><td align="left" valign="top" colspan="1" rowspan="1">140 &#177; 29</td><td align="left" valign="top" colspan="1" rowspan="1">67.83 &#177; 24.33</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">21</td><td align="left" valign="top" colspan="1" rowspan="1">Kurji et al. (<xref rid="B66" ref-type="bibr">66</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Diabetics</td><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">14.42 &#177; 3.03</td><td align="left" valign="top" colspan="1" rowspan="1">71.77 &#177; 9.26</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">5.63 &#177; 0.4</td><td align="left" valign="top" colspan="1" rowspan="1">1.7 &#177; 0.01</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">22</td><td align="left" valign="top" colspan="1" rowspan="1">Mattie et al. (<xref rid="B80" ref-type="bibr">80</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Patients with mixed infection</td><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">58.7 &#177; 30.9</td><td align="left" valign="top" colspan="1" rowspan="1">8.34</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">81.3 &#177; 28.4</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">23</td><td align="left" valign="top" colspan="1" rowspan="1">Fonnes et al. (<xref rid="B1" ref-type="bibr">1</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Patients with appendectomy</td><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">IP</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">5.4-9.5</td><td align="left" valign="top" colspan="1" rowspan="1">109-252</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">9.9-16.9</td><td align="left" valign="top" colspan="1" rowspan="1">1.0-4.2</td></tr></tbody></table><table-wrap-foot><fn id="T3_FN1"><label>
<sup>
<italic toggle="yes">a</italic>
</sup>
</label><p>L/kg.</p></fn><fn id="T3_FN2"><label>
<sup>
<italic toggle="yes">b</italic>
</sup>
</label><p>mL/min/kg.</p></fn><fn id="T3_FN3"><label>
<sup>
<italic toggle="yes">c</italic>
</sup>
</label><p>mL/min &#215; 1.73 m<sup>2</sup>.</p></fn><fn id="T3_FN4"><label>
<sup>
<italic toggle="yes">d</italic>
</sup>
</label><p>AUC<sub>0&#8211;24.</sub></p></fn><fn id="T3_FN5"><label>
<sup>
<italic toggle="yes">e</italic>
</sup>
</label><p>AUC<sub>0&#8211;10</sub>.</p></fn><fn id="T3_FN6"><label>
<sup>
<italic toggle="yes">f</italic>
</sup>
</label><p>AUC<sub>ss</sub>.</p></fn><fn id="T3_FN7"><label>
<sup>
<italic toggle="yes">g</italic>
</sup>
</label><p>CAPD: continuous ambulatory peritoneal dialysis, HD: hemodialysis, HM: hydroxy metabolite, IP: intraperitoneal, ND: not detected, RF: renal failure, ROA: route of administration.</p></fn></table-wrap-foot></table-wrap></sec></sec></sec><sec id="s3-6"><title>Oral administration of MTZ</title><sec id="s3-6-1"><title>Hepatic impairment</title><p>Only one study that has reported the oral administration of MTZ to patients with hepatic impairment, demonstrated AUC<sub>0&#8211;&#8734;</sub> in patients with cirrhosis and schistosomiasis as 157.8 &#177; 36 and 128.7 &#177; 18.0 &#181;g&#183;h/mL, respectively (<xref rid="B45" ref-type="bibr">45</xref>).</p></sec><sec id="s3-6-2"><title>Enteric disease</title><p>One of the clinical studies has reported Cl<sub>R</sub> as 0.1 &#177; 0.02 mL/min/kg in patients with Crohn&#8217;s disease after administering a 250 mg oral dose of MTZ (<xref rid="B57" ref-type="bibr">57</xref>). Another study has depicted a 1.3-fold decrease in AUC<sub>0&#8211;&#8734;</sub> in patients with ulcerative colitis compared to Crohn&#8217;s patients (<xref rid="B10" ref-type="bibr">10</xref>). Moreover, a clinical study has presented Cl<sub>T</sub> of 32.33 &#177; 4.1 mL/min in patients after ileostomy (<xref rid="B30" ref-type="bibr">30</xref>).</p></sec><sec id="s3-6-3"><title>Type II diabetes</title><p>One study has investigated the effect of diabetes on the PK of MTZ, which reported an increase in <italic toggle="yes">C</italic><sub>max</sub> and <italic toggle="yes">T</italic><sub>max</sub> by 25.73% and 20.69% in diabetic patients in comparison to the non-diabetic population (<xref rid="B66" ref-type="bibr">66</xref>).</p></sec><sec id="s3-6-4"><title>Infection</title><p>A clinical study has reported AUC<sub>0&#8211;&#8734;</sub> 87.37 &#177; 2.56 &#181;g&#183;h/mL among patients with amoebiasis following oral administration of MTZ (<xref rid="B51" ref-type="bibr">51</xref>). Another study has demonstrated Cl<sub>T</sub> of 81.3 &#177; 28.4 mL/min when a dose of 500 mg TID was delivered to patients with mixed aerobic and anaerobic infection (<xref rid="B80" ref-type="bibr">80</xref>). The detailed information is provided in <xref rid="T3" ref-type="table">Table 3</xref>.</p></sec></sec><sec id="s3-7"><title>Other routes of administration of MTZ</title><p>One of the research studies has discussed intraperitoneal administration of MTZ in patients with appendicitis, where the <italic toggle="yes">C</italic><sub>max</sub> was reported as 9.9&#8211;16.9 &#181;g/mL (<xref rid="B15" ref-type="bibr">15</xref>). All PK parameters are summarized in <xref rid="T3" ref-type="table">Table 3</xref>.</p></sec><sec id="s3-8"><title>PK of MTZ in special population</title><sec id="s3-8-1"><title>IV administration of MTZ</title><sec id="s3-8-1-1"><title>Pregnant women</title><p>A study has revealed that AUC<sub>0&#8211;48</sub> was 108 &#177; 33 &#181;g&#183;h/mL after administering a 500 mg IV dose of MTZ to pregnant women (<xref rid="B42" ref-type="bibr">42</xref>).</p></sec><sec id="s3-8-1-2"><title>Infants</title><p>Among 67 studies, only 1 investigated PK parameters in infants, which demonstrated an age-proportional increase in Cl<sub>T</sub> (<xref rid="B67" ref-type="bibr">67</xref>). The additional parameters are shown in <xref rid="T4" ref-type="table">Table 4</xref>.</p><table-wrap position="float" id="T4" orientation="portrait"><label>TABLE 4</label><caption><p>Pharmacokinetic parameters of metronidazole in special population<xref rid="T4_FN6" ref-type="table-fn"><sup><italic toggle="yes">f</italic></sup></xref></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" valign="top" colspan="1" rowspan="1">Sr. no.</th><th align="left" valign="top" colspan="1" rowspan="1">Authors</th><th align="left" valign="top" colspan="1" rowspan="1">Population</th><th align="left" valign="bottom" colspan="1" rowspan="1"/><th align="left" valign="top" colspan="1" rowspan="1">ROA</th><th align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">V</italic><sub>d</sub><break/>(L)</th><th align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">t</italic><sub>1/2</sub><break/>(h)</th><th align="left" valign="top" colspan="1" rowspan="1">AUC<sub>0&#8211;&#8734;</sub><break/>(&#181;g&#183;h/mL)</th><th align="left" valign="top" colspan="1" rowspan="1">Cl<sub>T</sub><break/>(mL/min)</th><th align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>max</sub><break/>(&#181;g/mL)</th><th align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">T</italic><sub>max</sub><break/>(h)</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="1" rowspan="1">1</td><td align="left" valign="top" colspan="1" rowspan="1">Visser et al. (<xref rid="B42" ref-type="bibr">42</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Pregnant women</td><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">6.9 &#177; 2.68</td><td align="left" valign="top" colspan="1" rowspan="1">108 &#177; 33<xref rid="T4_FN3" ref-type="table-fn"><sup><italic toggle="yes">c</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">1.19 &#177; 0.33<xref rid="T4_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">2</td><td align="left" valign="top" rowspan="3" colspan="1">Jager-Roman et al. (<xref rid="B67" ref-type="bibr">67</xref>)</td><td align="left" valign="top" rowspan="3" colspan="1">Infants</td><td align="left" valign="top" colspan="1" rowspan="1">28&#8211;30<xref rid="T4_FN5" ref-type="table-fn"><sup><italic toggle="yes">e</italic></sup></xref></td><td align="left" valign="top" rowspan="3" colspan="1">IV</td><td align="left" valign="top" colspan="1" rowspan="1">0.65 &#177; 0.06<xref rid="T4_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">75.3 &#177; 16.9</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">0.12 &#177; 0.05<xref rid="T4_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">32&#8211;35<xref rid="T4_FN5" ref-type="table-fn"><sup><italic toggle="yes">e</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">0.71 &#177; 0.03<xref rid="T4_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">35.4 &#177; 1.5</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">0.44 &#177; 0.06<xref rid="T4_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">36&#8211;40<xref rid="T4_FN5" ref-type="table-fn"><sup><italic toggle="yes">e</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">0.69 &#177; 0.06<xref rid="T4_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">24.8 &#177; 1.6</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">0.99 &#177; 0.07<xref rid="T4_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">3</td><td align="left" valign="top" colspan="1" rowspan="1">Passmore et al. (<xref rid="B9" ref-type="bibr">9</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Nursing mothers and infants</td><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>M</sub>: 12.9 &#177; 0.6<break/><italic toggle="yes">C</italic>p<sub>I</sub>: 1.6 &#177; 0.1</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">4</td><td align="left" valign="top" colspan="1" rowspan="1">Heistrberg et al. (<xref rid="B44" ref-type="bibr">44</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Nursing mothers and infants</td><td align="left" valign="top" colspan="1" rowspan="1"/><td align="left" valign="top" colspan="1" rowspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">C<sub>M</sub>: 11.6&#8211;18<break/>Cp<sub>I</sub>: 0.6&#8211;4.9</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">5</td><td align="left" valign="top" rowspan="2" colspan="1">Amon et al. (<xref rid="B27" ref-type="bibr">27</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Infants</td><td align="left" valign="top" rowspan="2" colspan="1"/><td align="left" valign="top" rowspan="2" colspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">0.87<xref rid="T4_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">10.66</td><td align="left" valign="top" colspan="1" rowspan="1">374.9</td><td align="left" valign="top" colspan="1" rowspan="1">0.94<xref rid="T4_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Children</td><td align="left" valign="top" colspan="1" rowspan="1">0.64 &#177; 0.18<xref rid="T4_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">8.98 &#177; 3.56</td><td align="left" valign="top" colspan="1" rowspan="1">175.0 &#177; 57.1</td><td align="left" valign="top" colspan="1" rowspan="1">0.94 &#177; 0.37<xref rid="T4_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" rowspan="4" colspan="1">6</td><td align="left" valign="top" rowspan="4" colspan="1">Amon et al. (<xref rid="B58" ref-type="bibr">58</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Pregnant women</td><td align="left" valign="top" colspan="1" rowspan="1">1,000</td><td align="left" valign="top" rowspan="4" colspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">0.752 &#177; 0.09<xref rid="T4_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">7.73 &#177; 1.11</td><td align="left" valign="top" colspan="1" rowspan="1">233.35 &#177; 18.2</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Non-pregnant women</td><td align="left" valign="top" colspan="1" rowspan="1">1,000</td><td align="left" valign="top" colspan="1" rowspan="1">0.692 &#177; 0.153</td><td align="left" valign="top" colspan="1" rowspan="1">7.80 &#177; 1.30</td><td align="left" valign="top" colspan="1" rowspan="1">281.94 &#177; 75.39</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Pregnant women</td><td align="left" valign="top" colspan="1" rowspan="1">250</td><td align="left" valign="top" colspan="1" rowspan="1">0.59 &#177; 0.19</td><td align="left" valign="top" colspan="1" rowspan="1">5.70 &#177; 3.46</td><td align="left" valign="top" colspan="1" rowspan="1">40.09 &#177; 16.366</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Non-pregnant women</td><td align="left" valign="top" colspan="1" rowspan="1">250</td><td align="left" valign="top" colspan="1" rowspan="1">0.62 &#177; 0.17</td><td align="left" valign="top" colspan="1" rowspan="1">5.92 &#177; 30</td><td align="left" valign="top" colspan="1" rowspan="1">50.2 &#177; 3.9</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">7</td><td align="left" valign="top" rowspan="3" colspan="1">Wang et al. (<xref rid="B75" ref-type="bibr">75</xref>)</td><td align="left" valign="top" rowspan="3" colspan="1">Pregnant women</td><td align="left" valign="top" colspan="1" rowspan="1">ET</td><td align="left" valign="top" rowspan="3" colspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">0.517 &#177; 0.55<xref rid="T4_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">117.4 &#177; 121.8<xref rid="T4_FN4" ref-type="table-fn"><sup><italic toggle="yes">d</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">1.04 &#177; 1.13<xref rid="T4_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">17.0 &#177; 19.7</td><td align="left" valign="top" colspan="1" rowspan="1">1.5</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">MD</td><td align="left" valign="top" colspan="1" rowspan="1">0.793 &#177; 0.29<xref rid="T4_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">69.2 &#177; 19.9<xref rid="T4_FN4" ref-type="table-fn"><sup><italic toggle="yes">d</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">1.8 &#177; 0.89<xref rid="T4_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">11.7 &#177; 3.1</td><td align="left" valign="top" colspan="1" rowspan="1">1.3 &#177; 0.4</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">LT</td><td align="left" valign="top" colspan="1" rowspan="1">0.717 &#177; 0.33<xref rid="T4_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">79.2 &#177; 14.7<xref rid="T4_FN4" ref-type="table-fn"><sup><italic toggle="yes">d</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">1.37 &#177; 0.45<xref rid="T4_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">14.2 &#177; 4.2</td><td align="left" valign="top" colspan="1" rowspan="1">1.3 &#177; 0.8</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">8</td><td align="left" valign="top" rowspan="2" colspan="1">Lares-Asseff et al. (<xref rid="B61" ref-type="bibr">61</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Malnourished children</td><td align="left" valign="top" rowspan="2" colspan="1"/><td align="left" valign="top" rowspan="2" colspan="1">PO</td><td align="left" valign="top" colspan="1" rowspan="1">1.500 &#177; 0.87<xref rid="T4_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">11.73 &#177; 6.1</td><td align="left" valign="top" colspan="1" rowspan="1">191.65 &#177; 101.7</td><td align="left" valign="top" colspan="1" rowspan="1">1.56 &#177; 0.9<xref rid="T4_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">10.48 &#177; 5.2</td><td align="left" valign="top" colspan="1" rowspan="1">3.4 &#177; 1.9</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Nutritionally rehabilitated children</td><td align="left" valign="top" colspan="1" rowspan="1">1.598 &#177; 0.97<xref rid="T4_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">5.68 &#177; 1.97</td><td align="left" valign="top" colspan="1" rowspan="1">140.04 &#177; 46.9</td><td align="left" valign="top" colspan="1" rowspan="1">3.11 &#177; 0.1<xref rid="T4_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">10.49 &#177; 3.4</td><td align="left" valign="top" colspan="1" rowspan="1">4.48 &#177; 1.7</td></tr></tbody></table><table-wrap-foot><fn id="T4_FN1"><label>
<sup>
<italic toggle="yes">a</italic>
</sup>
</label><p>L/kg.</p></fn><fn id="T4_FN2"><label>
<sup>
<italic toggle="yes">b</italic>
</sup>
</label><p>mL/min/kg.</p></fn><fn id="T4_FN3"><label>
<sup>
<italic toggle="yes">c</italic>
</sup>
</label><p>AUC<sub>0&#8211;48</sub>.</p></fn><fn id="T4_FN4"><label>
<sup>
<italic toggle="yes">d</italic>
</sup>
</label><p>AUC<sub>0&#8211;12.</sub></p></fn><fn id="T4_FN5"><label>
<sup>
<italic toggle="yes">e</italic>
</sup>
</label><p>Gestational age in weeks.</p></fn><fn id="T4_FN6"><label>
<sup>
<italic toggle="yes">f</italic>
</sup>
</label><p>Cp<sub>I</sub>: infant plasma concentration, Cp<sub>M</sub>: mother plasma concentration, ET: early term, LT: late-term, MT: middle term, ROA: route of administration.</p></fn></table-wrap-foot></table-wrap></sec></sec></sec><sec id="s3-9"><title>Oral administration of MTZ</title><sec id="s3-9-1"><title>Pregnant women</title><p>Of a total 67 studies, 2 were conducted in pregnant women. One study has reported a lowered AUC<sub>0&#8211;&#8734;</sub> in pregnant women compared to non-pregnant women, that is, 233.35 &#177; 18.21 versus 281.94 &#177; 75.39 &#181;g&#183;h/mL (<xref rid="B58" ref-type="bibr">58</xref>). In another study, the <italic toggle="yes">C</italic><sub>max</sub> of MTZ was reported to be decreased by 1.5- and 1.2-fold during the middle and later terms of pregnancy in contrast to the early term (<xref rid="B75" ref-type="bibr">75</xref>).</p></sec><sec id="s3-9-2"><title>Infants</title><p>A study has depicted higher AUC<sub>0&#8211;&#8734;</sub> in infants than children, that is, 374.9 and 175 &#181;g&#183;h/mL, respectively (<xref rid="B27" ref-type="bibr">27</xref>). Another study comparing PK of MTZ in malnourished and nutritionally rehabilitated children has revealed that the former had lower Cl<sub>T</sub>, that is, 1.56 &#177; 0.90 versus 3.11 &#177; 0.1 mL/min/kg (<xref rid="B61" ref-type="bibr">61</xref>).</p></sec><sec id="s3-9-3"><title>Nursing mothers and infants</title><p>Two studies have found that when oral MTZ was administered to nursing mothers, its traces were observed in infants&#8217; plasma, that is, 1.69 &#177; 0.17 and 0.6-4.9 &#181;g/mL, respectively (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B44" ref-type="bibr">44</xref>), as demonstrated in <xref rid="T4" ref-type="table">Table 4</xref>.</p></sec></sec><sec id="s3-10"><title>PK of MTZ in drug-drug interaction and drug-food interaction</title><sec id="s3-10-1"><title>Drug-drug interaction</title><p>A study has reported that silymarin decreased MTZ AUC<sub>0&#8211;48</sub> from 230.58 &#177; 84.57 to 166.22 &#177; 63.84 &#181;g&#183;h/mL (<xref rid="B73" ref-type="bibr">73</xref>). The diosmin on co-administration with MTZ caused an increase in its <italic toggle="yes">C</italic><sub>max</sub>, that is, 17.5 &#177; 4.1 versus 21.2 &#177; 3.5 &#181;g/mL (<xref rid="B72" ref-type="bibr">72</xref>). A clinical study has reported an increase in Cl<sub>T</sub> of MTZ when co-administered with omeprazole, that is, 75.5 &#177; 17.83 mL/min versus 82.83 &#177; 23.8 mL/min at an oral dose of 500 mg (<xref rid="B78" ref-type="bibr">78</xref>). The other PK parameters are outlined in <xref rid="T5" ref-type="table">Table 5</xref>.</p><table-wrap position="float" id="T5" orientation="portrait"><label>TABLE 5</label><caption><p>Pharmacokinetic parameters of metronidazole in drug-drug and drug-food interaction<xref rid="T5_FN7" ref-type="table-fn"><sup><italic toggle="yes">g</italic></sup></xref><sup>,<xref rid="T5_FN8" ref-type="table-fn"><italic toggle="yes">h</italic></xref></sup></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" valign="top" colspan="1" rowspan="1">Sr. no.</th><th align="left" valign="top" colspan="1" rowspan="1">Authors</th><th align="left" valign="top" colspan="1" rowspan="1">Drugs</th><th align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">V</italic><sub>d</sub><break/>(L)</th><th align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">t</italic><sub>1/2</sub><break/>(h)</th><th align="left" valign="top" colspan="1" rowspan="1">AUC<sub>0&#8211;&#8734;</sub><break/>(&#181;g&#183;h/mL)</th><th align="left" valign="top" colspan="1" rowspan="1">Cl<sub>T</sub><break/>(mL/min)</th><th align="left" valign="top" colspan="1" rowspan="1">Cl<sub>R</sub><break/>(mL/min)</th><th align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>max</sub><break/>(&#181;g/mL)</th><th align="left" valign="top" colspan="1" rowspan="1"><italic toggle="yes">T</italic><sub>max</sub><break/>(h)</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="10" rowspan="1">Pharmacokinetic parameters of metronidazole in drug-drug interaction</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">1</td><td align="left" valign="top" rowspan="2" colspan="1">Sakurai et al. (<xref rid="B26" ref-type="bibr">26</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">52.95 &#177; 6.1560</td><td align="left" valign="top" colspan="1" rowspan="1">11.03 &#177; 2.93</td><td align="left" valign="top" colspan="1" rowspan="1">75.53 &#177; 18.822<xref rid="T5_FN4" ref-type="table-fn"><sup><italic toggle="yes">d</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">58.7 &#177; 16.02</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">8.987 &#177; 1.809</td><td align="left" valign="top" colspan="1" rowspan="1">2 &#177; 4.0</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">MTZ + AMOX + VPZ</td><td align="left" valign="top" colspan="1" rowspan="1">51.71 &#177; 5.0214</td><td align="left" valign="top" colspan="1" rowspan="1">10.76 &#177; 2.80</td><td align="left" valign="top" colspan="1" rowspan="1">75.520 &#177; 19580<xref rid="T5_FN4" ref-type="table-fn"><sup><italic toggle="yes">d</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">59.01 &#177; 16.78</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">8.874 &#177; 1.806</td><td align="left" valign="top" colspan="1" rowspan="1">3 &#177; 6.0</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">2</td><td align="left" valign="top" rowspan="2" colspan="1">Dilger et al. (<xref rid="B49" ref-type="bibr">49</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">BDS</td><td align="left" valign="top" colspan="1" rowspan="1">43.8 &#177; 15.2</td><td align="left" valign="top" colspan="1" rowspan="1">2.1&#8211;5.1</td><td align="left" valign="top" colspan="1" rowspan="1">0.0048 &#177; 0.002</td><td align="left" valign="top" colspan="1" rowspan="1">0.17 &#177; 0.08<xref rid="T5_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">0.001 &#177; 0.0003</td><td align="left" valign="top" colspan="1" rowspan="1">4.1&#8211;6.2</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">BDS + MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">60.6 &#177; 38.1</td><td align="left" valign="top" colspan="1" rowspan="1">2.6&#8211;6.0</td><td align="left" valign="top" colspan="1" rowspan="1">0.00477 &#177; 0.002</td><td align="left" valign="top" colspan="1" rowspan="1">0.18 &#177; 0.09<xref rid="T5_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">0.00104 &#177; 0.0004</td><td align="left" valign="top" colspan="1" rowspan="1">3.9&#8211;4.8</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">3</td><td align="left" valign="top" rowspan="2" colspan="1">Kim and Park (<xref rid="B59" ref-type="bibr">59</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">FEXO</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">4.7 &#177; 1.0</td><td align="left" valign="top" colspan="1" rowspan="1">20.757 &#177; 55.71</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">0.3044 &#177; 0.1396</td><td align="left" valign="top" colspan="1" rowspan="1">2.2 &#177; 1.1</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">FEXO + MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">5.4 &#177; 2.8</td><td align="left" valign="top" colspan="1" rowspan="1">19.99 &#177; 39.73</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">0.293 &#177; 0.137</td><td align="left" valign="top" colspan="1" rowspan="1">2.4 &#177; 1.1</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">4</td><td align="left" valign="top" rowspan="2" colspan="1">Loft et al. (<xref rid="B64" ref-type="bibr">64</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">51 &#177; 16</td><td align="left" valign="top" colspan="1" rowspan="1">7.6 &#177; 1.3</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">77 &#177; 20</td><td align="left" valign="top" colspan="1" rowspan="1">6.4 &#177; 2.6</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Cimetidine + MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">51 &#177; 12</td><td align="left" valign="top" colspan="1" rowspan="1">7.9 &#177; 0.8</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">75 &#177; 21</td><td align="left" valign="top" colspan="1" rowspan="1">6.6 &#177; 1.4</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">5</td><td align="left" valign="top" rowspan="2" colspan="1">Das et al. (<xref rid="B31" ref-type="bibr">31</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">8.4 &#177; 1.5</td><td align="left" valign="top" colspan="1" rowspan="1">115.0 &#177; 19.4</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">21.0 &#177; 19.7</td><td align="left" valign="top" colspan="1" rowspan="1">1&#8211;1.50</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">MTZ + CAZ +<break/>AVI</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">9.0 &#177; 1.5</td><td align="left" valign="top" colspan="1" rowspan="1">121.0 &#177; 19.0</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">21.4 &#177; 17.4</td><td align="left" valign="top" colspan="1" rowspan="1">1&#8211;2.50</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">6</td><td align="left" valign="top" colspan="1" rowspan="1">Obodozie et al. (<xref rid="B32" ref-type="bibr">32</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">NIPRD-AM1 + MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">73.52</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">7.83</td><td align="left" valign="top" colspan="1" rowspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">7</td><td align="left" valign="top" rowspan="2" colspan="1">Rajnarayana et al. (<xref rid="B72" ref-type="bibr">72</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">5.7 &#177; 4.1</td><td align="left" valign="top" colspan="1" rowspan="1">249 &#177; 80</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">17.5 &#177; 4.1</td><td align="left" valign="top" colspan="1" rowspan="1">1.2 &#177; 0.4</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Diosmin +<break/>MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">7.6 &#177; 2.2</td><td align="left" valign="top" colspan="1" rowspan="1">315 &#177; 88</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">21.2 &#177; 3.5</td><td align="left" valign="top" colspan="1" rowspan="1">1 &#177; 0.3</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">8</td><td align="left" valign="top" rowspan="2" colspan="1">Rajnarayana et al. (<xref rid="B73" ref-type="bibr">73</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">0.442 &#177; 0.215<xref rid="T5_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">10.61 &#177; 4.32</td><td align="left" valign="top" colspan="1" rowspan="1">230.58 &#177; 84.57<xref rid="T5_FN3" ref-type="table-fn"><sup><italic toggle="yes">c</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">0.51 &#177; 0.16<xref rid="T5_FN2" ref-type="table-fn"><sup><italic toggle="yes">b</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">16.91 &#177; 4.24</td><td align="left" valign="top" colspan="1" rowspan="1">1.12 &#177; 0.56</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">SIL + MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">0.454 &#177; 0.243<xref rid="T5_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">8.08 &#177; 3.96</td><td align="left" valign="top" colspan="1" rowspan="1">166.22 &#177; 63.84<xref rid="T5_FN3" ref-type="table-fn"><sup><italic toggle="yes">c</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">0.728 &#177; 0.29</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">12.00 &#177; 2.92</td><td align="left" valign="top" colspan="1" rowspan="1">1.5 &#177; 0.97</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">9</td><td align="left" valign="top" rowspan="2" colspan="1">Wang et al. (<xref rid="B76" ref-type="bibr">76</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">MDZ</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">2 &#177; 0.3</td><td align="left" valign="top" colspan="1" rowspan="1">0.19 &#177; 0.0643</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">0.0586 &#177; 0.030</td><td align="left" valign="top" colspan="1" rowspan="1">1</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">MDZ + MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">2.2 &#177; 0.9</td><td align="left" valign="top" colspan="1" rowspan="1">0.177 &#177; 60.9</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">0.0551 &#177; 0.0208</td><td align="left" valign="top" colspan="1" rowspan="1">1.25</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">10</td><td align="left" valign="top" rowspan="2" colspan="1">Pierce et al. (<xref rid="B77" ref-type="bibr">77</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">30.60 &#177; 76.627<xref rid="T5_FN5" ref-type="table-fn"><sup><italic toggle="yes">e</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">28.193 &#177; 6.249</td><td align="left" valign="top" colspan="1" rowspan="1">0.50-3.00</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">MTZ + MMX</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">30.43 &#177; 74.308<xref rid="T5_FN5" ref-type="table-fn"><sup><italic toggle="yes">e</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">28.057 &#177; 5.522</td><td align="left" valign="top" colspan="1" rowspan="1">0.5-3.00</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">11</td><td align="left" valign="top" rowspan="2" colspan="1">Goddard et al. (<xref rid="B69" ref-type="bibr">69</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">82.2&#8211;118.4</td><td align="left" valign="top" colspan="1" rowspan="1">58.33&#8211;80</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">7.94&#8211;10.76</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">MTZ + OMEP</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">69.9&#8211;123.0</td><td align="left" valign="top" colspan="1" rowspan="1">55&#8211;96.6</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">7.73&#8211;10.52</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">12</td><td align="left" valign="top" rowspan="2" colspan="1">Calafatti et al. (<xref rid="B70" ref-type="bibr">70</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">14.16&#8211;20.22<xref rid="T5_FN6" ref-type="table-fn"><sup><italic toggle="yes">f</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">10.99&#8211;16.05</td><td align="left" valign="top" colspan="1" rowspan="1">1.08&#8211;1.77</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">MTZ + OMEP</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">13.54&#8211;21.12<xref rid="T5_FN6" ref-type="table-fn"><sup><italic toggle="yes">f</italic></sup></xref></td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">8.29&#8211;49.81</td><td align="left" valign="top" colspan="1" rowspan="1">0.78&#8211;1.5</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">13</td><td align="left" valign="top" rowspan="2" colspan="1">Jessa et al. (<xref rid="B78" ref-type="bibr">78</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">47.9 &#177; 10.2</td><td align="left" valign="top" colspan="1" rowspan="1">7.49 &#177; 1.53</td><td align="left" valign="top" colspan="1" rowspan="1">62.5156 &#177; 15.2087</td><td align="left" valign="top" colspan="1" rowspan="1">75.5 &#177; 17.83</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">MTZ + OMEP</td><td align="left" valign="top" colspan="1" rowspan="1">56.1 &#177; 18.8</td><td align="left" valign="top" colspan="1" rowspan="1">7.91 &#177; 1.78</td><td align="left" valign="top" colspan="1" rowspan="1">57.2541 &#177; 12.8025</td><td align="left" valign="top" colspan="1" rowspan="1">82.83 &#177; 23.8</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">14</td><td align="left" valign="top" rowspan="2" colspan="1">David et al. (<xref rid="B68" ref-type="bibr">68</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">MTZ</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">8.7&#8211;11</td><td align="left" valign="top" colspan="1" rowspan="1">103.4&#8211;130.8</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">8.3&#8211;10.6</td><td align="left" valign="top" colspan="1" rowspan="1">0.5&#8211;3</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">MTZ + OMEP</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">8.2&#8211;10</td><td align="left" valign="top" colspan="1" rowspan="1">97&#8211;124.4</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">8.3&#8211;9.5</td><td align="left" valign="top" colspan="1" rowspan="1">0.5&#8211;6</td></tr><tr><td align="left" valign="top" colspan="10" rowspan="1">Pharmacokinetic parameters of metronidazole in drug-food interaction</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">15</td><td align="left" valign="top" rowspan="2" colspan="1">Hamberg et al. (<xref rid="B82" ref-type="bibr">82</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">EDD</td><td align="left" valign="top" colspan="1" rowspan="1">6.8</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">4310</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">11</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">3.56</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">PDD</td><td align="left" valign="top" colspan="1" rowspan="1">7.9</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">4820</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">7.8</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">3.41</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">16</td><td align="left" valign="top" rowspan="2" colspan="1">Wu et al. (<xref rid="B84" ref-type="bibr">84</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Fasting</td><td align="left" valign="top" colspan="1" rowspan="1">44.88 &#177; 5.79</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">101.2 &#177; 19.2</td><td align="left" valign="top" colspan="1" rowspan="1">63.83 &#177; 12.55</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">7.562 &#177; 0.790</td><td align="left" valign="top" colspan="1" rowspan="1">1.58 &#177; 0.71</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Non-fasting</td><td align="left" valign="top" colspan="1" rowspan="1">46.62 &#177; 4.67</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">31.88 &#177; 4.28</td><td align="left" valign="top" colspan="1" rowspan="1">66.43 &#177; 8.83</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">2.257 &#177; 0.381</td><td align="left" valign="top" colspan="1" rowspan="1">2.46 &#177; 1.50</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">17</td><td align="left" valign="top" rowspan="2" colspan="1">Melande et al. (<xref rid="B74" ref-type="bibr">74</xref>)</td><td align="left" valign="top" colspan="1" rowspan="1">Fasting</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">3.9&#8211;19.2</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">6.68&#8211;12.5</td><td align="left" valign="top" colspan="1" rowspan="1">0.5&#8211;2</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Non-fasting</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">7.05&#8211;19.38</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">N/M</td><td align="left" valign="top" colspan="1" rowspan="1">6.32&#8211;10.7</td><td align="left" valign="top" colspan="1" rowspan="1">0.53&#8211;4</td></tr></tbody></table><table-wrap-foot><fn id="T5_FN1"><label>
<sup>
<italic toggle="yes">a</italic>
</sup>
</label><p>L/kg.</p></fn><fn id="T5_FN2"><label>
<sup>
<italic toggle="yes">b</italic>
</sup>
</label><p>mL/min/kg.</p></fn><fn id="T5_FN3"><label>
<sup>
<italic toggle="yes">c</italic>
</sup>
</label><p>AUC<sub>0&#8211;48.</sub></p></fn><fn id="T5_FN4"><label>
<sup>
<italic toggle="yes">d</italic>
</sup>
</label><p>AUC<sub>0&#8211;12.</sub></p></fn><fn id="T5_FN5"><label>
<sup>
<italic toggle="yes">e</italic>
</sup>
</label><p>AUC<sub>0&#8211;24</sub>.</p></fn><fn id="T5_FN6"><label>
<sup>
<italic toggle="yes">f</italic>
</sup>
</label><p>AUC<sub>0&#8211;2.</sub></p></fn><fn id="T5_FN7"><label>
<sup>
<italic toggle="yes">g</italic>
</sup>
</label><p>mg.</p></fn><fn id="T5_FN8"><label>
<sup>
<italic toggle="yes">h</italic>
</sup>
</label><p>ALP: Alprazolam, AMOX: amoxicillin, AVI: avibactam, BDS: budesonide, CAZ: ceftazidime, EDD: energy deficient diet, FEXO: fexofenadine, LRP: Lorazepam, LVX: levofloxacin, MDZ: midazolam, MMX: mesalamine, MTZ: metronidazole, OMEP: omeprazole, PDD: protein deficient diet, PHT: Phenytoin, SIL: silymarin, VPZ: vonoprazan.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-10-2"><title>Drug-food interaction</title><p>In an investigation, the AUC<sub>0&#8211;&#8734;</sub> was reported to be reduced in the fed state compared to the fasted state, that is, 31.88 &#177; 4.28 versus 101.2 &#177; 19.2 &#181;g&#183;h/mL (<xref rid="B84" ref-type="bibr">84</xref>). Similarly, an extended <italic toggle="yes">t</italic><sub>1/2</sub> was observed when the drug was given on an empty stomach, that is, 7.05&#8211;19.38 h (<xref rid="B74" ref-type="bibr">74</xref>). The remaining values are mentioned in <xref rid="T5" ref-type="table">Table 5</xref>.</p></sec></sec><sec id="s3-11"><title>Meta-analysis</title><p>The pooled AUC for doses 250 mg, 400 mg, 500 mg (PO), 500 mg (IV), 1,000 mg, and 1,500&#8211;2,000 mg was 48.27 (95% confidence interval [CI]: 41.09&#8211;55.45), 92.83 (95% CI: 83.99&#8211;101.67), 110.43 (95% CI: 92.81&#8211;128.04), 116.69 (95% CI: 99.34&#8211;134.05), 245.63 (95% CI: 219.99&#8211;289.27), and 528.90 (95% CI: 445.54&#8211;612.27), respectively (<xref rid="F3" ref-type="fig">Fig. 3</xref> to <xref rid="F8" ref-type="fig">8</xref>). The 0% <italic toggle="yes">I</italic><sup>2</sup> of 0% at a dose of 250 mg indicated lower heterogeneity across the studies. Similarly, higher <italic toggle="yes">I</italic><sup>2</sup> values after 400 mg, 500 mg (IV), 1,000 mg, and 1,500&#8211;2,000 mg doses exhibited significant heterogeneity.</p><fig position="float" fig-type="figure" id="F3" orientation="portrait"><label>Fig 3</label><caption><p>Forest plot of AUC for MTZ 250 mg single dose. The figure displays the mean of AUC and sample size (black square and its size) and 95% CI (the horizontal lines) for adult healthy population across studies, with the blue diamond at the bottom showing the overall pooled AUC estimate and its CI. The vertical red dashed line is a reference for the overall pooled AUC estimate, allowing for a visual comparison across studies. In this figure, the pooled AUC for the 250 mg single dose is 48.27 (95% CI: 41.09&#8211;55.45), and <italic toggle="yes">I</italic><sup>2</sup> of 0% indicates low heterogeneity across the studies.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.01904-24.f003.jpg"><alt-text>Forest plot of metronidazole 250 mg single dose in healthy adults showing consistent AUC values across studies, with a pooled mean AUC of 48.27 mcg&#183;h/mL [41.09, 55.45] and no observed heterogeneity (I&#178; = 0%).</alt-text></graphic></fig><fig position="float" fig-type="figure" id="F4" orientation="portrait"><label>Fig 4</label><caption><p>Forest plot of AUC for MTZ 400 mg single dose. The figure displays the mean of AUC and sample size (black square and its size) and 95% CI (the horizontal lines) for adult healthy population across studies, with the blue diamond at the bottom showing the overall pooled AUC estimate and its CI. The vertical red dashed line is a reference for the overall pooled AUC estimate, allowing for a visual comparison across studies. In this figure, the pooled AUC for the 400 mg single dose is 92.83 (95% CI: 83.99&#8211;101.67), and <italic toggle="yes">I</italic><sup>2</sup> of 79.3% indicates moderate heterogeneity across the studies.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.01904-24.f004.jpg"><alt-text>Forest plot of metronidazole 400 mg single dose in healthy adults indicates moderate heterogeneity (I&#178; = 79.3%), with a pooled AUC of 92.83 mcg&#183;h/mL [83.99, 101.67] across seven studies.</alt-text></graphic></fig><fig position="float" fig-type="figure" id="F5" orientation="portrait"><label>Fig 5</label><caption><p>Forest plot of AUC for MTZ 500 mg single oral dose. The figure displays the mean of AUC and sample size (black square and its size) and 95% CI (the horizontal lines) for adult healthy population across studies, with the blue diamond at the bottom showing the overall pooled AUC estimate and its CI. The vertical red dashed line is a reference for the overall pooled AUC estimate, allowing for a visual comparison across studies. In this figure, the pooled AUC for the 500 mg single dose is 110.43 (95% CI: 92.81&#8211;128.04), and <italic toggle="yes">I</italic><sup>2</sup> of 94.1% indicates high heterogeneity across the studies.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.01904-24.f005.jpg"><alt-text>Forest plot of metronidazole 500 mg single oral dose in healthy adults reveals high heterogeneity (I&#178; = 94.1%) with a pooled AUC of 110.43 mcg&#183;h/mL [92.81, 128.04] across 11 studies.</alt-text></graphic></fig><fig position="float" fig-type="figure" id="F6" orientation="portrait"><label>Fig 6</label><caption><p>Forest plot of AUC for MTZ 500 mg single IV dose. The figure displays the mean of AUC and sample size (black square and its size) and 95% CI (the horizontal lines) for adult healthy population across studies, with the blue diamond at the bottom showing the overall pooled AUC estimate and its CI. The vertical red dashed line is a reference for the overall pooled AUC estimate, allowing for a visual comparison across studies. In this figure, the pooled AUC for the 500 mg single dose is 116.69 (95% CI: 99.34&#8211;134.05), and <italic toggle="yes">I</italic><sup>2</sup> of 79.2% indicates moderate heterogeneity across the studies.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.01904-24.f006.jpg"><alt-text>Forest plot of metronidazole 500 mg single IV dose in healthy adults shows moderate heterogeneity (I&#178; = 79.2%) with a pooled AUC of 116.69 mcg&#183;h/mL [99.34, 134.05] from six studies.</alt-text></graphic></fig><fig position="float" fig-type="figure" id="F7" orientation="portrait"><label>Fig 7</label><caption><p>Forest plot of AUC for MTZ 1000 mg single dose. The figure displays the mean of AUC and sample size (black square and its size) and 95% CI (the horizontal lines) for adult healthy population across studies, with the blue diamond at the bottom showing the overall pooled AUC estimate and its CI. The vertical red dashed line is a reference for the overall pooled AUC estimate, allowing for a visual comparison across studies. In this figure, the pooled AUC for the 1,000 mg single dose is 254.63 (95% CI: 220&#8211;289.3), and <italic toggle="yes">I</italic><sup>2</sup> of 72.3% indicates moderate heterogeneity across the studies.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.01904-24.f007.jpg"><alt-text>Forest plot of metronidazole 1000 mg single dose in healthy adults shows moderate heterogeneity (I&#178; = 72.3%) with a pooled AUC of 254.63 mcg&#183;h/mL [219.99, 289.27] across four studies.</alt-text></graphic></fig><fig position="float" fig-type="figure" id="F8" orientation="portrait"><label>Fig 8</label><caption><p>Forest plot of AUC for MTZ 1,500 mg (Soreide and Solhaug) and 2,000 mg (Loft and Lau) single dose. The figure displays the mean of AUC and sample size (black square and its size) and 95% CI (the horizontal lines) for adult healthy population across studies, with the blue diamond at the bottom showing the overall pooled AUC estimate and its CI. The vertical red dashed line is a reference for the overall pooled AUC estimate, allowing for a visual comparison across studies. In this figure, the pooled AUC is 528.9 (95% CI: 445.54&#8211;612.27), and <italic toggle="yes">I</italic><sup>2</sup> of 89.7% indicates moderate heterogeneity across the studies.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.01904-24.f008.jpg"><alt-text>Forest plot for metronidazole 1500&#8211;2000 mg single dose in healthy adults indicates high heterogeneity (I&#178; = 89.7%). The pooled AUC is 528.90 mcg&#183;h/mL [445.54, 612.27] based on four studies.</alt-text></graphic></fig><p>The pooled effect size of AUC for patients with mild-moderate and severe liver impairment was 127.73 (95% CI: 116.95&#8211;138.50), and 199.29 (95% CI: 138.63&#8211;2.59.94) correspondingly. The pooled dose-normalized AUC for individuals with moderate to severe renal impairment, patients on dialysis, and pregnant women was 0.32 (95% CI: 0.30&#8211;0.35), 0.23 (95% CI: 0.20&#8211;0.26), and 0.18 (95% CI: 0.15&#8211;0.21), respectively. Low heterogeneity was observed among studies conducted in patients with mild to moderate liver disease and moderate to severe renal impairment as the value of <italic toggle="yes">I</italic><sup>2</sup> was 0%. The higher values of <italic toggle="yes">I</italic><sup>2</sup> indicated moderate heterogeneity across the studies performed in renal patients on dialysis, pregnant women, and patients with severe liver disease, that is, 60.2%, 88.2%, and 83%, respectively. <xref rid="F9" ref-type="fig">Figures 9</xref> to <xref rid="F13" ref-type="fig">13</xref> present the forest plots of these results.</p><fig position="float" fig-type="figure" id="F9" orientation="portrait"><label>Fig 9</label><caption><p>Forest plot of AUC for MTZ 500 mg single dose in Schistosomiasis-induced liver disease (<xref rid="B45" ref-type="bibr">45</xref>, <xref rid="B50" ref-type="bibr">50</xref>) and class A and B Child-Pugh liver cirrhosis (<xref rid="B50" ref-type="bibr">50</xref>). The figure displays the mean of AUC and sample size (black square and its size) and 95% CI (the horizontal lines) for adult healthy population across studies, with the blue diamond at the bottom showing the overall pooled AUC estimate and its CI. The vertical red dashed line is a reference for the overall pooled AUC estimate, allowing for a visual comparison across studies. In this population, the pooled AUC is 127.73 (95% CI: 116.95&#8211;138.5), and <italic toggle="yes">I</italic><sup>2</sup> of 0% indicates low heterogeneity across the studies.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.01904-24.f009.jpg"><alt-text>Forest plot for metronidazole 500 mg single dose in mild to moderate liver impairment shows no heterogeneity (I&#178; = 0%). Pooled AUC is 127.73 mcg&#183;h/mL [116.95, 138.50] across four studies.</alt-text></graphic></fig><fig position="float" fig-type="figure" id="F10" orientation="portrait"><label>Fig 10</label><caption><p>Forest plot of AUC for MTZ 500 mg single dose in severe liver impairment. The figure displays the mean of AUC and sample size (black square and its size) and 95% CI (the horizontal lines) for adult healthy population across studies, with the blue diamond at the bottom showing the overall pooled AUC estimate and its CI. The vertical red dashed line is a reference for the overall pooled AUC estimate, allowing for a visual comparison across studies. In this population, the pooled AUC is 199.29 (95% CI: 138.63&#8211;259.94), and <italic toggle="yes">I</italic><sup>2</sup> of 83% indicates moderate heterogeneity across the studies.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.01904-24.f010.jpg"><alt-text>Forest plot for metronidazole 500 mg single dose in severe liver impairment shows high heterogeneity (I&#178; = 83%). Pooled AUC is 199.29 mcg&#183;h/mL [138.63, 259.94] across three studies.</alt-text></graphic></fig><fig position="float" fig-type="figure" id="F11" orientation="portrait"><label>Fig 11</label><caption><p>Forest plot of dose-normalized AUC for MTZ in patients with moderate to severe renal impairment.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.01904-24.f011.jpg"><alt-text>Forest plot for population with moderate to severe renal impairment depicts no heterogeneity (I&#178; = 0%). Pooled dose-normalized AUC is 0.32 mcg&#183;h/mL [0.30, 0.35] across three studies.</alt-text></graphic></fig><fig position="float" fig-type="figure" id="F12" orientation="portrait"><label>Fig 12</label><caption><p>Forest plot of dose-normalized AUC for MTZ in patients with renal impairment on dialysis.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.01904-24.f012.jpg"><alt-text>Forest plot for renal impairment on dialysis depicts moderate heterogeneity (I&#178; = 60.2%). Pooled dose-normalized AUC is 0.23 mcg&#183;h/mL [0.20, 0.26] across four studies.</alt-text></graphic></fig><fig position="float" fig-type="figure" id="F13" orientation="portrait"><label>Fig 13</label><caption><p>Forest plot of dose-normalized AUC for MTZ in pregnant women.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.01904-24.f013.jpg"><alt-text>Forest plot for pregnant women depicts high heterogeneity (I&#178; = 88.2%). Pooled dose-normalized AUC is 0.18 mcg&#183;h/mL [0.15, 0.21] across six studies.</alt-text></graphic></fig><p>To illustrate differences in effect sizes across populations, we present the pooled estimates alongside their 95% CIs in <xref rid="F14" ref-type="fig">Fig. 14</xref>. Visual inspection of the CIs enables identification of differences between groups, as non-overlapping or minimally overlapping intervals are generally indicative of statistically meaningful differences (<xref rid="B103" ref-type="bibr">103</xref>). This method provides a straightforward and transparent way to assess variation across populations without formal hypothesis testing.</p><fig position="float" fig-type="figure" id="F14" orientation="portrait"><label>Fig 14</label><caption><p>Forest plot of dose-normalized AUC values for each population subgroup. The figure displays dose-normalized AUC values (and 95% confidence intervals [CIs]) for individual population groups: Healthy, Enteric Diseases, Hepatic Impairment, Pregnant Women, Renal Impairment, and Renal Impairment on Dialysis. Each effect size is represented by a circle. The horizontal lines indicate the 95% CIs for each population&#8217;s AUC estimate. The vertical dashed line represents the overall pooled AUC estimate of the healthy population, allowing for a visual comparison across populations. Non-overlapping or minimally overlapping CIs suggest meaningful differences between populations. This visual comparison allows for an intuitive assessment of variability across groups.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.01904-24.f014.jpg"><alt-text>Effect size plot comparing dose-normalized AUCs across populations. Pregnant women and dialysis patients have lowest exposure. Hepatic and renal impairment groups show higher AUCs, exceeding healthy baseline.</alt-text></graphic></fig></sec></sec><sec sec-type="discussion" id="s4"><title>DISCUSSION</title><p>The main objective of this review was to systematically compile, summarize, and evaluate all available data on the PK of MTZ. Out of 67 studies, 36 were conducted in healthy individuals, 23 in diseased persons, and 8 in special populations. Among those 36 studies performed on healthy subjects, 5 evaluated the effect of age, regimen, smoking, gender, and obesity on the PK of MTZ, while 14 depicted drug-drug interaction and 3 discussed the drug-food interactions.</p><p>The age-related decline in renal function is the most likely reason for lower Cl<sub>R</sub> seen in elders using MTZ; nevertheless, since the overall elimination of MTZ is conserved in old age, no dosage adjustment is required (<xref rid="B47" ref-type="bibr">47</xref>). MTZ exhibits approximately the same <italic toggle="yes">C</italic><sub>max</sub> in saliva as in plasma due to its higher diffusion from blood to saliva. It is a low molecular weight drug; therefore, it can easily permeate all tissues and body fluids (<xref rid="B6" ref-type="bibr">6</xref>). Mustofa et al. recommended using saliva instead of plasma to measure the PK parameters of MTZ (<xref rid="B104" ref-type="bibr">104</xref>). The elevated <italic toggle="yes">C</italic><sub>max</sub> of MTZ in the male population is because of its more efficient absorption in men than in women. The altered PK parameters necessitate dose monitoring in males (<xref rid="B60" ref-type="bibr">60</xref>). The interaction between tobacco and MTZ is influenced by the number of cigarettes smoked daily. Smoking 15 or more cigarettes per day reduces the <italic toggle="yes">C</italic><sub>max</sub> of MTZ in the body. Polycyclic aromatic hydrocarbon, a chemical found in cigarette smoke, causes the induction of CYP1A1, CYP1A2, and CYP2E1 enzymes that accelerate the hepatic biotransformation of MTZ. Therefore, a dose adjustment in chain smokers is necessary to achieve optimum therapeutic effects (<xref rid="B56" ref-type="bibr">56</xref>). Obese persons have greater <italic toggle="yes">V</italic><sub>d</sub> and lower <italic toggle="yes">C</italic><sub>max</sub> due to the high-fat content in their bodies; therefore, a high dose is recommended for these patients to get the therapeutic concentration (<xref rid="B28" ref-type="bibr">28</xref>). Multiple-dosage regimens of MTZ exhibit higher <italic toggle="yes">C</italic><sub>max</sub> compared to a single-dose administration because of drug accumulation in the body to reach the study state concentration. The variations are negligible in healthy individuals, but patients with hepatic or renal impairment need dose adjustments to avoid drug toxicity (<xref rid="B48" ref-type="bibr">48</xref>). The physicochemical properties of MTZ, particularly poor lipid solubility, may contribute to its low vaginal absorption; yet, these dosage forms are good for local effects (<xref rid="B85" ref-type="bibr">85</xref>). The relative bioavailability of MTZ suppositories is 90% compared to the oral tablets due to partial bypass of the first-pass effect; thus, rectal administration might be used as an alternate treatment (<xref rid="B15" ref-type="bibr">15</xref>). Moreover, the proportional increase in <italic toggle="yes">C</italic><sub>max</sub> of MTZ with dose indicates its linear PK (<xref rid="B83" ref-type="bibr">83</xref>).</p><p>The Cl<sub>R</sub> of MTZ is decreased in patients with renal impairment, but no significant accumulation occurs because only 10% of the dose is excreted through Cl<sub>R</sub> in its parent form and the rest of the drug is metabolized by the liver, making hepatic clearance a major route of elimination (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B43" ref-type="bibr">43</xref>). However, severe renal dysfunction modifies the PK parameters of MTZ metabolites (hydroxy and acidic metabolites). Since these metabolites are biologically active, they can cause toxicity; thus, close monitoring of renal function is required to avoid potential side effects of the drug (<xref rid="B7" ref-type="bibr">7</xref>). Hemodialysis may also change the PK of MTZ as it significantly increases Cl<sub>T</sub>; hence, appropriate time and dose adjustments are necessary for these patients (<xref rid="B65" ref-type="bibr">65</xref>). Hepatic clearance accounts for &gt;50% of Cl<sub>T</sub> of MTZ; that is why liver insufficiency prolongs its <italic toggle="yes">t</italic><sub>1/2</sub> and decreases Cl<sub>T</sub>, which may be due to the poor metabolism of MTZ caused by impaired cytochrome P450 system. Consequently, dose adjustment is required to avoid drug toxicity (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B45" ref-type="bibr">45</xref>, <xref rid="B50" ref-type="bibr">50</xref>, <xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B63" ref-type="bibr">63</xref>). Diabetes-related physiological changes, such as elevated fat content and impaired renal, hepatic, and GIT functioning, are the source of increased <italic toggle="yes">C</italic><sub>max</sub> and <italic toggle="yes">T</italic><sub>max</sub> of MTZ in the diabetic population. About 80% of diabetic patients develop hepatic glycogen lesion that results in hepatomegaly, which interferes with the metabolism of MTZ (<xref rid="B66" ref-type="bibr">66</xref>). Patients with different anaerobic and protozoa infections do not exhibit a substantial change in PK of MTZ, indicating no need for dosage adjustment (<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B51" ref-type="bibr">51</xref>, <xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B80" ref-type="bibr">80</xref>). Oral administration of MTZ in enteric diseases may affect its PK parameters due to differences in GIT absorption. In contrast, IV therapy does not show any change in PK of MTZ (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B52" ref-type="bibr">52</xref>, <xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B81" ref-type="bibr">81</xref>).</p><p>Due to an increase in mean plasma volume and a decrease in plasma protein concentrations, the PK parameters of MTZ differ during pregnancy (<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B58" ref-type="bibr">58</xref>, <xref rid="B75" ref-type="bibr">75</xref>). A considerable amount of MTZ may enter newborns via breast milk; so, it would be important to prescribe it with caution to nursing mothers (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B44" ref-type="bibr">44</xref>). Infants show higher AUC<sub>0&#8211;&#8734;</sub> compared to adults due to their developing bodies and immature GIT, liver, and kidney functions (<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B67" ref-type="bibr">67</xref>). The prolonged <italic toggle="yes">t</italic><sub>1/2</sub> and lower Cl<sub>T</sub> of MTZ in severely malnourished children warrant dose adjustment in these patients (<xref rid="B61" ref-type="bibr">61</xref>).</p><p>Drug-drug interactions make treatment goals more difficult to achieve. Cytochrome 450 enzymes, including CYP3As, CYP2E1, and CYP2A6, are involved in the metabolism of MTZ. The PK parameters of MTZ may be affected by the concurrent use of medications that affect these enzymes; it necessitates cautious co-administration of such drugs with MTZ. Diosmin inhibits CYP2A6 and CYP3A4 enzymes, resulting in a decreased Cl<sub>T</sub> and increased <italic toggle="yes">C</italic><sub>max</sub> of MTZ (<xref rid="B72" ref-type="bibr">72</xref>). Silymarin increases CL<sub>T</sub> of MTZ via inducing P-glycoprotein, which on average, results in a 29.3% drop in <italic toggle="yes">C</italic><sub>max</sub>of the drug (<xref rid="B73" ref-type="bibr">73</xref>). Food delays the absorption of MTZ but has little effect on its PK parameters, so no dose adjustment is required (<xref rid="B74" ref-type="bibr">74</xref>, <xref rid="B84" ref-type="bibr">84</xref>).</p><p>The meta-analysis was conducted to robustly assess the variability of a PK parameter, AUC, across multiple studies. It allows us to estimate the pooled effect size more precisely. This meta-analysis indirectly evaluates AUC-dose proportionality by examining how the AUC scales with increased doses of MTZ. Moreover, it also compares the pooled effect size of AUC among healthy, diseased, and special populations. It shows that MTZ behaves consistently across various dosing regimens and in different populations, which is necessary for the safe and effective use of the drug. It helps clinicians with the individualization of therapy. Our meta-analysis revealed altered MTZ exposure in several special populations compared to healthy individuals. Specifically, lower pooled AUC values were observed in pregnant women and patients undergoing dialysis, while higher pooled AUCs were found in individuals with renal impairment, hepatic insufficiency, and enteric diseases. These findings suggest potential implications for dose adjustment in clinical practice. However, current regulatory sources do not recommend dosing modifications for MTZ during pregnancy. The FDA label for MTZ does not provide specific pharmacokinetic data or dosing guidance for pregnant women (<xref rid="B105" ref-type="bibr">105</xref>), and the scientific clinical database (Lexicomp) reports that MTZ PK in pregnancy are similar to those in non-pregnant individuals (1<xref rid="B106" ref-type="bibr">106</xref>). Therefore, while our analysis identified lower pooled AUCs in pregnancy, this difference may not be clinically significant and does not, at present, justify empirical dose changes without further clinical evidence.</p><p>In renal impairment, the FDA reports that decreased renal function does not significantly alter the PK of MTZ itself; however, substantial increases are observed in the systemic exposure of its metabolites, specifically, a twofold increase in hydroxy-MTZ and a fivefold increase in MTZ acetate in end-stage renal disease patients. As a result, dose adjustment is not explicitly recommended, but monitoring for adverse events is advised, especially in dialysis patients, to mitigate potential toxicity from metabolite accumulation (<xref rid="B107" ref-type="bibr">107</xref>). This supports our interpretation that while the parent drug AUC may be reduced, caution remains warranted.</p><p>In contrast, the FDA recommends dose modifications in severe hepatic impairment (Child-Pugh C), citing a 114% increase in AUC of MTZ and advising a 50% dose reduction for amebiasis and increased dosing intervals for trichomoniasis. For mild to moderate hepatic impairment, no dose adjustment is required, though monitoring is recommended (<xref rid="B107" ref-type="bibr">107</xref>). Our pooled results align with this pattern, as increased AUCs in hepatic impairment were consistent with a need for dose reductions in patients with significant liver dysfunction. Generally, our findings complement current global regulatory guidance by providing quantitative pooled evidence of altered exposure across populations. However, we emphasize that any dosing changes should be guided by clinical context, therapeutic indications, and safety considerations, consistent with individualized treatment principles recommended by the FDA and other regulatory authorities.</p><p>The strength of this review article is that it covers the maximum number of studies published on healthy, diseased, and special populations until July 2024. However, it is necessary to be aware that certain limitations must be considered. This review includes only English-language articles, which may result in excluding relevant studies published in other languages. Only four databases were accessed for data retrieval, which might lead to the omission of crucial data and jeopardize the accuracy of results. Moreover, 94 relevant studies were inaccessible, which may limit the robustness of the analysis. The majority of the included studies have a clear risk of bias, which could affect the validity of the results. Furthermore, most studies do not give complete information on all included PK parameters.</p><p>Because of inter-population variability in AUC, individualized dosage regimes for MTZ should be considered to optimize therapeutic outcomes. Therapeutic drug monitoring can be beneficial in a population at risk of altered PK of MTZ, that is, hepatic patients, to provide adequate drug exposure and minimize toxicity. Future research should develop and validate PBPK models to predict MTZ disposition across diverse physiological and pathological conditions. Moreover, investigating the effect of genetic polymorphism on MTZ metabolism can improve dosing strategies. The results of this review article and meta-analysis should be used to develop dosing guidelines for MTZ by collaborating with regulatory authorities.</p></sec><sec sec-type="conclusions" id="s5"><title>CONCLUSIONS</title><p>This systematic review covers the majority of studies on the PK of MTZ in humans from five included databases. The PK studies include data on healthy, diseased, and special populations to identify the factors influencing the PK of MTZ. This information can be used to develop PK models that may help clinicians adjust the dose regimens for different populations to achieve optimal therapeutic effects and avoid toxicity. The heterogeneity in multiple studies suggests the need for future research strategies to ensure consistency in study design, implementation, and result reporting.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>The authors extend their appreciation to the King Salman Center for Disability Research for funding this work through Research group no KSRG-2024-433.</p><p>King Salman Center for Disability Research Research group no KSRG-2024-433.</p><p>I.S.: Conceptualization, Investigation, Methodology, Software, Visualization, Writing&#8212;original draft. M.S.A.: Funding acquisition, Investigation, Visualization, Writing&#8212;original draft. A.Z.: Data curation, Formal analysis, Software, Writing&#8212;review &amp; editing. M.F.R.: Conceptualization, Formal analysis, Methodology, Project administration, Supervision, Writing&#8212;review &amp; editing. F.A.: Data curation, Funding acquisition, Methodology, Project administration, Software, Supervision.</p><p>This study was registered by PROSPERO (Registration ID: CRD42024609345).</p></ack><sec sec-type="data-availability" id="s6-1"><title>DATA AVAILABILITY</title><p>The data discussed in this article are obtained from publicly available sources cited in this review. All data summarized and analyzed during this study are included in the article or its supplementary information file.</p></sec><sec sec-type="supplementary-material" id="s6-2"><title>SUPPLEMENTAL MATERIAL</title><p specific-use="print-only">The following material is available online at <ext-link xlink:href="https://doi.org/10.1128/aac.01904-24" ext-link-type="uri">https://doi.org/10.1128/aac.01904-24</ext-link>.</p><supplementary-material id="SuF1" position="float" content-type="local-data" orientation="portrait"><object-id pub-id-type="doi">10.1128/aac.01904-24.SuF1</object-id><label>Table S1</label><caption><title>aac.01904-24-s0001.docx</title><p>Screening and exclusion of articles based on their titles, abstract, animal studies, reviews, and accessibility.</p></caption><media xlink:href="aac.01904-24-s0001.docx" position="float" orientation="portrait"/></supplementary-material><p specific-use="online-only">ASM does not own the copyrights to Supplemental Material that may be linked to, or accessed through, an article. The authors have granted ASM a non-exclusive, world-wide license to publish the Supplemental Material files. Please contact the corresponding author directly for reuse. </p></sec><ref-list><title>REFERENCES</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fonnes</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Weisser</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Holzknecht</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Arpi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rosenberg</surname><given-names>J</given-names></string-name></person-group>. <year>2020</year>. <article-title>The plasma pharmacokinetics of fosfomycin and metronidazole after intraperitoneal administration in patients undergoing appendectomy for uncomplicated appendicitis</article-title>. <source>Fundam Clin Pharmacol</source><volume>34</volume>:<fpage>504</fpage>&#8211;<lpage>512</lpage>. doi:<pub-id pub-id-type="doi">10.1111/fcp.12535</pub-id><pub-id pub-id-type="pmid">31944378</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hern&#225;ndez Ceruelos</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Romero-Quezada</surname><given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>Ruvalcaba Ledezma</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>L&#243;pez Contreras</surname><given-names>L</given-names></string-name></person-group>. <year>2019</year>. <article-title>Therapeutic uses of metronidazole and its side effects: an update</article-title>. <source>Eur Rev Med Pharmacol Sci</source><volume>23</volume>:<fpage>397</fpage>&#8211;<lpage>401</lpage>. doi:<pub-id pub-id-type="doi">10.26355/eurrev_201901_16788</pub-id><pub-id pub-id-type="pmid">30657582</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shinn</surname><given-names>DLS</given-names></string-name></person-group>. <year>1962</year>. <article-title>Metronidazole in acute ulcerative gingivitis</article-title>. <source>The Lancet</source><volume>279</volume>:<fpage>1191</fpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(62)92243-2</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="report"><person-group person-group-type="author"><string-name name-style="western"><surname>Weir</surname><given-names>CB</given-names></string-name>, <string-name name-style="western"><surname>Le</surname><given-names>JK</given-names></string-name></person-group>. <year>2019</year>. <article-title>Metronidazole.</article-title><pub-id pub-id-type="pmid">30969550</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Drug.com</collab></person-group>. <year>2023</year>. <source>Metronidazole</source>. <comment>Available from</comment>: <ext-link xlink:href="https://www.drugs.com/metronidazole.html" ext-link-type="uri">https://www.drugs.com/metronidazole.html</ext-link>. <comment>Retrieved</comment><date-in-citation> Aug 25</date-in-citation></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>de C Bergamaschi</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Berto</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Ven&#226;ncio</surname><given-names>PC</given-names></string-name>, <string-name name-style="western"><surname>Cogo</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Franz-Montan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Motta</surname><given-names>RHL</given-names></string-name>, <string-name name-style="western"><surname>Santamaria</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Groppo</surname><given-names>FC</given-names></string-name></person-group>. <year>2014</year>. <article-title>Concentrations of metronidazole in human plasma and saliva after tablet or gel administration</article-title>. <source>J Pharm Pharmacol</source><volume>66</volume>:<fpage>40</fpage>&#8211;<lpage>47</lpage>. doi:<pub-id pub-id-type="doi">10.1111/jphp.12161</pub-id><pub-id pub-id-type="pmid">24341948</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Houghton</surname><given-names>GW</given-names></string-name>, <string-name name-style="western"><surname>Dennis</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Gabriel</surname><given-names>R</given-names></string-name></person-group>. <year>1985</year>. <article-title>Pharmacokinetics of metronidazole in patients with varying degrees of renal failure</article-title>. <source>Br J Clin Pharmacol</source><volume>19</volume>:<fpage>203</fpage>&#8211;<lpage>209</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2125.1985.tb02632.x</pub-id><pub-id pub-id-type="pmid">3986078</pub-id><pub-id pub-id-type="pmcid">PMC1463713</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Koss</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Baras</surname><given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Lane</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Aubry</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Marcus</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Markowitz</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Koumans</surname><given-names>EH</given-names></string-name></person-group>. <year>2012</year>. <article-title>Investigation of metronidazole use during pregnancy and adverse birth outcomes</article-title>. <source>Antimicrob Agents Chemother</source><volume>56</volume>:<fpage>4800</fpage>&#8211;<lpage>4805</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.06477-11</pub-id><pub-id pub-id-type="pmid">22751543</pub-id><pub-id pub-id-type="pmcid">PMC3421860</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Passmore</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>McElnay</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Rainey</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>D&#8217;Arcy</surname><given-names>PF</given-names></string-name></person-group>. <year>1988</year>. <article-title>Metronidazole excretion in human milk and its effect on the suckling neonate</article-title>. <source>Br J Clin Pharmacol</source><volume>26</volume>:<fpage>45</fpage>&#8211;<lpage>51</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2125.1988.tb03362.x</pub-id><pub-id pub-id-type="pmid">3203060</pub-id><pub-id pub-id-type="pmcid">PMC1386498</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shaffer</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Kershaw</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Houston</surname><given-names>JB</given-names></string-name></person-group>. <year>1986</year>. <article-title>Disposition of metronidazole and its effects on sulphasalazine metabolism in patients with inflammatory bowel disease</article-title>. <source>Br J Clin Pharmacol</source><volume>21</volume>:<fpage>431</fpage>&#8211;<lpage>435</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2125.1986.tb05218.x</pub-id><pub-id pub-id-type="pmid">2871853</pub-id><pub-id pub-id-type="pmcid">PMC1400944</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cooper</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Stankiewicz</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Sneddon</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Seaton</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>A</given-names></string-name></person-group>. <year>2022</year>. <article-title>Indications for the use of metronidazole in the treatment of non-periodontal dental infections: a systematic review</article-title>. <source>JAC Antimicrob Resist</source><volume>4</volume>:<elocation-id>dlac072</elocation-id>. doi:<pub-id pub-id-type="doi">10.1093/jacamr/dlac072</pub-id><pub-id pub-id-type="pmid">35959239</pub-id><pub-id pub-id-type="pmcid">PMC9361036</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>L&#246;fmark</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Edlund</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Nord</surname><given-names>CE</given-names></string-name></person-group>. <year>2010</year>. <article-title>Metronidazole is still the drug of choice for treatment of anaerobic infections</article-title>. <source>Clin Infect Dis</source><volume>50 Suppl 1</volume>:<fpage>S16</fpage>&#8211;<lpage>S23</lpage>. doi:<pub-id pub-id-type="doi">10.1086/647939</pub-id><pub-id pub-id-type="pmid">20067388</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>M&#252;ller</surname><given-names>M</given-names></string-name></person-group>. <year>1983</year>. <article-title>Mode of action of metronidazole on anaerobic bacteria and protozoa</article-title>. <source>Surgery</source><volume>93</volume>:<fpage>165</fpage>&#8211;<lpage>171</lpage>.<pub-id pub-id-type="pmid">6849201</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Samuelson</surname><given-names>J</given-names></string-name></person-group>. <year>1999</year>. <article-title>Why metronidazole is active against both bacteria and parasites</article-title>. <source>Antimicrob Agents Chemother</source><volume>43</volume>:<fpage>1533</fpage>&#8211;<lpage>1541</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.43.7.1533</pub-id><pub-id pub-id-type="pmid">10390199</pub-id><pub-id pub-id-type="pmcid">PMC89320</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bergan</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Arnold</surname><given-names>E</given-names></string-name></person-group>. <year>1980</year>. <article-title>Pharmacokinetics of metronidazole in healthy adult volunteers after tablets and suppositories</article-title>. <source>Chemotherapy</source><volume>26</volume>:<fpage>231</fpage>&#8211;<lpage>241</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000237911</pub-id><pub-id pub-id-type="pmid">7389423</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Goolsby</surname><given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Jakeman</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Gaynes</surname><given-names>RP</given-names></string-name></person-group>. <year>2018</year>. <article-title>Clinical relevance of metronidazole and peripheral neuropathy: a systematic review of the literature</article-title>. <source>Int J Antimicrob Agents</source><volume>51</volume>:<fpage>319</fpage>&#8211;<lpage>325</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ijantimicag.2017.08.033</pub-id><pub-id pub-id-type="pmid">28887203</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lamp</surname><given-names>KC</given-names></string-name>, <string-name name-style="western"><surname>Freeman</surname><given-names>CD</given-names></string-name>, <string-name name-style="western"><surname>Klutman</surname><given-names>NE</given-names></string-name>, <string-name name-style="western"><surname>Lacy</surname><given-names>MK</given-names></string-name></person-group>. <year>1999</year>. <article-title>Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials</article-title>. <source>Clin Pharmacokinet</source><volume>36</volume>:<fpage>353</fpage>&#8211;<lpage>373</lpage>. doi:<pub-id pub-id-type="doi">10.2165/00003088-199936050-00004</pub-id><pub-id pub-id-type="pmid">10384859</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rediguieri</surname><given-names>CF</given-names></string-name>, <string-name name-style="western"><surname>Porta</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>G Nunes</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Nunes</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Junginger</surname><given-names>HE</given-names></string-name>, <string-name name-style="western"><surname>Kopp</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Midha</surname><given-names>KK</given-names></string-name>, <string-name name-style="western"><surname>Shah</surname><given-names>VP</given-names></string-name>, <string-name name-style="western"><surname>Stavchansky</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dressman</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Barends</surname><given-names>DM</given-names></string-name></person-group>. <year>2011</year>. <article-title>Biowaiver monographs for immediate release solid oral dosage forms: metronidazole</article-title>. <source>J Pharm Sci</source><volume>100</volume>:<fpage>1618</fpage>&#8211;<lpage>1627</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jps.22409</pub-id><pub-id pub-id-type="pmid">21374600</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Somogyi</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Kong</surname><given-names>CB</given-names></string-name>, <string-name name-style="western"><surname>Gurr</surname><given-names>FW</given-names></string-name>, <string-name name-style="western"><surname>Sabto</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Spicer</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>McLean</surname><given-names>AJ</given-names></string-name></person-group>. <year>1984</year>. <article-title>Metronidazole pharmacokinetics in patients with acute renal failure</article-title>. <source>J Antimicrob Chemother</source><volume>13</volume>:<fpage>183</fpage>&#8211;<lpage>189</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jac/13.2.183</pub-id><pub-id pub-id-type="pmid">6706889</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lau</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Evans</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>CW</given-names></string-name>, <string-name name-style="western"><surname>Seligsohn</surname><given-names>R</given-names></string-name></person-group>. <year>1987</year>. <article-title>Pharmacokinetics of metronidazole in patients with alcoholic liver disease</article-title>. <source>Antimicrob Agents Chemother</source><volume>31</volume>:<fpage>1662</fpage>&#8211;<lpage>1664</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.31.11.1662</pub-id><pub-id pub-id-type="pmid">3435113</pub-id><pub-id pub-id-type="pmcid">PMC175016</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><string-name name-style="western"><surname>Laboratories</surname><given-names>P</given-names></string-name></person-group>. <year>2024</year>. <article-title>Flagyl- metronidazole tablet, film coated</article-title>. <comment>Available from</comment>: <ext-link xlink:href="https://labeling.pfizer.com/ShowLabeling.aspx?id=570#:~:text=The%20average%20elimination%20half%2Dlife,healthy%20subjects%20is%20eight%20hours" ext-link-type="uri">https://labeling.pfizer.com/ShowLabeling.aspx?id=570#:~:text=The%20average%20elimination%20half%2Dlife,healthy%20subjects%20is%20eight%20hours</ext-link>. <comment>Retrieved</comment><date-in-citation>16 Aug 2024</date-in-citation>.</mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Chua</surname><given-names>KYL</given-names></string-name></person-group>. <year>2017</year>. <part-title>Metronidazole</part-title>, <comment>p</comment><fpage>1807</fpage>&#8211;<lpage>1849</lpage>. In <source>Kucers&#8217; the use of antibiotics</source>. <publisher-name>CRC Press</publisher-name>.</mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>PubChem</collab></person-group>. <year>2022</year>. <article-title>Metronidazole</article-title>. <comment>Available from</comment>: <ext-link xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/Metronidazole" ext-link-type="uri">https://pubchem.ncbi.nlm.nih.gov/compound/Metronidazole</ext-link>. <comment>Retrieved</comment><date-in-citation> Aug 2025</date-in-citation>.</mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lopes-de-Campos</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Nunes</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Sarmento</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Jakobtorweihen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Reis</surname><given-names>S</given-names></string-name></person-group>. <year>2018</year>. <article-title>Metronidazole within phosphatidylcholine lipid membranes: new insights to improve the design of imidazole derivatives</article-title>. <source>Eur J Pharm Biopharm</source><volume>129</volume>:<fpage>204</fpage>&#8211;<lpage>214</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejpb.2018.05.036</pub-id><pub-id pub-id-type="pmid">29859282</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mahfouz</surname><given-names>NM</given-names></string-name>, <string-name name-style="western"><surname>Hassan</surname><given-names>MA</given-names></string-name></person-group>. <year>2001</year>. <article-title>Synthesis, chemical and enzymatic hydrolysis, and bioavailability evaluation in rabbits of metronidazole amino acid ester prodrugs with enhanced water solubility</article-title>. <source>J Pharm Pharmacol</source><volume>53</volume>:<fpage>841</fpage>&#8211;<lpage>848</lpage>. doi:<pub-id pub-id-type="doi">10.1211/0022357011776199</pub-id><pub-id pub-id-type="pmid">11428660</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sakurai</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Shiino</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Okamoto</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Nishimura</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Nakamura</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Hasegawa</surname><given-names>S</given-names></string-name></person-group>. <year>2016</year>. <article-title>Pharmacokinetics and safety of triple therapy with vonoprazan, amoxicillin, and clarithromycin or metronidazole: a phase 1, open-label, randomized, crossover study</article-title>. <source>Adv Ther</source><volume>33</volume>:<fpage>1519</fpage>&#8211;<lpage>1535</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s12325-016-0374-x</pub-id><pub-id pub-id-type="pmid">27432383</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Amon</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Amon</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Scharp</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Franke</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Nagel</surname><given-names>F</given-names></string-name></person-group>. <year>1983</year>. <article-title>Disposition kinetics of metronidazole in children</article-title>. <source>Eur J Clin Pharmacol</source><volume>24</volume>:<fpage>113</fpage>&#8211;<lpage>119</lpage>. doi:<pub-id pub-id-type="doi">10.1007/BF00613937</pub-id><pub-id pub-id-type="pmid">6832193</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dorn</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Petroff</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Stoelzel</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kees</surname><given-names>MG</given-names></string-name>, <string-name name-style="western"><surname>Kratzer</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Dietrich</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kloft</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zeitlinger</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kees</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Wrigge</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Simon</surname><given-names>P</given-names></string-name></person-group>. <year>2021</year>. <article-title>Perioperative administration of cefazolin and metronidazole in obese and non-obese patients: a pharmacokinetic study in plasma and interstitial fluid</article-title>. <source>J Antimicrob Chemother</source><volume>76</volume>:<fpage>2114</fpage>&#8211;<lpage>2120</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jac/dkab143</pub-id><pub-id pub-id-type="pmid">33969405</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schwartz</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Jeunet</surname><given-names>F</given-names></string-name></person-group>. <year>1976</year>. <article-title>Comparative pharmacokinetic studies of ornidazole and metronidazole in man</article-title>. <source>Chemotherapy</source><volume>22</volume>:<fpage>19</fpage>&#8211;<lpage>29</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000221906</pub-id><pub-id pub-id-type="pmid">1253627</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bergan</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Bjerke</surname><given-names>PE</given-names></string-name>, <string-name name-style="western"><surname>Fausa</surname><given-names>O</given-names></string-name></person-group>. <year>1981</year>. <article-title>Pharmacokinetics of metronidazole in patients with enteric disease compared to normal volunteers</article-title>. <source>Chemotherapy</source><volume>27</volume>:<fpage>233</fpage>&#8211;<lpage>238</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000237985</pub-id><pub-id pub-id-type="pmid">7249785</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Das</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Armstrong</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Learoyd</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Edeki</surname><given-names>T</given-names></string-name></person-group>. <year>2015</year>. <article-title>Randomized pharmacokinetic and drug-drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects</article-title>. <source>Pharmacol Res Perspect</source><volume>3</volume>:<elocation-id>e00172</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/prp2.172</pub-id><pub-id pub-id-type="pmid">26516584</pub-id><pub-id pub-id-type="pmcid">PMC4618643</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Obodozie</surname><given-names>OO</given-names></string-name>, <string-name name-style="western"><surname>Ebeshi</surname><given-names>BU</given-names></string-name>, <string-name name-style="western"><surname>Mustapha</surname><given-names>KB</given-names></string-name>, <string-name name-style="western"><surname>Kirim</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Ekpenyong</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Inyang</surname><given-names>US</given-names></string-name></person-group>. <year>2011</year>. <article-title>The effects of an investigational antimalarial agent, NIPRD-AM1 on the single dose pharmacokinetics of metronidazole in healthy human volunteers</article-title>. <source>Eur J Drug Metab Pharmacokinet</source><volume>35</volume>:<fpage>103</fpage>&#8211;<lpage>108</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s13318-010-0012-y</pub-id><pub-id pub-id-type="pmid">21302036</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hauth</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Goldenberg</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Andrews</surname><given-names>WW</given-names></string-name>, <string-name name-style="western"><surname>DuBard</surname><given-names>MB</given-names></string-name>, <string-name name-style="western"><surname>Copper</surname><given-names>RL</given-names></string-name></person-group>. <year>1995</year>. <article-title>Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis</article-title>. <source>N Engl J Med</source><volume>333</volume>:<fpage>1732</fpage>&#8211;<lpage>1736</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJM199512283332603</pub-id><pub-id pub-id-type="pmid">7491136</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Agarwal</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kanekar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sabat</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Thamburaj</surname><given-names>K</given-names></string-name></person-group>. <year>2016</year>. <article-title>Metronidazole-induced cerebellar toxicity</article-title>. <source>Neurol Int</source><volume>8</volume>:<elocation-id>6365</elocation-id>. doi:<pub-id pub-id-type="doi">10.4081/ni.2016.6365</pub-id><pub-id pub-id-type="pmid">27127600</pub-id><pub-id pub-id-type="pmcid">PMC4830366</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mitchell</surname><given-names>DA</given-names></string-name></person-group>. <year>1984</year>. <article-title>Metronidazole: its use in clinical dentistry</article-title>. <source>J Clin Periodontol</source><volume>11</volume>:<fpage>145</fpage>&#8211;<lpage>158</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1600-051x.1984.tb01318.x</pub-id><pub-id pub-id-type="pmid">6368609</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ataee</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Karimi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Eftekhari</surname><given-names>K</given-names></string-name></person-group>. <year>2020</year>. <article-title>Hepatic failure following metronidazole in children with cockayne syndrome</article-title>. <source>Case Rep Pediatr</source><volume>2020</volume>:<fpage>9634196</fpage>. doi:<pub-id pub-id-type="doi">10.1155/2020/9634196</pub-id><pub-id pub-id-type="pmid">32082677</pub-id><pub-id pub-id-type="pmcid">PMC7008298</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Passmore</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>McElnay</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>D&#8217;Arcy</surname><given-names>PF</given-names></string-name></person-group>. <year>1984</year>. <article-title>Drugs taken by mothers in the puerperium: inpatient survey in Northern Ireland</article-title>. <source>Br Med J (Clin Res Ed)</source><volume>289</volume>:<fpage>1593</fpage>&#8211;<lpage>1596</lpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.289.6458.1593</pub-id><pub-id pub-id-type="pmcid">PMC1443918</pub-id><pub-id pub-id-type="pmid">6439334</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lau</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Lam</surname><given-names>NP</given-names></string-name>, <string-name name-style="western"><surname>Piscitelli</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Wilkes</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Danziger</surname><given-names>LH</given-names></string-name></person-group>. <year>1992</year>. <article-title>Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives</article-title>. <source>Clin Pharmacokinet</source><volume>23</volume>:<fpage>328</fpage>&#8211;<lpage>364</lpage>. doi:<pub-id pub-id-type="doi">10.2165/00003088-199223050-00002</pub-id><pub-id pub-id-type="pmid">1478003</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ralph</surname><given-names>ED</given-names></string-name></person-group>. <year>1983</year>. <article-title>Clinical pharmacokinetics of metronidazole</article-title>. <source>Clin Pharmacokinet</source><volume>8</volume>:<fpage>43</fpage>&#8211;<lpage>62</lpage>. doi:<pub-id pub-id-type="doi">10.2165/00003088-198308010-00003</pub-id><pub-id pub-id-type="pmid">6340904</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Moher</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Liberati</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Tetzlaff</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Altman</surname><given-names>DG</given-names></string-name>, <collab>PRISMA Group</collab></person-group>. <year>2009</year>. <article-title>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</article-title>. <source>Ann Intern Med</source><volume>151</volume>:<fpage>264</fpage>&#8211;<lpage>269</lpage>. doi:<pub-id pub-id-type="doi">10.7326/0003-4819-151-4-200908180-00135</pub-id><pub-id pub-id-type="pmid">19622511</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Chandler</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cumpston</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Page</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Welch</surname><given-names>V</given-names></string-name></person-group>. <year>2019</year>. <source>Cochrane handbook for systematic reviews of interventions</source>. <publisher-name>Wiley</publisher-name>, <publisher-loc>Hoboken</publisher-loc>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.ED000142</pub-id><pub-id pub-id-type="pmcid">PMC10284251</pub-id><pub-id pub-id-type="pmid">31643080</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Visser</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Hundt</surname><given-names>HK</given-names></string-name></person-group>. <year>1984</year>. <article-title>The pharmacokinetics of a single intravenous dose of metronidazole in pregnant patients</article-title>. <source>J Antimicrob Chemother</source><volume>13</volume>:<fpage>279</fpage>&#8211;<lpage>283</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jac/13.3.279</pub-id><pub-id pub-id-type="pmid">6725177</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Plaisance</surname><given-names>KI</given-names></string-name>, <string-name name-style="western"><surname>Quintiliani</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Nightingale</surname><given-names>CH</given-names></string-name></person-group>. <year>1988</year>. <article-title>The pharmacokinetics of metronidazole and its metabolites in critically ill patients</article-title>. <source>J Antimicrob Chemother</source><volume>21</volume>:<fpage>195</fpage>&#8211;<lpage>200</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jac/21.2.195</pub-id><pub-id pub-id-type="pmid">3360682</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Heisterberg</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Branebjerg</surname><given-names>PE</given-names></string-name></person-group>. <year>1983</year>. <article-title>Blood and milk concentrations of metronidazole in mothers and infants</article-title>. <source>J Perinat Med</source><volume>11</volume>:<fpage>114</fpage>&#8211;<lpage>120</lpage>. doi:<pub-id pub-id-type="doi">10.1515/jpme.1983.11.2.114</pub-id><pub-id pub-id-type="pmid">6854509</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Daneshmend</surname><given-names>TK</given-names></string-name>, <string-name name-style="western"><surname>Homeida</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kaye</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Elamin</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Roberts</surname><given-names>CJ</given-names></string-name></person-group>. <year>1982</year>. <article-title>Disposition of oral metronidazole in hepatic cirrhosis and in hepatosplenic schistosomiasis</article-title>. <source>Gut</source><volume>23</volume>:<fpage>807</fpage>&#8211;<lpage>813</lpage>. doi:<pub-id pub-id-type="doi">10.1136/gut.23.10.807</pub-id><pub-id pub-id-type="pmid">7117899</pub-id><pub-id pub-id-type="pmcid">PMC1419829</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ti</surname><given-names>TY</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>HS</given-names></string-name>, <string-name name-style="western"><surname>Khoo</surname><given-names>YM</given-names></string-name></person-group>. <year>1996</year>. <article-title>Disposition of intravenous metronidazole in Asian surgical patients</article-title>. <source>Antimicrob Agents Chemother</source><volume>40</volume>:<fpage>2248</fpage>&#8211;<lpage>2251</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.40.10.2248</pub-id><pub-id pub-id-type="pmid">8891123</pub-id><pub-id pub-id-type="pmcid">PMC163512</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Loft</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Egsmose</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Sonne</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Poulsen</surname><given-names>HE</given-names></string-name>, <string-name name-style="western"><surname>D&#248;ssing</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Andreasen</surname><given-names>PB</given-names></string-name></person-group>. <year>1990</year>. <article-title>Metronidazole elimination is preserved in the elderly</article-title>. <source>Hum Exp Toxicol</source><volume>9</volume>:<fpage>155</fpage>&#8211;<lpage>159</lpage>. doi:<pub-id pub-id-type="doi">10.1177/096032719000900306</pub-id><pub-id pub-id-type="pmid">2375881</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jensen</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Gugler</surname><given-names>R</given-names></string-name></person-group>. <year>1983</year>. <article-title>Single- and multiple-dose metronidazole kinetics</article-title>. <source>Clin Pharmacol Ther</source><volume>34</volume>:<fpage>481</fpage>&#8211;<lpage>487</lpage>. doi:<pub-id pub-id-type="doi">10.1038/clpt.1983.201</pub-id><pub-id pub-id-type="pmid">6617070</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dilger</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Fux</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>R&#246;ck</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>M&#246;rike</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Gleiter</surname><given-names>CH</given-names></string-name></person-group>. <year>2007</year>. <article-title>Effect of high-dose metronidazole on pharmacokinetics of oral budesonide and vice versa: a double drug interaction study</article-title>. <source>J Clin Pharmacol</source><volume>47</volume>:<fpage>1532</fpage>&#8211;<lpage>1539</lpage>. doi:<pub-id pub-id-type="doi">10.1177/0091270007308617</pub-id><pub-id pub-id-type="pmid">18048573</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Muscar&#225;</surname><given-names>MN</given-names></string-name>, <string-name name-style="western"><surname>Pedrazzoli</surname><given-names>J</given-names><suffix>Jr</suffix></string-name>, <string-name name-style="western"><surname>Miranda</surname><given-names>EL</given-names></string-name>, <string-name name-style="western"><surname>Ferraz</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Hofst&#228;tter</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Leite</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Magalh&#227;es</surname><given-names>AF</given-names></string-name>, <string-name name-style="western"><surname>Leonardi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>De Nucci</surname><given-names>G</given-names></string-name></person-group>. <year>1995</year>. <article-title>Plasma hydroxy-metronidazole/metronidazole ratio in patients with liver disease and in healthy volunteers</article-title>. <source>Br J Clin Pharmacol</source><volume>40</volume>:<fpage>477</fpage>&#8211;<lpage>480</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2125.1995.tb05792.x</pub-id><pub-id pub-id-type="pmid">8703652</pub-id><pub-id pub-id-type="pmcid">PMC1365194</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ashiq</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Usman</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ashraf</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Omer</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Khokhar</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Saeed-ul-Hassan</surname><given-names>S</given-names></string-name></person-group>. <year>2011</year>. <article-title>Comparative pharmacokinetics of metronidazole in healthy volunteers and in patients suffering from amoebiasis</article-title>. <source>Pak J Pharm</source><volume>24</volume>:<fpage>41</fpage>&#8211;<lpage>46</lpage>.</mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Thiercelin</surname><given-names>JF</given-names></string-name>, <string-name name-style="western"><surname>Diquet</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Levesque</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ghesqui&#233;re</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Simon</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Viars</surname><given-names>P</given-names></string-name></person-group>. <year>1984</year>. <article-title>Metronidazole kinetics and bioavailability in patients undergoing gastrointestinal surgery</article-title>. <source>Clin Pharmacol Ther</source><volume>35</volume>:<fpage>510</fpage>&#8211;<lpage>519</lpage>. doi:<pub-id pub-id-type="doi">10.1038/clpt.1984.69</pub-id><pub-id pub-id-type="pmid">6705449</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Guay</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Meatherall</surname><given-names>RC</given-names></string-name>, <string-name name-style="western"><surname>Baxter</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Jacyk</surname><given-names>WR</given-names></string-name>, <string-name name-style="western"><surname>Penner</surname><given-names>B</given-names></string-name></person-group>. <year>1984</year>. <article-title>Pharmacokinetics of metronidazole in patients undergoing continuous ambulatory peritoneal dialysis</article-title>. <source>Antimicrob Agents Chemother</source><volume>25</volume>:<fpage>306</fpage>&#8211;<lpage>310</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.25.3.306</pub-id><pub-id pub-id-type="pmid">6721462</pub-id><pub-id pub-id-type="pmcid">PMC185505</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Loft</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sonne</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>D&#248;ssing</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Andreasen</surname><given-names>PB</given-names></string-name></person-group>. <year>1987</year>. <article-title>Metronidazole pharmacokinetics in patients with hepatic encephalopathy</article-title>. <source>Scand J Gastroenterol</source><volume>22</volume>:<fpage>117</fpage>&#8211;<lpage>123</lpage>. doi:<pub-id pub-id-type="doi">10.3109/00365528708991867</pub-id><pub-id pub-id-type="pmid">3563404</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Karjagin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>P&#228;hkla</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Karki</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Starkopf</surname><given-names>J</given-names></string-name></person-group>. <year>2005</year>. <article-title>Distribution of metronidazole in muscle tissue of patients with septic shock and its efficacy against Bacteroides fragilis in vitro</article-title>. <source>J Antimicrob Chemother</source><volume>55</volume>:<fpage>341</fpage>&#8211;<lpage>346</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jac/dkh544</pub-id><pub-id pub-id-type="pmid">15728145</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Montalli</surname><given-names>VA</given-names></string-name>, <string-name name-style="western"><surname>Bergamaschi</surname><given-names>C de C</given-names></string-name>, <string-name name-style="western"><surname>Ramacciato</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Nolasco</surname><given-names>FP</given-names></string-name>, <string-name name-style="western"><surname>Groppo</surname><given-names>FC</given-names></string-name>, <string-name name-style="western"><surname>Brito</surname><given-names>R de</given-names><suffix>Jr</suffix></string-name>, <string-name name-style="western"><surname>Haas</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Motta</surname><given-names>RHL</given-names></string-name></person-group>. <year>2012</year>. <article-title>The effect of smoking on the bioavailability of metronidazole in plasma and saliva</article-title>. <source>J Am Dent Assoc</source><volume>143</volume>:<fpage>149</fpage>&#8211;<lpage>156</lpage>. doi:<pub-id pub-id-type="doi">10.14219/jada.archive.2012.0125</pub-id><pub-id pub-id-type="pmid">22298556</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Eradiri</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Jamali</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Thomson</surname><given-names>ABR</given-names></string-name></person-group>. <year>1987</year>. <article-title>Steady&#8208;state pharmacokinetics of metronidazole in Crohn&#8217;s disease</article-title>. <source>Biopharm Drug Disp</source><volume>8</volume>:<fpage>249</fpage>&#8211;<lpage>259</lpage>. doi:<pub-id pub-id-type="doi">10.1002/bdd.2510080306</pub-id><pub-id pub-id-type="pmid">3593902</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Amon</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Amon</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Franke</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Mohr</surname><given-names>C</given-names></string-name></person-group>. <year>1981</year>. <article-title>Pharmacokinetics of metronidazole in pregnant women</article-title>. <source>Chemotherapy</source><volume>27</volume>:<fpage>73</fpage>&#8211;<lpage>79</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000237958</pub-id><pub-id pub-id-type="pmid">7471904</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kim</surname><given-names>K-A</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>J-Y</given-names></string-name></person-group>. <year>2010</year>. <article-title>Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers</article-title>. <source>Eur J Clin Pharmacol</source><volume>66</volume>:<fpage>721</fpage>&#8211;<lpage>725</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00228-010-0797-2</pub-id><pub-id pub-id-type="pmid">20306185</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><string-name name-style="western"><surname>Hanifah</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mustofa</surname><given-names>E</given-names></string-name></person-group>. <year>2007</year>. <article-title>Sex differences on the metronidazole&#8217;s pharmacokinetic profile</article-title>. <conf-name>Internaitonal Conference: Update on Pharmaceutical Innovation Adn New Drug Delivery System</conf-name>.</mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lares-Asseff</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Cravioto</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Santiago</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>P&#233;rez-Ort&#237;z</surname><given-names>B</given-names></string-name></person-group>. <year>1992</year>. <article-title>Pharmacokinetics of metronidazole in severely malnourished and nutritionally rehabilitated children</article-title>. <source>Clin Pharmacol Ther</source><volume>51</volume>:<fpage>42</fpage>&#8211;<lpage>50</lpage>. doi:<pub-id pub-id-type="doi">10.1038/clpt.1992.6</pub-id><pub-id pub-id-type="pmid">1732076</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ljungberg</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Nilsson-Ehle</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Ursing</surname><given-names>B</given-names></string-name></person-group>. <year>1984</year>. <article-title>Metronidazole: pharmacokinetic observations in severely ill patients</article-title>. <source>J Antimicrob Chemother</source><volume>14</volume>:<fpage>275</fpage>&#8211;<lpage>283</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jac/14.3.275</pub-id><pub-id pub-id-type="pmid">6490572</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Farrell</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Baird-Lambert</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cvejic</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Buchanan</surname><given-names>N</given-names></string-name></person-group>. <year>1984</year>. <article-title>Disposition and metabolism of metronidazole in patients with liver failure</article-title>. <source>Hepatology</source><volume>4</volume>:<fpage>722</fpage>&#8211;<lpage>726</lpage>. doi:<pub-id pub-id-type="doi">10.1002/hep.1840040427</pub-id><pub-id pub-id-type="pmid">6745863</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Loft</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>D&#248;ssing</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sonne</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dalhof</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Bjerrum</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Poulsen</surname><given-names>HE</given-names></string-name></person-group>. <year>1988</year>. <article-title>Lack of effect of cimetidine on the pharmacokinetics and metabolism of a single oral dose of metronidazole</article-title>. <source>Eur J Clin Pharmacol</source><volume>35</volume>:<fpage>65</fpage>&#8211;<lpage>68</lpage>. doi:<pub-id pub-id-type="doi">10.1007/BF00555509</pub-id><pub-id pub-id-type="pmid">3220096</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Somogyi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kong</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Sabto</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gurr</surname><given-names>FW</given-names></string-name>, <string-name name-style="western"><surname>Spicer</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>McLean</surname><given-names>AJ</given-names></string-name></person-group>. <year>1983</year>. <article-title>Disposition and removal of metronidazole in patients undergoing haemodialysis</article-title>. <source>Eur J Clin Pharmacol</source><volume>25</volume>:<fpage>683</fpage>&#8211;<lpage>687</lpage>. doi:<pub-id pub-id-type="doi">10.1007/BF00542359</pub-id><pub-id pub-id-type="pmid">6662167</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>A. Kurji</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>M. Ghareeb</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>H. Zalzala</surname><given-names>M</given-names></string-name></person-group>. <year>2011</year>. <article-title>Serum level profile and pharmacokinetic parameters of single oral dose of metronidazole in Type II diabetic patients</article-title>. <source>IJPS</source><volume>20</volume>:<fpage>14</fpage>&#8211;<lpage>18</lpage>. doi:<pub-id pub-id-type="doi">10.31351/vol20iss1pp14-18</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jager-Roman</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Doyle</surname><given-names>PE</given-names></string-name>, <string-name name-style="western"><surname>Baird-Lambert</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cvejic</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Buchanan</surname><given-names>N</given-names></string-name></person-group>. <year>1982</year>. <article-title>Pharmacokinetics and tissue distribution of metronidazole in the newborn infant</article-title>. <source>J Pediatr</source><volume>100</volume>:<fpage>651</fpage>&#8211;<lpage>654</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0022-3476(82)80779-8</pub-id><pub-id pub-id-type="pmid">7062220</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>David</surname><given-names>FL</given-names></string-name>, <string-name name-style="western"><surname>Da Silva</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Mendes</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Ferraz</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Muscara</surname><given-names>MN</given-names></string-name>, <string-name name-style="western"><surname>Moreno</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Nucci</surname><given-names>GD</given-names></string-name>, <string-name name-style="western"><surname>Pedrazzoli</surname><given-names>JJ</given-names></string-name></person-group>. <year>1998</year>. <article-title>Acid suppression by omeprazole does not affect orally administered metronidazole bioavailability and metabolism in healthy male volunteers</article-title>. <source>Aliment Pharmacol Ther</source><volume>12</volume>:<fpage>349</fpage>&#8211;<lpage>354</lpage>. doi:<pub-id pub-id-type="doi">10.1046/j.1365-2036.1998.00298.x</pub-id><pub-id pub-id-type="pmid">9690724</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Goddard</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Jessa</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Barrett</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Shaw</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Idstrom</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cederberg</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Spiller</surname><given-names>R</given-names></string-name></person-group>. <year>1996</year>. <article-title>Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice</article-title>. <source>Gastroenterology</source><volume>111</volume>:<fpage>358</fpage>&#8211;<lpage>367</lpage>. doi:<pub-id pub-id-type="doi">10.1053/gast.1996.v111.pm8690200</pub-id><pub-id pub-id-type="pmid">8690200</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Calafatti</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>dos Santos</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>da Silva</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Deguer</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Carvalho</surname><given-names>AF</given-names><suffix>Jr</suffix></string-name>, <string-name name-style="western"><surname>Mendes</surname><given-names>FD</given-names></string-name>, <string-name name-style="western"><surname>Ferraz</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Bento</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Pereira</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Piovesana</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>de Nucci</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Lerner</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Pedrazzoli</surname><given-names>J</given-names><suffix>Jr</suffix></string-name></person-group>. <year>2000</year>. <article-title>Transfer of metronidazole to gastric juice: impact of Helicobacter pylori infection and omeprazole</article-title>. <source>Scand J Gastroenterol</source><volume>35</volume>:<fpage>699</fpage>&#8211;<lpage>704</lpage>. doi:<pub-id pub-id-type="doi">10.1080/003655200750023354</pub-id><pub-id pub-id-type="pmid">10972172</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Houghton</surname><given-names>GW</given-names></string-name>, <string-name name-style="western"><surname>Thorne</surname><given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Templeton</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Collier</surname><given-names>J</given-names></string-name></person-group>. <year>1979</year>. <article-title>Comparison of the pharmacokinetics of metronidazole in healthy female volunteers following either a single oral or intravenous dose</article-title>. <source>Br J Clin Pharmacol</source><volume>8</volume>:<fpage>337</fpage>&#8211;<lpage>341</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2125.1979.tb04715.x</pub-id><pub-id pub-id-type="pmid">508508</pub-id><pub-id pub-id-type="pmcid">PMC1429835</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rajnarayana</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Reddy</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Krishna</surname><given-names>DR</given-names></string-name></person-group>. <year>2003</year>. <article-title>Diosmin pretreatment affects bioavailability of metronidazole</article-title>. <source>Eur J Clin Pharmacol</source><volume>58</volume>:<fpage>803</fpage>&#8211;<lpage>807</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00228-002-0543-5</pub-id><pub-id pub-id-type="pmid">12698306</pub-id></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rajnarayana</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Reddy</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Vidyasagar</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Krishna</surname><given-names>DR</given-names></string-name></person-group>. <year>2004</year>. <article-title>Study on the influence of silymarin pretreatment on metabolism and disposition of metronidazole</article-title>. <source>Arzneimittelforschung</source><volume>54</volume>:<fpage>109</fpage>&#8211;<lpage>113</lpage>. doi:<pub-id pub-id-type="doi">10.1055/s-0031-1296944</pub-id><pub-id pub-id-type="pmid">15038460</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Melander</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kahlmeter</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Kamme</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ursing</surname><given-names>B</given-names></string-name></person-group>. <year>1977</year>. <article-title>Bioavailability of metronidazole in fasting and non-fasting healthy subjects and in patients with Crohn&#8217;s disease</article-title>. <source>Eur J Clin Pharmacol</source><volume>12</volume>:<fpage>69</fpage>&#8211;<lpage>72</lpage>. doi:<pub-id pub-id-type="doi">10.1007/BF00561408</pub-id><pub-id pub-id-type="pmid">332504</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Nanovskaya</surname><given-names>TN</given-names></string-name>, <string-name name-style="western"><surname>Zhan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Abdel-Rahman</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Jasek</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hankins</surname><given-names>GDV</given-names></string-name>, <string-name name-style="western"><surname>Ahmed</surname><given-names>MS</given-names></string-name></person-group>. <year>2011</year>. <article-title>Pharmacokinetics of metronidazole in pregnant patients with bacterial vaginosis</article-title>. <source>J Matern Fetal Neonatal Med</source><volume>24</volume>:<fpage>444</fpage>&#8211;<lpage>448</lpage>. doi:<pub-id pub-id-type="doi">10.3109/14767058.2010.497573</pub-id><pub-id pub-id-type="pmid">20608802</pub-id><pub-id pub-id-type="pmcid">PMC3033962</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Backman</surname><given-names>JT</given-names></string-name>, <string-name name-style="western"><surname>Kivist&#246;</surname><given-names>KT</given-names></string-name>, <string-name name-style="western"><surname>Neuvonen</surname><given-names>PJ</given-names></string-name></person-group>. <year>2000</year>. <article-title>Effects of metronidazole on midazolam metabolism in vitro and in vivo</article-title>. <source>Eur J Clin Pharmacol</source><volume>56</volume>:<fpage>555</fpage>&#8211;<lpage>559</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s002280000201</pub-id><pub-id pub-id-type="pmid">11151744</pub-id></mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pierce</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Corcoran</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Martin</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Barrett</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Inglis</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Preston</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Thompson</surname><given-names>TN</given-names></string-name>, <string-name name-style="western"><surname>Willsie</surname><given-names>SK</given-names></string-name></person-group>. <year>2014</year>. <article-title>Effect of MMX mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials</article-title>. <source>Drug Des Devel Ther</source><volume>8</volume>:<fpage>529</fpage>&#8211;<lpage>543</lpage>. doi:<pub-id pub-id-type="doi">10.2147/DDDT.S55373</pub-id><pub-id pub-id-type="pmcid">PMC4029757</pub-id><pub-id pub-id-type="pmid">24868146</pub-id></mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jessa</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Goddard</surname><given-names>AF</given-names></string-name>, <string-name name-style="western"><surname>Barrett</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Shaw</surname><given-names>PN</given-names></string-name>, <string-name name-style="western"><surname>Spiller</surname><given-names>RC</given-names></string-name></person-group>. <year>1997</year>. <article-title>The effect of omeprazole on the pharmacokinetics of metronidazole and hydroxymetronidazole in human plasma, saliva and gastric juice</article-title>. <source>Br J Clin Pharmacol</source><volume>44</volume>:<fpage>245</fpage>&#8211;<lpage>253</lpage>. doi:<pub-id pub-id-type="doi">10.1046/j.1365-2125.1997.t01-1-00572.x</pub-id><pub-id pub-id-type="pmid">9296318</pub-id><pub-id pub-id-type="pmcid">PMC2042841</pub-id></mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mattila</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>M&#228;nnist&#246;</surname><given-names>PT</given-names></string-name>, <string-name name-style="western"><surname>M&#228;ntyl&#228;</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Nyk&#228;nen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lamminsivu</surname><given-names>U</given-names></string-name></person-group>. <year>1983</year>. <article-title>Comparative pharmacokinetics of metronidazole and tinidazole as influenced by administration route</article-title>. <source>Antimicrob Agents Chemother</source><volume>23</volume>:<fpage>721</fpage>&#8211;<lpage>725</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.23.5.721</pub-id><pub-id pub-id-type="pmid">6870221</pub-id><pub-id pub-id-type="pmcid">PMC184797</pub-id></mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mattie</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Dijkmans</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>van Gulpen</surname><given-names>C</given-names></string-name></person-group>. <year>1982</year>. <article-title>The pharmacokinetics of metronidazole and tinidazole in patients with mixed aerobic--anaerobic infections</article-title>. <source>J Antimicrob Chemother</source><volume>10 Suppl A</volume>:<fpage>59</fpage>&#8211;<lpage>64</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jac/10.suppl_a.59</pub-id><pub-id pub-id-type="pmid">7118776</pub-id></mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ventura Cerd&#225;</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Al&#243;s Almi&#241;ana</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Nomdedeu Guinot</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Merino Sanju&#225;n</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Salvador Sanch&#237;s</surname><given-names>JL</given-names></string-name></person-group>. <year>2008</year>. <article-title>The pharmacokinetics of metronidazole and gentamicin in a single preoperative dose as antibiotic prophylaxis in colorectal surgery</article-title>. <source>Farm Hosp</source><volume>32</volume>:<fpage>77</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">18783706</pub-id></mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hamberg</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Ovesen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Dorfeldt</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Loft</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sonne</surname><given-names>J</given-names></string-name></person-group>. <year>1990</year>. <article-title>The effect of dietary energy and protein deficiency on drug metabolism</article-title>. <source>Eur J Clin Pharmacol</source><volume>38</volume>:<fpage>567</fpage>&#8211;<lpage>570</lpage>. doi:<pub-id pub-id-type="doi">10.1007/BF00278583</pub-id><pub-id pub-id-type="pmid">2373130</pub-id></mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sprandel</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Schriever</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Pendland</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Quinn</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Gotfried</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Hackett</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Graham</surname><given-names>MB</given-names></string-name>, <string-name name-style="western"><surname>Danziger</surname><given-names>LH</given-names></string-name>, <string-name name-style="western"><surname>Rodvold</surname><given-names>KA</given-names></string-name></person-group>. <year>2004</year>. <article-title>Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects</article-title>. <source>Antimicrob Agents Chemother</source><volume>48</volume>:<fpage>4597</fpage>&#8211;<lpage>4605</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.48.12.4597-4605.2004</pub-id><pub-id pub-id-type="pmid">15561831</pub-id><pub-id pub-id-type="pmcid">PMC529226</pub-id></mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ding</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>NY</given-names></string-name>, <string-name name-style="western"><surname>Wen</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>WB</given-names></string-name></person-group>. <year>2015</year>. <article-title>Pharmacokinetics of metronidazole, tetracycline and bismuth in healthy volunteers after oral administration of compound tablets containing a combination of metronidazole, tetracycline hydrochloride and bismuth oxide</article-title>. <source>Drug Res (Stuttg)</source><volume>65</volume>:<fpage>74</fpage>&#8211;<lpage>81</lpage>. doi:<pub-id pub-id-type="doi">10.1055/s-0034-1372611</pub-id><pub-id pub-id-type="pmid">24764254</pub-id></mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Salas-Herrera</surname><given-names>IG</given-names></string-name>, <string-name name-style="western"><surname>Lawson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Johnston</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Turner</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Gott</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Dennis</surname><given-names>MJ</given-names></string-name></person-group>. <year>1991</year>. <article-title>Plasma metronidazole concentrations after single and repeated vaginal pessary administration</article-title>. <source>Br J Clin Pharmacol</source><volume>32</volume>:<fpage>621</fpage>&#8211;<lpage>623</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2125.1991.tb03962.x</pub-id><pub-id pub-id-type="pmid">1954077</pub-id><pub-id pub-id-type="pmcid">PMC1368641</pub-id></mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fredricsson</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Hagstr&#246;m</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Nord</surname><given-names>C-E</given-names></string-name>, <string-name name-style="western"><surname>Rane</surname><given-names>A</given-names></string-name></person-group>. <year>1987</year>. <article-title>Systemic concentrations of metronidazole and its main metabolites after intravenous oral and vaginal administration</article-title>. <source>Gynecol Obstet Invest</source><volume>24</volume>:<fpage>200</fpage>&#8211;<lpage>207</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000298803</pub-id><pub-id pub-id-type="pmid">3692332</pub-id></mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Roux</surname><given-names>AF</given-names></string-name>, <string-name name-style="western"><surname>Moirot</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Delhotal</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Leroy</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Bonmarchand</surname><given-names>GP</given-names></string-name>, <string-name name-style="western"><surname>Humbert</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Flouvat</surname><given-names>B</given-names></string-name></person-group>. <year>1984</year>. <article-title>Metronidazole kinetics in patients with acute renal failure on dialysis: a cumulative study</article-title>. <source>Clin Pharmacol Ther</source><volume>36</volume>:<fpage>363</fpage>&#8211;<lpage>368</lpage>. doi:<pub-id pub-id-type="doi">10.1038/clpt.1984.188</pub-id><pub-id pub-id-type="pmid">6467795</pub-id></mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Houghton</surname><given-names>GW</given-names></string-name>, <string-name name-style="western"><surname>Hundt</surname><given-names>HK</given-names></string-name>, <string-name name-style="western"><surname>Muller</surname><given-names>FO</given-names></string-name>, <string-name name-style="western"><surname>Templeton</surname><given-names>R</given-names></string-name></person-group>. <year>1982</year>. <article-title>A comparison of the pharmacokinetics of metronidazole in man after oral administration of single doses of benzoylmetronidazole and metronidazole</article-title>. <source>Br J Clin Pharmacol</source><volume>14</volume>:<fpage>201</fpage>&#8211;<lpage>206</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2125.1982.tb01962.x</pub-id><pub-id pub-id-type="pmid">7104172</pub-id><pub-id pub-id-type="pmcid">PMC1427741</pub-id></mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Loft</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>D&#248;ssing</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Poulsen</surname><given-names>HE</given-names></string-name>, <string-name name-style="western"><surname>Sonne</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Olesen</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Simonsen</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Andreasen</surname><given-names>PB</given-names></string-name></person-group>. <year>1986</year>. <article-title>Influence of dose and route of administration on disposition of metronidazole and its major metabolites</article-title>. <source>Eur J Clin Pharmacol</source><volume>30</volume>:<fpage>467</fpage>&#8211;<lpage>473</lpage>. doi:<pub-id pub-id-type="doi">10.1007/BF00607962</pub-id><pub-id pub-id-type="pmid">3743624</pub-id></mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cunningham</surname><given-names>FE</given-names></string-name>, <string-name name-style="western"><surname>Kraus</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Brubaker</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Fischer</surname><given-names>JH</given-names></string-name></person-group>. <year>1994</year>. <article-title>Pharmacokinetics of intravaginal metronidazole gel</article-title>. <source>J Clin Pharmacol</source><volume>34</volume>:<fpage>1060</fpage>&#8211;<lpage>1065</lpage>. doi:<pub-id pub-id-type="doi">10.1002/j.1552-4604.1994.tb01981.x</pub-id><pub-id pub-id-type="pmid">7876396</pub-id></mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lau</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Emmons</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Seligsohn</surname><given-names>R</given-names></string-name></person-group>. <year>1991</year>. <article-title>Pharmacokinetics of intravenous metronidazole at different dosages in healthy subjects</article-title>. <source>Int J Clin Pharmacol Ther Toxicol</source><volume>29</volume>:<fpage>386</fpage>&#8211;<lpage>390</lpage>.<pub-id pub-id-type="pmid">1748538</pub-id></mixed-citation></ref><ref id="B92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Amon</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Amon</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>H&#252;ller</surname><given-names>H</given-names></string-name></person-group>. <year>1978</year>. <article-title>Pharmacokinetics and therapeutic efficacy of metronidazole at different dosages</article-title>. <source>Int J Clin Pharmacol Biopharm</source><volume>16</volume>:<fpage>384</fpage>&#8211;<lpage>286</lpage>.<pub-id pub-id-type="pmid">357311</pub-id></mixed-citation></ref><ref id="B93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Alper</surname><given-names>MMB</given-names></string-name>, <string-name name-style="western"><surname>McLean</surname><given-names>BN</given-names></string-name>, <string-name name-style="western"><surname>William</surname><given-names>M</given-names></string-name></person-group>. <year>1985</year>. <article-title>Systemic absorption of metronidazole by the vaginal route</article-title>. <source>Obstet Gynecol</source><volume>65</volume>:<fpage>781</fpage>&#8211;<lpage>784</lpage>.<pub-id pub-id-type="pmid">4000568</pub-id></mixed-citation></ref><ref id="B94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Clark</surname><given-names>HD</given-names></string-name>, <string-name name-style="western"><surname>Wells</surname><given-names>GA</given-names></string-name>, <string-name name-style="western"><surname>Hu&#235;t</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>McAlister</surname><given-names>FA</given-names></string-name>, <string-name name-style="western"><surname>Salmi</surname><given-names>LR</given-names></string-name>, <string-name name-style="western"><surname>Fergusson</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Laupacis</surname><given-names>A</given-names></string-name></person-group>. <year>1999</year>. <article-title>Assessing the quality of randomized trials: reliability of the Jadad scale</article-title>. <source>Control Clin Trials</source><volume>20</volume>:<fpage>448</fpage>&#8211;<lpage>452</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s0197-2456(99)00026-4</pub-id><pub-id pub-id-type="pmid">10503804</pub-id></mixed-citation></ref><ref id="B95"><label>95</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Anonymous</collab></person-group>. <year>2009</year>. <source>On biostatistics and clinical trials</source>. <comment>Available from</comment>: <ext-link xlink:href="http://onbiostatistics.blogspot.com/2009/03/jadad-scale-to-assess-quality-of.html#:~:text=The%20Jadad%20score%20was%20used,of%20all%20patients%2C%20including%20withdrawals" ext-link-type="uri">http://onbiostatistics.blogspot.com/2009/03/jadad-scale-to-assess-quality-of.html#:~:text=The%20Jadad%20score%20was%20used,of%20all%20patients%2C%20including%20withdrawals</ext-link></mixed-citation></ref><ref id="B96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Long</surname><given-names>HA</given-names></string-name>, <string-name name-style="western"><surname>French</surname><given-names>DP</given-names></string-name>, <string-name name-style="western"><surname>Brooks</surname><given-names>JM</given-names></string-name></person-group>. <year>2020</year>. <article-title>Optimising the value of the critical appraisal skills programme (CASP) tool for quality appraisal in qualitative evidence synthesis</article-title>. <source>Res Methods Med Health Sci</source><volume>1</volume>:<fpage>31</fpage>&#8211;<lpage>42</lpage>. doi:<pub-id pub-id-type="doi">10.1177/2632084320947559</pub-id></mixed-citation></ref><ref id="B97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Al-Dirini</surname><given-names>RMA</given-names></string-name>, <string-name name-style="western"><surname>Thewlis</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Paul</surname><given-names>G</given-names></string-name></person-group>. <year>2012</year>. <article-title>A comprehensive literature review of the pelvis and the lower extremity FE human models under quasi-static conditions</article-title>. <source>Work</source><volume>41 Suppl 1</volume>:<fpage>4218</fpage>&#8211;<lpage>4229</lpage>. doi:<pub-id pub-id-type="doi">10.3233/WOR-2012-1039-4218</pub-id><pub-id pub-id-type="pmid">22317369</pub-id></mixed-citation></ref><ref id="B98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Soliman</surname><given-names>ABE</given-names></string-name>, <string-name name-style="western"><surname>Pawluk</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Wilby</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Rachid</surname><given-names>O</given-names></string-name></person-group>. <year>2022</year>. <article-title>The use of a modified Delphi technique to develop a critical appraisal tool for clinical pharmacokinetic studies</article-title>. <source>Int J Clin Pharm</source><volume>44</volume>:<fpage>894</fpage>&#8211;<lpage>903</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11096-022-01390-y</pub-id><pub-id pub-id-type="pmid">35307788</pub-id><pub-id pub-id-type="pmcid">PMC9393138</pub-id></mixed-citation></ref><ref id="B99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Higgins</surname><given-names>JPT</given-names></string-name>, <string-name name-style="western"><surname>Altman</surname><given-names>DG</given-names></string-name>, <string-name name-style="western"><surname>G&#248;tzsche</surname><given-names>PC</given-names></string-name>, <string-name name-style="western"><surname>J&#252;ni</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Moher</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Oxman</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Savovic</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Schulz</surname><given-names>KF</given-names></string-name>, <string-name name-style="western"><surname>Weeks</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sterne</surname><given-names>JAC</given-names></string-name>, <collab>Cochrane Bias Methods Group</collab>, <collab>Cochrane Statistical Methods Group</collab></person-group>. <year>2011</year>. <article-title>The Cochrane Collaboration&#8217;s tool for assessing risk of bias in randomised trials</article-title>. <source>BMJ</source><volume>343</volume>:<elocation-id>d5928</elocation-id>. doi:<pub-id pub-id-type="doi">10.1136/bmj.d5928</pub-id><pub-id pub-id-type="pmid">22008217</pub-id><pub-id pub-id-type="pmcid">PMC3196245</pub-id></mixed-citation></ref><ref id="B100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Savovi&#263;</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Weeks</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sterne</surname><given-names>JAC</given-names></string-name>, <string-name name-style="western"><surname>Turner</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Altman</surname><given-names>DG</given-names></string-name>, <string-name name-style="western"><surname>Moher</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Higgins</surname><given-names>JPT</given-names></string-name></person-group>. <year>2014</year>. <article-title>Evaluation of the Cochrane Collaboration&#8217;s tool for assessing the risk of bias in randomized trials: focus groups, online survey, proposed recommendations and their implementation</article-title>. <source>Syst Rev</source><volume>3</volume>:<fpage>1</fpage>&#8211;<lpage>12</lpage>. doi:<pub-id pub-id-type="doi">10.1186/2046-4053-3-37</pub-id><pub-id pub-id-type="pmid">24731537</pub-id><pub-id pub-id-type="pmcid">PMC4022341</pub-id></mixed-citation></ref><ref id="B101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Viechtbauer</surname><given-names>W</given-names></string-name></person-group>. <year>2010</year>. <article-title>Conducting meta-analyses in R with the metafor package</article-title>. <source>J Stat Softw</source><volume>36</volume>:<fpage>1</fpage>&#8211;<lpage>48</lpage>. doi:<pub-id pub-id-type="doi">10.18637/jss.v036.i03</pub-id></mixed-citation></ref><ref id="B102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rokkas</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Papaxoinis</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Triantafyllou</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Ladas</surname><given-names>SD</given-names></string-name></person-group>. <year>2010</year>. <article-title>A meta-analysis evaluating the accuracy of colon capsule endoscopy in detecting colon polyps</article-title>. <source>Gastrointest Endosc</source><volume>71</volume>:<fpage>792</fpage>&#8211;<lpage>798</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.gie.2009.10.050</pub-id><pub-id pub-id-type="pmid">20363421</pub-id></mixed-citation></ref><ref id="B103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cumming</surname><given-names>G</given-names></string-name></person-group>. <year>2009</year>. <article-title>Inference by eye: reading the overlap of independent confidence intervals</article-title>. <source>Stat Med</source><volume>28</volume>:<fpage>205</fpage>&#8211;<lpage>220</lpage>. doi:<pub-id pub-id-type="doi">10.1002/sim.3471</pub-id><pub-id pub-id-type="pmid">18991332</pub-id></mixed-citation></ref><ref id="B104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>M. Mustofa</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Santoso B.</surname><given-names>S</given-names></string-name></person-group>. <year>1991</year>. <article-title>Pharmacokinetics of metronidazole in saliva</article-title>. <source>Int J Clin Pharmacol</source><volume>29</volume>:<fpage>474</fpage>&#8211;<lpage>478</lpage>.<pub-id pub-id-type="pmid">1813432</pub-id></mixed-citation></ref><ref id="B105"><label>105</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>FDA</collab>, <collab>USFaDA</collab></person-group>. <year>2018</year>. <article-title>Metronidazole injection, USP [Prescribing information]</article-title>. <comment>Available from</comment>: <ext-link xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018890s052lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018890s052lbl.pdf</ext-link>. <comment>Retrieved</comment><date-in-citation>20 May 2025</date-in-citation>.</mixed-citation></ref><ref id="B106"><label>106</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><string-name name-style="western"><surname>Kluwer</surname><given-names>LW</given-names></string-name></person-group>. <year>2025</year>. <source>Metronidazole: drug Information</source>. <comment>Available from</comment>: <ext-link xlink:href="https://www.wolterskluwer.com/en/solutions/uptodate/enterprise/lexidrug" ext-link-type="uri">https://www.wolterskluwer.com/en/solutions/uptodate/enterprise/lexidrug</ext-link>. <comment>Retrieved</comment><date-in-citation>20 May 2025</date-in-citation>.</mixed-citation></ref><ref id="B107"><label>107</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><string-name name-style="western"><surname>PFizer</surname><given-names>L</given-names></string-name></person-group>. <year>2021</year>. <source>Flagyl</source>. <comment>Available from</comment>: <ext-link xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/012623s069lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/012623s069lbl.pdf</ext-link>. <comment>Retrieved</comment><date-in-citation>28 May 2025</date-in-citation>.</mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>